

GenCore version 5.1.4-p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 13, 2003, 11:31:12 ; Search time 38.7752 Seconds  
(Without alignments)  
711.353 Million cell updates/sec

Title: US-09-917-791-21

Perfect score: 1071

Sequence: 1 IKVNMNLFPSSEDFNTND.....NIGNMLYKDDFVGAIFSGA 207

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_101002:\*

1: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1980.DAT:\*  
2: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1981.DAT:\*  
3: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1982.DAT:\*  
4: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1983.DAT:\*  
5: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1984.DAT:\*  
6: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1985.DAT:\*  
7: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1986.DAT:\*  
8: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1987.DAT:\*  
9: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1988.DAT:\*  
10: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1989.DAT:\*  
11: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1990.DAT:\*  
12: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1991.DAT:\*  
13: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1992.DAT:\*  
14: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1993.DAT:\*  
15: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1994.DAT:\*  
16: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1995.DAT:\*  
17: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1996.DAT:\*  
18: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1997.DAT:\*  
19: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1998.DAT:\*  
20: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA1999.DAT:\*  
21: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA2000.DAT:\*  
22: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA2001.DAT:\*  
23: /SIDSL/gcgdata/geneseq/geneseqp-emb1/AA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1071	100.0	207	22	AAG79295	Amino acid sequence
2	1071	100.0	407	21	AAV77141	Native botulinum n
3	1071	100.0	413	23	AA804168	Botulinum toxin hea
4	1071	100.0	413	23	ABG69074	Botulinum neurotox
5	1071	100.0	423	21	AA836302	C. botulinum BONT/
6	1071	100.0	837	21	AAV77140	Native botulinum n
7	1071	100.0	861	23	ABG69075	Botulinum neurotox
8	1071	100.0	871	19	AAW56019	Recombinant botuli
9	1071	100.0	871	19	AAW56007	Recombinant botuli
10	1071	100.0	871	19	AAW56008	Botulinum neurotox

11	1071	100.0	873	19	AAW56016	Recombinant botuli
12	1071	100.0	875	19	AAW56009	Recombinant botuli
13	1071	100.0	878	19	AAW56010	Recombinant botuli
14	1071	100.0	894	19	AAW56015	Recombinant botuli
15	1071	100.0	907	19	AAW56012	Recombinant botuli
16	1071	100.0	953	19	AAW56011	Recombinant botuli
17	1071	100.0	1013	19	AAW56013	Recombinant botuli
18	1071	100.0	1067	21	AAV93307	A manganese supero
19	1071	100.0	1092	21	AAV93310	A manganese supero
20	1071	100.0	1295	23	AAU99339	Clostridium botuli
21	1071	100.0	1296	17	AAW5010	C. botulinum type
22	1054.5	98.5	847	22	AAW40481	Botulinum toxin hea
23	377	35.2	410	22	AAW404102	Botulinum toxin hea
24	368.5	34.4	804	23	ABG69083	Botulinum neurotox
25	368.5	34.4	804	23	ABG69083	Botulinum neurotox
26	368.5	34.2	413	22	AAW40497	Botulinum toxin hea
27	368.5	34.2	848	22	AAW40482	Botulinum neurotox
28	368.5	34.2	852	23	ABG69077	Recombinant botuli
29	368.5	34.2	858	19	AAW56018	Recombinant botuli
30	368.5	34.2	1070	21	AAV93308	A manganese supero
31	368.5	34.2	1095	21	AAV93311	A manganese supero
32	368.5	34.2	1169	19	AAW56017	Recombinant botuli
33	368.5	34.0	848	23	ABG69087	Botulinum neurotox
34	364.5	34.0	1059	21	AAV93309	A manganese supero
35	364.5	34.0	1084	21	AAV93312	A manganese supero
36	364.5	34.0	1291	19	AAW68392	Clostridium botuli
37	316	29.5	408	22	AAW404101	Botulinum toxin hea
38	316	29.5	858	23	ABG69085	Botulinum neurotox
39	312	29.1	1315	22	AAW61169	Clostridium tetani
40	290.5	27.1	386	22	AAW40499	Botulinum toxin hea
41	290.5	27.1	824	23	ABG69081	Botulinum neurotox
42	263	24.6	399	22	AAW40498	Botulinum toxin hea
43	263	24.6	811	23	ABG69079	Botulinum neurotox
44	263	24.6	1291	20	AAW5814	Non-toxic modified
45	116.5	10.9	548	19	AAW56014	Recombinant botuli

## ALIGNMENTS

RESULT 1

AAG79295

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

AAW404101

ABG69085

AAW61169

AAW40499

ABG69081

AAW40498

ABG69079

AAW5814

AAW56014

AAW56016

AAW56009

AAW56010

AAW56015

AAW56012

AAW56011

AAW56013

AAV93307

AAV93310

AAU99339

AAW5010

AAW40481

AAW404102

ABG69083

ABG69083

AAW40497

AAW40482

ABG69077

AAW56018

AAV93308

AAV93311

AAW56017

ABG69087

AAV93309

AAV93312

AAW68392

XX The present sequence represents a fragment of the Clostridium botulinum  
 CC neurotoxin (BoNT). It was produced by amplifying overlapping fragments  
 CC of the BoNT gene. The amplified fragments were cloned expressed to  
 CC identify immunogenic polypeptides which are capable of giving rise to  
 CC protective antibodies. The BoNT polypeptide fragment are useful as  
 CC vaccines, for immunizing against botulism, and as diagnostic agents  
 CC to identify protective antibodies.

XX  
 SQ Sequence 207 AA:

Query Match 100.0%; Score 1071; DB 22; Length 207;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNMWDLFFSPSEDNFTNDLKGEBITSDTNEAAEENISDLIOQYLTFFNPEPN 60  
 DB 1 IKVNMWDLFFSPSEDNFTNDLKGEBITSDTNEAAEENISDLIOQYLTFFNPEPN 60  
 QY 61 ISENLSDDITQLELMPNIEERPNGKKELDKYMFMHRAQEFHGKSRALNNSVNE 120  
 DB 61 ISENLSDDITQLELMPNIEERPNGKKELDKYMFMHRAQEFHGKSRALNNSVNE 120  
 QY 121 ALLNPSRVYTFPSSDYKKVKNKATEAMFLGWVEQLVYDFTDETSEVSTTDKIADITITII 180  
 DB 121 ALLNPSRVYTFPSSDYKKVKNKATEAMFLGWVEQLVYDFTDETSEVSTTDKIADITITII 180  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 DB 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207

RESULT 2  
 AAY77141  
 ID AAY77141 standard; Protein; 407 AA.

XX  
 AC AAY77141;

XX  
 DT 08-MAY-2000 (first entry)

XX  
 DE Native botulinum neurotoxin serotype A (BoNTA) N-terminal fragment (Hn).

XX  
 KM Botulinum neurotoxin; heavy chain; BoNT; serotype A;  
 KM N-terminal fragment; Hn; Venezuelan equine encephalitis virus replicon;  
 KM VEE; botulism; vaccine; diagnosis; drug screening.

XX  
 OS Clostridium botulinum.

XX  
 PN WO200002524-A2.

XX  
 PD 20-JAN-2000.

XX  
 PF 09-JUL-1999; 99WO-US15570.

XX  
 PR 10-JUL-1998; 98US-0092416.  
 PR 12-MAY-1999; 99US-0133870.

XX  
 PA (USME-) US MEDICAL RES INST INFECTIOUS DISEASES.

XX  
 PI Lee JS, Pushko P, Smith JF, Parker M, Dertzbaugh MT, Smith L;  
 XX WPI; 2000-160827/14.  
 DR N-PSDB; AA287219.

XX  
 PT Novel Botulinum neurotoxin vaccine comprising a fragment from botulinum  
 PT toxin serotypes A-G, is used for inducing an immune response against  
 PT botulinum -

XX  
 PS Example 3; Page 51; 54pp; English.

XX  
 CC The invention relates to novel vaccines that induce a protective immune  
 CC response against botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F  
 CC and G (BoNTA-BoNTG). The vaccine of the invention is novel recombinant

CC DNA construct comprising a vector, and at least one nucleic acid  
 CC fragment comprising a C-terminal heavy chain fragment (Hc) from BoNT  
 CC serotypes A-G. In preferred embodiments of the invention, the vector is a  
 CC Venezuelan equine encephalitis virus (VEE) replicon vector. Use of this  
 CC vector results in the production of large amounts of a protein encoded by  
 CC a sequence cloned into the replicon. The constructs are used to produce  
 CC vaccines against botulism. The proteins can also be used as diagnostic  
 CC tools for the diagnosis of botulism. The transformed host cells can be  
 CC used to analyse the effectiveness of drugs and agents which inhibit toxin  
 CC effects. The vaccine currently used against botulism is dangerous  
 CC and expensive to produce, and contains formalin, which is very painful  
 CC for the recipient. Also, the vaccine is incomplete, in that only 5 of  
 CC the 7 serotypes are represented in the formulation. The novel vaccine  
 CC of overcomes these problems, as it is easily purified, and available in  
 CC large quantities. It is also expressed in the lymph nodes for a better  
 CC immune response. The present sequence represents the native BoNTA heavy  
 CC chain N-terminal fragment (Hn) used in an exemplification of the present  
 CC invention.

XX  
 SQ Sequence 407 AA:

Query Match 100.0%; Score 1071; DB 21; Length 407;  
 Best Local Similarity 100.0%; Pred. No. 3.2e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNMWDLFFSPSEDNFTNDLKGEBITSDTNEAAEENISDLIOQYLTFFNPEPN 60  
 DB 2 IKVNMWDLFFSPSEDNFTNDLKGEBITSDTNEAAEENISDLIOQYLTFFNPEPN 61  
 QY 61 ISENLSDDITQLELMPNIEERPNGKKELDKYMFMHRAQEFHGKSRALNNSVNE 120  
 DB 62 ISENLSDDITQLELMPNIEERPNGKKELDKYMFMHRAQEFHGKSRALNNSVNE 121  
 QY 121 ALLNPSRVYTFPSSDYKKVKNKATEAMFLGWVEQLVYDFTDETSEVSTTDKIADITITII 180  
 DB 122 ALLNPSRVYTFPSSDYKKVKNKATEAMFLGWVEQLVYDFTDETSEVSTTDKIADITITII 181  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 DB 182 PYIGPALNIGNMLYKDDFVGALIFSGA 208

RESULT 3  
 AAB04168  
 ID AAB04168 standard; Protein; 413 AA.

XX  
 AC AAB04168;

XX  
 DT 11-APR-2001 (first entry)

XX  
 DE Botulinum toxin heavy chain N-terminal sequence (serotype A).

XX  
 KM Botulism; toxin; neurotoxin; heavy chain; recombinant expression;  
 KM recombinant vector; antigen; immune response; vaccine; bacterium;  
 KM infection.

XX  
 OS Synthetic.

XX  
 OS Clostridium botulinum.

XX  
 PN WO200067700-A2.

XX  
 PD 16-NOV-2000.

XX  
 PF 12-MAY-2000; 2000WO-US12890.

XX  
 PR 12-MAY-1999; 99US-0133865.  
 PR 12-MAY-1999; 99US-0133866.  
 PR 12-MAY-1999; 99US-0133867.  
 PR 12-MAY-1999; 99US-0133868.  
 PR 12-MAY-1999; 99US-0133869.  
 PR 12-MAY-1999; 99US-0133873.  
 PR 29-JUL-1999; 99US-0146192.

PA (USSA ) US ARMY MEDICAL RES & MATERIAL COMMAND.  
 XX  
 PI Smith LA, Byrne MP, Middlebrook JL, Lapenotiere H.  
 XX  
 DR WPI; 2001-016048/02.  
 DR N-PSDB; AAA54590.  
 XX  
 PT New nucleic acids encoding the carboxy- or amino-terminal portions of  
 PT the heavy chain of botulinum neurotoxin of serotype A-G, useful as  
 PT vaccine against botulism  
 XX  
 PS Disclosure; Fig 11b; 73pp; English.  
 XX  
 CC Botulism neurotoxins are translated as a single 150 kDa polypeptide  
 CC chain and then posttranslationally nicked, forming a di-chain  
 CC consisting of a 100 kDa heavy chain and a 50 kDa light chain which  
 CC remain linked by a disulfide bond. Nucleic acids encoding the  
 CC carboxy-terminal (HC) or amino-terminal (HN) portion of the heavy  
 CC chain of botulinum neurotoxin (BoNT) can be used in recombinant  
 CC expression vectors and expressed in transformed cells to produce  
 CC peptide antigens useful for eliciting an immune response to give  
 CC protective immunity against botulinum neurotoxin, which causes  
 CC botulism. The nucleic acids are expressible in a recombinant  
 CC organisms such as Escherichia coli or Pichia pastoris. The use  
 CC of recombinant nucleic acids are advantageous since it eliminates  
 CC the need to culture large quantities of hazardous toxin-producing  
 CC bacterium. Production yield from the genetically engineered product  
 CC is also high and cost of production is lower. The nucleic acids can  
 CC be derived from Clostridium botulinum serotypes A-G.  
 XX  
 SQ Sequence 413 AA;  
 Query Match 100.0%; Score 1071; DB 22; Length 413;  
 Best Local Similarity 100.0%; Pred. No. 3.3e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 IKVNNMDLFFSPSDNFTNDLNGKEITSDNTEAEENISLDLQOYLLFNFNDNEPEN 60  
 DB 8 IKVNNMDLFFSPSDNFTNDLNGKEITSDNTEAEENISLDLQOYLLFNFNDNEPEN 67  
 QY 61 ISENLSDDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRIALTNSVNE 120  
 DB 68 ISENLSDDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRIALTNSVNE 127  
 QY 121 ALNPSRYVTFSSDYKVKVKAATEAMFLGVOLVDFDFTSEVSTDKIADITITII 180  
 DB 128 ALNPSRYVTFSSDYKVKVKAATEAMFLGVOLVDFDFTSEVSTDKIADITITII 187  
 QY 181 PYIGPALNIGMLYKDDPVGALIFSGA 207  
 DB 188 PYIGPALNIGMLYKDDPVGALIFSGA 214  
 RESULT 4  
 AAB69074  
 ID AAB69074 standard; Protein: 413 AA.  
 AC AAB69074;  
 XX  
 DT 07-OCT-2002 (first entry)  
 XX  
 DE Botulinum neurotoxin light chain polypeptide #8.  
 XX  
 KW Botulinum neurotoxin light chain; BoNT LC; botulism; dystonia; pain;  
 KW spasticity; ocular motility; facial dyskinesia; stiff-person syndrome;  
 KW bladder dysfunction; segmental myoclonus; hyperkinetic disorder;  
 KW cosmetic treatment; facial wrinkle; cerebral palsy; analgesic; relaxant;  
 KW lower motor neuron hyperactivity; autonomic nerve function; muscular;  
 KW immunostimulant; antibacterial.  
 XX  
 OS Clostridium botulinum.  
 XX  
 PN WO200236758-A2.

XX  
 PD 10-MAY-2002.  
 XX  
 PF 06-NOV-2001; 2001WO-US47230.  
 XX  
 PR 06-NOV-2000; 2000US-246774P.  
 PR 20-JUL-2001; 2001US-0910186.  
 PR 09-AUG-2001; 2001US-311966P.  
 XX  
 PA (USSA ) US ARMY MEDICAL RES & MATERIAL COMMAND.  
 XX  
 PI Smith LA, Jensen M;  
 XX  
 DR WPI; 2002-575192/61.  
 DR N-PSDB; ABR98544.  
 XX  
 PT Novel nucleic acid molecule encoding botulinum neurotoxin light chain  
 PT serotype A, useful for producing the neurotoxin for vaccination against  
 PT botulism, comprises sequence expressible in host other than Clostridium  
 PT  
 XX  
 PS Disclosure; Page 130-131; 166pp; English.  
 XX  
 CC The invention relates to a nucleic acid molecule encoding a botulinum  
 CC neurotoxin light chain (BoNT LC) serotype A, where the DNA has a sequence  
 CC that is expressible in a host organism other than Clostridium, or has a  
 CC total A+T content that is less than about 70%. The BoNT LC protein is  
 CC useful in vaccination against botulism, for eliciting protective immunity  
 CC in a mammal, for treating dystonias, spasticity, pain, ocular motility,  
 CC facial dyskinesias, stiff-person syndrome, bladder dysfunction, segmental  
 CC myoclonus, hyperkinetic disorders, cosmetic treatment of facial wrinkles,  
 CC conditions characterised by hyperactivity of the lower motor neuron, and  
 CC to control autonomic nerve function or lipoe-walking due to stiff  
 CC muscles common in children with cerebral palsy. The sequences are also  
 CC useful for screening for botulinum neurotoxin inhibitors. This sequence  
 CC represents a botulinum neurotoxin light chain serotype A protein.  
 XX  
 SQ Sequence 413 AA;  
 Query Match 100.0%; Score 1071; DB 23; Length 413;  
 Best Local Similarity 100.0%; Pred. No. 3.3e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 IKVNNMDLFFSPSDNFTNDLNGKEITSDNTEAEENISLDLQOYLLFNFNDNEPEN 60  
 DB 8 IKVNNMDLFFSPSDNFTNDLNGKEITSDNTEAEENISLDLQOYLLFNFNDNEPEN 67  
 QY 61 ISENLSDDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRIALTNSVNE 120  
 DB 68 ISENLSDDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRIALTNSVNE 127  
 QY 121 ALNPSRYVTFSSDYKVKVKAATEAMFLGVOLVDFDFTSEVSTDKIADITITII 180  
 DB 128 ALNPSRYVTFSSDYKVKVKAATEAMFLGVOLVDFDFTSEVSTDKIADITITII 187  
 QY 181 PYIGPALNIGMLYKDDPVGALIFSGA 207  
 DB 188 PYIGPALNIGMLYKDDPVGALIFSGA 214  
 RESULT 5  
 AAB36302  
 ID AAB36302 standard; Protein: 423 AA.  
 XX  
 AC AAB36302;  
 XX  
 DT 15-FEB-2001 (first entry)  
 XX  
 DE C. botulinum BoNT/A neurotoxin heavy chain prototoxin SEQ ID NO:8.  
 XX  
 KW Human; procholecystokinin; CCK A receptor; CCK B receptor;  
 KW pancreatitis; antiinflammatory.  
 XX

OS	Clostridium botulinum.
XX	
PN	WO20061192-A2.
PD	19-OCT-2000.
XX	
PF	06-APR-2000; 2000MO-US09142.
XX	
PR	08-APR-1999; 99US-0288326.
XX	
PA	(ALLR ) ALLERGAN SALES INC.
XX	
PI	Steward LE, Sachs G, Aoki KR;
XX	
DR	WPI: 2000-679416/66.
XX	
PT	New composition for treating acute pancreatitis, comprises a pancreatic
PT	cell surface marker binding element, a translocation element that
PT	transfers polypeptide across vesicular membrane, and a therapeutic
PT	element -
XX	
PS	Disclosure; Page 28; 50pp; English.
XX	
CC	The present invention describes a composition (I) for treating acute
CC	pancreatitis. (I) comprises a first element containing a binding element
CC	that binds to a pancreatic cell surface marker, a second element
CC	containing a translocation element that facilitates polypeptide transfer
CC	across the vesicular membrane, and a third element containing a
CC	therapeutic element that inhibits enzyme secretion in pancreatic cell
CC	cytoplasm. Also described is a method for making a therapeutic
CC	polypeptide having a binding element selective for cholecystokinin (CCK)
CC	receptor by expressing within a host cell a recombinant chimERIC
CC	polypeptide comprising an extein containing a therapeutic element and a
CC	translocational element, and an intein located to the carboxy terminal
CC	of extein having a cysteine, serine or threonine at its amino terminus,
CC	and contacting the extein with a synthetic peptide comprising a CCK
CC	amino acid sequence containing an amidated phenylalanine at a natural
CC	C-terminus, and a cysteine, serine or threonine at its N-terminus, and
CC	a nucleophilic reagent able to cause cleavage of the intein to form a
CC	peptide bond between the extein C-terminus and synthetic peptide
CC	N-terminus through the formation of an activated ester or thio ester
CC	intermediate. (I) has antiinflammatory activity and prevents accumulation
CC	of pancreatic digestive enzymes, and prevents exocytic fusion of vesicles
CC	containing secretory enzymes of pancreas. (I) is useful for treating
CC	acute pancreatitis. The present sequence represents the Clostridium
CC	botulinum BOMT/A neurotoxin heavy chain protoxin which is given in
CC	the exemplification of the present invention.
XX	
SQ	Sequence 423 AA:
	Query Match 100.0%; Score 1071; DB 21; Length 423;
	Best Local Similarity 100.0%; Pred. No. 3.4e-99;
	Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1 IKVNWDFPFSSENFNDLKNGETISDTNIEAAEINISDLIOOYYLTTFENDEPEN 60
DB	7 IKVNWDLFEPFSSDNFTNDLNKGEITSSTNIEAAEINISDLDIOOYYLTTFENDEPEN 66
QY	61 ISENTSSDIIGOLELMPRIEREFPNGKKKEELKRYTMFHFLRAOFPHGKSRLATNSVNE 120
DB	67 ISENTSSDIIGOLELMPRIEREFPNGKKKEELKRYTMFHFLRAOFPHGKSRLATNSVNE 126
QY	121 ALLNSRYTYFFSSDYVKVKNKATEAAMPLGWEOQLVYFPTDETSEVTDKADIADITIII 180
DB	127 ALLNSRYTYFFSSDYVKVKNKATEAAMPLGWEOQLVYFPTDETSEVTDKADIADITIII 186
QY	181 PYIGPALNIIGNMLKYDDFVGALIFSGA 207
DB	187 PYIGPALNIIGNMLKYDDFVGALIFSGA 213
RESULT 6	
LAAV77140	

ID	AAV7140 standard; Protein; 837 AA.
XX	
AC	AAV7140;
XX	
DT	08-MAY-2000 (first entry)
XX	
DE	Native botulinum neurotoxin serotype A (BONTA).
XX	
XX	Botulinum neurotoxin; heavy chain; BONT; serotype A;
KM	Venezuelan equine encephalitis virus replicon;
KW	VEE; botulism; vaccine; diagnosis; drug screening.
XX	
OS	Clostridium botulinum.
XX	
FM	Key
FT	Misc-difference 837
FT	/note= "Apparently encoded by GGATGGGAG AAGGCCACT G"
XX	
PN	WO200002524-A2.
XX	
PD	20-JAN-2000.
XX	
PF	09-JUL-1999; 99WO-US15570.
XX	
PR	10-JUL-1998; 98US-0092416.
PR	12-MAY-1999; 99US-0133870.
XX	
PA	(USME-) US MEDICAL RES INST INFECTIOUS DISEASES.
XX	
PI	Lee JS, Pushko P, Smith JF, Parker M, Dertzbaugh MT, Smith L;
XX	
DR	WPI: 2000-160827/14.
XX	
DR	N-PSDB; AAZ87218.
XX	
PT	Novel Botulinum neurotoxin vaccine comprising a fragment from botulinum
PT	toxin serotypes A-G, is used for inducing an immune response against
PT	botulinum -
XX	
XX	
PS	Example 3; Page 49; 54pp; English.
XX	
CC	The invention relates to novel vaccines that induce a protective immune
CC	response against botulinum neurotoxin (BONT) serotypes A, B, C, D, E, F
CC	and G (BONTA-BONTG). The vaccine of the invention is novel recombinant
CC	DNA construct comprising a vector, and at least one nucleic acid
CC	fragment comprising a C-terminal heavy chain fragment (HC) from BONT
CC	serotypes A-G, in preferred embodiments of the invention, the vector is a
CC	Venezuelan equine encephalitis virus (VEE) replicon vector. Use of this
CC	vector results in the production of large amounts of a protein encoded by
CC	a sequence cloned into the replicon. The constructs are used to produce
CC	vaccines against botulism. The proteins can also be used as diagnostic
CC	tools for the diagnosis of botulism. The transformed host cells can be
CC	used to analyse the effectiveness of drugs and agents which inhibit toxin
CC	effects. The vaccine currently used against botulism is dangerous
CC	and expensive to produce, and contains formalin, which is very painful
CC	for the recipient. Also, the vaccine is incomplete, in that only 5 of
CC	the 7 serotypes are represented in the formulation. The novel vaccine
CC	overcomes these problems, as it is easily purified, and available in
CC	large quantities. It is also expressed in the lymph nodes for a better
CC	immune response. The present sequence represents the native BONTA heavy
CC	chain used in an exemplification of the present invention.
XX	
SQ	Sequence 837 AA;
XX	
Query Match	100.0%; Score 1071; DB 21; Length 837;
Best Local Similarity	100.0%; Pred. No. 8, 9e-99;
Matches 207; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
DB	1 IKVNMWDLFSPSEDNFTNDLNKGEITSDFNIEAAEENISDLIQYYLTFNPNPEN 60
	2 IKVNMWDLFSPSEDNFTNDLNKGEITSDFNIEAAEENISDLIQYYLTFNPNPEN 61
YY	1 ISEHLSDDITIGOLELMNIEEFPPGKRYELDKYTFMFHFLRAQEEHGRKSRALTNSVNE 120



Db 62 ISENLSSDIIGOLELMPNIEERFPNGKKYELDKYTMFHYLRAQEEHCKSRIALTNSVNE 121  
 QY 121 ALLNSRYTFFSSDYVKVKKATEAAMFLGWEOLVYDFDETSEVSTTKIADITITII 180  
 Db 122 ALLNSRYTFFSSDYVKVKKATEAAMFLGWEOLVYDFDETSEVSTTKIADITITII 181  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 Db 182 PYIGPALNIGNMLYKDDFVGALIFSGA 208

RESULT 7  
 ABG69075  
 ID ABG69075 standard; Protein; 861 AA.  
 AC ABG69075;  
 XX  
 DT 07-OCT-2002 (first entry)  
 DE Botulinum neurotoxin light chain polypeptide #9a.  
 XX  
 KW Botulinum neurotoxin light chain; BoNT LC; botulism; dystonia; pain; spasticity; ocular motility; facial dyskinesia; stiff-person syndrome; bladder dysfunction; segmental myoclonus; hyperkinetic disorder; cosmetic treatment; facial wrinkle; cerebral palsy; analgesic; relaxant; lower motor neuron hyperactivity; autonomic nerve function; muscular; immunostimulant; antibacterial.  
 KM  
 XX  
 OS Clostridium botulinum.  
 XX  
 PN W0200236758-A2.  
 PD 10-MAY-2002.  
 XX  
 PF 06-NOV-2001; 2001WO-US47230.  
 XX  
 PR 06-NOV-2000; 2000US-246774P.  
 PR 20-JUL-2001; 2001US-0910186.  
 PR 09-AUG-2001; 2001US-311966P.  
 XX  
 PA (USSA ) US ARMY MEDICAL RES & MATERIAL COMMAND.  
 PI Smith LA, Jensen M;  
 XX  
 DR WPI: 2002-575192/61.  
 DR N-PSDB; ABR98545.  
 XX  
 PT Novel nucleic acid molecule encoding botulinum neurotoxin light chain serotype A, useful for producing the neurotoxin for vaccination against botulism, comprises sequence expressible in host other than Clostridium

Claim 13; Page 133-134; 166pp; English.

The invention relates to a nucleic acid molecule encoding a botulinum neurotoxin light chain (BoNT LC) serotype A, where the DNA has a sequence that is expressible in a host organism other than Clostridium, or has a total A+T content that is less than about 70%. The BoNT LC protein is useful in vaccination against botulism, for eliciting protective immunity in a mammal, for treating dystonias, spasticity, pain, ocular motility, facial dyskinesias, stiff-person syndrome, bladder dysfunction, segmental myoclonus, hyperkinetic disorders, cosmetic treatment of facial wrinkles, conditions characterised by hyperactivity of the lower motor neuron, and to control autonomic nerve function or tip-toe-walking due to stiff muscles common in children with cerebral palsy. The sequences are also useful for screening for botulinum neurotoxin inhibitors. This sequence represents a botulinum neurotoxin light chain serotype A protein.

Sequence 861 AA;

Query Match 100.0%; Score 1071; DB 23; Length 861;  
 Best Local Similarity 100.0%; Pred. No. 9.3e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNMWDLFFSPSEDNFTNDLNKGEITSDPTIEAAENISLDLIQOYYLTFNPNEN 60  
 Db 456 IKVNMWDLFFSPSEDNFTNDLNKGEITSDPTIEAAENISLDLIQOYYLTFNPNEN 515  
 QY 61 ISENLSSDIIGOLELMPNIEERFPNGKKYELDKYTMFHYLRAQEEHCKSRIALTNSVNE 120  
 Db 516 ISENLSSDIIGOLELMPNIEERFPNGKKYELDKYTMFHYLRAQEEHCKSRIALTNSVNE 575  
 QY 121 ALLNSRYTFFSSDYVKVKKATEAAMFLGWEOLVYDFDETSEVSTTKIADITITII 180  
 Db 576 ALLNSRYTFFSSDYVKVKKATEAAMFLGWEOLVYDFDETSEVSTTKIADITITII 635  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 Db 636 PYIGPALNIGNMLYKDDFVGALIFSGA 662

RESULT 8  
 AAM56019  
 ID AAM56019 standard; Protein; 871 AA.  
 AC AAM56019;  
 XX  
 DT 27-JUL-1998 (first entry)  
 DE Recombinant botulinum neurotoxin type A LHA23/A (Q2E,N26K,A27Y).  
 XX  
 KW Botulinum; recombinant; Clostridium botulinum; neurotoxin; immunogen; detection; tetanus; non-toxic; toxin.  
 KM  
 XX  
 OS Synthetic.  
 OS Clostridium botulinum.  
 PN W09807864-A1.  
 PD 26-FEB-1998.  
 XX  
 PF 22-AUG-1997; 97WO-GB02273.  
 XX  
 PR 13-DEC-1996; 96GB-0025996.  
 PR 23-AUG-1996; 96GB-0011671.  
 XX  
 PA (MICR-) MICROBIOLOGICAL RES AUTHORITY.  
 PA (SPEY-) SPEYWOOD LAB LTD.  
 PI Foster KA, Quinn CP, Shone CC;  
 XX  
 DR WPI: 1998-169168/15.  
 DR N-PSDB; AAV26291.  
 XX  
 PT Recombinant neurotoxin polypeptides - used to develop therapeutic agents, immunogens or as non-toxic standards for the detection of neurotoxins

Example 1; Page 108-111; 137pp; English.

The present sequence represents a recombinant neurotoxin protein from the present invention. The present invention describes recombinant neurotoxin proteins which comprise a first and second domain, where the first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and where the second domain is adapted: (a) to translocate the protein into a cell; (b) to increase the solubility of the protein compared to the solubility of the first domain on its own, or (c) both to translocate the protein into a cell and to increase the solubility of the protein compared to the solubility of the first domain on its own, the protein being free of clostridial neurotoxin (CN) and free of CN precursor that can be converted into toxin by proteolytic action. The recombinant proteins can be used as therapeutic agents for targeting cells expressing a relevant substrate. The products can also be used as immunogens and as non-toxic standards for the assessment and development of in vitro assays for the detection of functional botulinum or tetanus

CC neurotoxins either in foodstuffs or in environmental samples.  
 XX Sequence 871 AA:

Query Match 100.0%; Score 1071; DB 19; Length 871;  
 Best Local Similarity 100.0%; Pred. No. 9.4e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNMNDFEFPSEDNFTDNLKGEITSDPTNEAEENISLDLIQOYYLTFFNDPEN 60  
 DB 455 IKVNMNDFEFPSEDNFTDNLKGEITSDPTNEAEENISLDLIQOYYLTFFNDPEN 514  
 QY 61 ISEINSSDIIGOLELMPNIERFPNGKYYELDKYTFMHLRAQEFHGKSRIALTNSVNE 120  
 DB 515 ISEINSSDIIGOLELMPNIERFPNGKYYELDKYTFMHLRAQEFHGKSRIALTNSVNE 574  
 QY 121 ALINPSRVYTFESSDYVKVKNKATEAMFLGWVEOLVYDFTDETSEVSTTDKADITITII 180  
 DB 575 ALINPSRVYTFESSDYVKVKNKATEAMFLGWVEOLVYDFTDETSEVSTTDKADITITII 634  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 DB 635 PYIGPALNIGNMLYKDDFVGALIFSGA 661

## RESULT 9

AAW56007  
 ID AAW56007 standard; Protein; 871 AA.

AC AAW56007;

DT 27-JUL-1998 (first entry)

DE Recombinant botulinum neurotoxin type A LH423/A.

KW Botulinum; recombinant; Clostridium botulinum; neurotoxin;

KW Immunogen; detection; tetanus; non-toxic; toxin.

OS Synthetic.

OS Clostridium botulinum.

PN WO9807864-A1.

PD 26-FEB-1998.

PF 22-AUG-1997; 97WO-GB02273.

PR 13-DEC-1996; 96GB-0025996.

PR 23-AUG-1996; 96GB-0017671.

PA (MICR-) MICROBIOLOGICAL RES AUTHORITY.

PA (SPEY-) SPEYWOOD LAB LTD.

PI Foster KA, Quinn CP, Shone CC;

DR WPI; 1998-169168/15.

DR N-PsDB; AAV26279.

PT Recombinant neurotoxin polypeptides - used to develop therapeutic  
 PT agents, immunogens or as non-toxic standards for the detection of  
 PT neurotoxins

PS Example 1; Page 33-35; 137pp; English.

CC The present sequence represents a recombinant neurotoxin protein from  
 CC the present invention. The present invention describes recombinant  
 CC neurotoxin proteins which comprise a first and second domain, where  
 CC the first domain is adapted to cleave one or more vesicle or  
 CC plasma-membrane associated proteins essential to exocytosis, and where  
 CC the second domain is adapted: (a) to translocate the protein into a  
 CC cell; (b) to increase the solubility of the protein compared to the  
 CC solubility of the first domain on its own, or (c) both to translocate  
 CC the protein into a cell and to increase the solubility of the protein

CC compared to the solubility of the first domain on its own, the protein  
 CC being free of clostridial neurotoxin (CN) and free of CN precursor that  
 CC can be converted into toxin by proteolytic action. The recombinant  
 CC proteins can be used as therapeutic agents for targeting cells  
 CC expressing a relevant substrate. The products can also be used as  
 CC immunogens and as non-toxic standards for the assessment and development  
 CC of in vitro assays for the detection of functional botulinum or tetanus  
 CC neurotoxins either in foodstuffs or in environmental samples.

SO Sequence 871 AA:

Query Match 100.0%; Score 1071; DB 19; Length 871;  
 Best Local Similarity 100.0%; Pred. No. 9.4e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNMNDFEFPSEDNFTDNLKGEITSDPTNEAEENISLDLIQOYYLTFFNDPEN 60  
 DB 455 IKVNMNDFEFPSEDNFTDNLKGEITSDPTNEAEENISLDLIQOYYLTFFNDPEN 514  
 QY 61 ISEINSSDIIGOLELMPNIERFPNGKYYELDKYTFMHLRAQEFHGKSRIALTNSVNE 120  
 DB 515 ISEINSSDIIGOLELMPNIERFPNGKYYELDKYTFMHLRAQEFHGKSRIALTNSVNE 574  
 QY 121 ALINPSRVYTFESSDYVKVKNKATEAMFLGWVEOLVYDFTDETSEVSTTDKADITITII 180  
 DB 575 ALINPSRVYTFESSDYVKVKNKATEAMFLGWVEOLVYDFTDETSEVSTTDKADITITII 634  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 DB 635 PYIGPALNIGNMLYKDDFVGALIFSGA 661

## RESULT 10

AAW56008  
 ID AAW56008 standard; Protein; 871 AA.

AC AAW56008;

DT 27-JUL-1998 (first entry)

DE Botulinum neurotoxin type A BONT/A.

KW Botulinum; recombinant; Clostridium botulinum; neurotoxin;

KW Immunogen; detection; tetanus; non-toxic; toxin.

OS Clostridium botulinum.

PN WO9807864-A1.

PD 26-FEB-1998.

PF 22-AUG-1997; 97WO-GB02273.

PR 13-DEC-1996; 96GB-0025996.

PR 23-AUG-1996; 96GB-0017671.

PA (MICR-) MICROBIOLOGICAL RES AUTHORITY.

PA (SPEY-) SPEYWOOD LAB LTD.

PI Foster KA, Quinn CP, Shone CC;

DR WPI; 1998-169168/15.

DR N-PsDB; AAV26280.

PT Recombinant neurotoxin polypeptides - used to develop therapeutic  
 PT agents, immunogens or as non-toxic standards for the detection of  
 PT neurotoxins

PS Disclosure; Page 52-54; 137pp; English.

CC The present sequence represents botulinum neurotoxin type A from  
 CC the present invention. The present invention describes recombinant  
 CC neurotoxin proteins which comprise a first and second domain, where

CC the first domain is adapted to cleave one or more vesicle or  
CC plasma-membrane associated proteins essential to exocytosis, and where  
CC the second domain is adapted: (a) to translocate the protein into a  
CC cell; (b) to increase the solubility of the protein compared to the  
CC solubility of the first domain on its own, or (c) both to translocate  
CC the protein into a cell and to increase the solubility of the protein  
CC compared to the solubility of the first domain on its own, the protein  
CC being free of clostridial neurotoxin (CN) and free of CN precursor that  
CC can be converted into toxin by proteolytic action. The recombinant  
CC proteins can be used as therapeutic agents for targeting cells  
CC expressing a relevant substrate. The products can also be used as  
CC immunogens and as non-toxic standards for the assessment and development  
CC of in vitro assays for the detection of functional botulinum or tetanus  
CC neurotoxins either in foodstuffs or in environmental samples.

XX Sequence 871 AA;

Query Match 100.0%; Score 1071; DB 19; Length 871;  
Best Local Similarity 100.0%; Pred. No. 9.4e-99;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNNWDLFFSPSDNFTNDLNKGEITSDTNIEAEENISLDLIQOYYLTFFNDEPEN 60  
DB 455 IKVNNWDLFFSPSDNFTNDLNKGEITSDTNIEAEENISLDLIQOYYLTFFNDEPEN 514  
QY 61 ISINLSSDIIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAOEFEGKSRIALTNSVNE 120  
DB 515 ISINLSSDIIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAOEFEGKSRIALTNSVNE 574  
QY 121 ALNPSRYVTFEFSDDYKKVKKATEAAMFLGWVOLYDFDETSEVSTDKADIITII 180  
DB 575 ALNPSRYVTFEFSDDYKKVKKATEAAMFLGWVOLYDFDETSEVSTDKADIITII 634  
QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
DB 635 PYIGPALNIGNMLYKDDFVGALIFSGA 661

RESULT 11  
AAM56016

ID AAM56016 standard; Protein: 873 AA.

AC AAM56016;

DT 27-JUL-1998 (first entry)

DE Recombinant botulinum neurotoxin type A 2LH423/A (Q2E,N26K,A27Y).

KW Botulinum; recombinant; Clostridium botulinum; neurotoxin;  
KM immunogen; detection; tetanus; non-toxic; toxin.

XX Synthetic.

OS Clostridium botulinum.

PN WO9807864-A1.

PD 26-FEB-1998.

PF 22-AUG-1997; 97WO-GB02273.

PR 13-DEC-1996; 96GB-0025996.

PR 23-AUG-1996; 96GB-0017671.

PA (MICR-) MICROBIOLOGICAL RES AUTHORITY.  
(SPEY-) SPEYWOOD LAB LTD.

PI Foster KA, Quinn CP, Shone CC;

DR WPI: 1998-169168/15.

DR N-PsDB; AAV26288.

XX Recombinant neurotoxin polypeptides - used to develop therapeutic  
PT agents, immunogens or as non-toxic standards for the detection of

PT neurotoxins

XX Example 1; Page 45-48; 137pp; English.

PS The present sequence represents a recombinant neurotoxin protein from  
XX the present invention. The present invention describes recombinant  
CC neurotoxin proteins which comprise a first and second domain, where  
CC the first domain is adapted to cleave one or more vesicle or  
CC plasma-membrane associated proteins essential to exocytosis, and where  
CC the second domain is adapted: (a) to translocate the protein into a  
CC cell; (b) to increase the solubility of the protein compared to the  
CC solubility of the first domain on its own, or (c) both to translocate  
CC the protein into a cell and to increase the solubility of the protein  
CC compared to the solubility of the first domain on its own, the protein  
CC being free of clostridial neurotoxin (CN) and free of CN precursor that  
CC can be converted into toxin by proteolytic action. The recombinant  
CC proteins can be used as therapeutic agents for targeting cells  
CC expressing a relevant substrate. The products can also be used as  
CC immunogens and as non-toxic standards for the assessment and development  
CC of in vitro assays for the detection of functional botulinum or tetanus  
CC neurotoxins either in foodstuffs or in environmental samples.

XX Sequence 873 AA;

Query Match 100.0%; Score 1071; DB 19; Length 873;  
Best Local Similarity 100.0%; Pred. No. 9.5e-99;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNNWDLFFSPSDNFTNDLNKGEITSDTNIEAEENISLDLIQOYYLTFFNDEPEN 60  
DB 457 IKVNNWDLFFSPSDNFTNDLNKGEITSDTNIEAEENISLDLIQOYYLTFFNDEPEN 516  
QY 61 ISINLSSDIIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAOEFEGKSRIALTNSVNE 120  
DB 517 ISINLSSDIIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAOEFEGKSRIALTNSVNE 576  
QY 121 ALNPSRYVTFEFSDDYKKVKKATEAAMFLGWVOLYDFDETSEVSTDKADIITII 180  
DB 577 ALNPSRYVTFEFSDDYKKVKKATEAAMFLGWVOLYDFDETSEVSTDKADIITII 636  
QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
DB 637 PYIGPALNIGNMLYKDDFVGALIFSGA 663

RESULT 12  
AAM56009

ID AAM56009 standard; Protein: 875 AA.

AC AAM56009;

DT 27-JUL-1998 (first entry)

DE Recombinant botulinum neurotoxin type A L/4H423/A.

KW Botulinum; recombinant; Clostridium botulinum; neurotoxin;  
KM immunogen; detection; tetanus; non-toxic; toxin.

XX Synthetic.

OS Clostridium botulinum.

PN WO9807864-A1.

PD 26-FEB-1998.

PF 22-AUG-1997; 97WO-GB02273.

PR 13-DEC-1996; 96GB-0025996.

PR 23-AUG-1996; 96GB-0017671.

PA (MICR-) MICROBIOLOGICAL RES AUTHORITY.  
(SPEY-) SPEYWOOD LAB LTD.

XX

PI Foster KA, Quinn CP, Shone CC;  
 XX  
 DR WPI; 1998-169168/15.  
 DR N-PSDB; AAV26281.  
 XX  
 PT Recombinant neurotoxin polypeptides - used to develop therapeutic  
 PT agents; immunogens or as non-toxic standards for the detection of  
 PT neurotoxins  
 XX  
 PS Example 1; Page 58-60; 137pp; English.  
 XX  
 CC The present sequence represents a recombinant neurotoxin protein from  
 CC the present invention. The present invention describes recombinant  
 CC neurotoxin proteins which comprise a first and second domain, where  
 CC the first domain is adapted to cleave one or more vesicle or  
 CC plasma-membrane associated proteins essential to exocytosis, and where  
 CC the second domain is adapted: (a) to translocate the protein into a  
 CC cell; (b) to increase the solubility of the protein compared to the  
 CC solubility of the first domain on its own, or (c) both to translocate  
 CC the protein into a cell and to increase the solubility of the protein  
 CC compared to the solubility of the first domain on its own, the protein  
 CC being free of clostridial neurotoxin (CN) and free of CN precursor that  
 CC can be converted into toxin by proteolytic action. The recombinant  
 CC proteins can be used as therapeutic agents for targeting cells  
 CC expressing a relevant substrate. The products can also be used as  
 CC immunogens and as non-toxic standards for the assessment and development  
 CC of in vitro assays for the detection of functional botulinum or tetanus  
 CC neurotoxins either in foodstuffs or in environmental samples.  
 XX  
 SQ Sequence 875 AA;  
 Query Match 100.0%; Score 1071; DB 19; Length 875;  
 Best Local Similarity 100.0%; Pred. No. 9.5e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 IKVNMWDLFFSSSEDNFTNDLNGKEITSDTNEAEENISLDLIQYYLTFNFPNEPEN 60  
 DB 459 IKVNMWDLFFSSSEDNFTNDLNGKEITSDTNEAEENISLDLIQYYLTFNFPNEPEN 518  
 QY 61 ISTEINSSDIIGOLELMPNIEERFPNGKYEIDKYMFMHYLRAQEFHGKSRALNSVNE 120  
 DB 519 ISTEINSSDIIGOLELMPNIEERFPNGKYEIDKYMFMHYLRAQEFHGKSRALNSVNE 578  
 QY 121 ALLNPSRVYTFPSSDYVKKVKNKATEAMFLGWVEOLVYDFDETSEVSTTDKIADITITII 180  
 DB 579 ALLNPSRVYTFPSSDYVKKVKNKATEAMFLGWVEOLVYDFDETSEVSTTDKIADITITII 638  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 DB 639 PYIGPALNIGNMLYKDDFVGALIFSGA 665  
 RESULT 13  
 AAW56010  
 ID AAW56010 standard; Protein; 878 AA.  
 XX  
 AC AAW56010;  
 XX  
 DT 27-JUL-1998 (first entry)  
 XX  
 DE Recombinant botulinum neurotoxin type A LFXA/3H423/A.  
 XX  
 KW Botulinum; recombinant; Clostridium botulinum; neurotoxin;  
 KW immunogen; detection; tetanus; non-toxic; toxin.  
 XX  
 OS Synthetic.  
 OS Clostridium botulinum.  
 XX  
 PN WO9807864-A1.  
 XX  
 KW 26-FEB-1998.  
 PD  
 XX 22-AUG-1997; 97WO-GB02273.  
 PF

XX  
 PR 13-DEC-1996; 96GB-0025996.  
 PR 23-AUG-1996; 96GB-0017671.  
 XX  
 PA (MICR-) MICROBIOLOGICAL RES AUTHORITY.  
 PA (SPEY-) SPEYWOOD LAB LTD.  
 XX  
 PI Foster KA, Quinn CP, Shone CC;  
 XX  
 DR WPI; 1998-169168/15.  
 DR N-PSDB; AAV26282.  
 XX  
 PT Recombinant neurotoxin polypeptides - used to develop therapeutic  
 PT agents; immunogens or as non-toxic standards for the detection of  
 PT neurotoxins  
 XX  
 PS Example 1; Page 64-66; 137pp; English.  
 XX  
 CC The present sequence represents a recombinant neurotoxin protein from  
 CC the present invention. The present invention describes recombinant  
 CC neurotoxin proteins which comprise a first and second domain, where  
 CC the first domain is adapted to cleave one or more vesicle or  
 CC plasma-membrane associated proteins essential to exocytosis, and where  
 CC the second domain is adapted: (a) to translocate the protein into a  
 CC cell; (b) to increase the solubility of the protein compared to the  
 CC solubility of the first domain on its own, or (c) both to translocate  
 CC the protein into a cell and to increase the solubility of the protein  
 CC compared to the solubility of the first domain on its own, the protein  
 CC being free of clostridial neurotoxin (CN) and free of CN precursor that  
 CC can be converted into toxin by proteolytic action. The recombinant  
 CC proteins can be used as therapeutic agents for targeting cells  
 CC expressing a relevant substrate. The products can also be used as  
 CC immunogens and as non-toxic standards for the assessment and development  
 CC of in vitro assays for the detection of functional botulinum or tetanus  
 CC neurotoxins either in foodstuffs or in environmental samples.  
 XX  
 SQ Sequence 878 AA;  
 Query Match 100.0%; Score 1071; DB 19; Length 878;  
 Best Local Similarity 100.0%; Pred. No. 9.5e-99;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 IKVNMWDLFFSSSEDNFTNDLNGKEITSDTNEAEENISLDLIQYYLTFNFPNEPEN 60  
 DB 462 IKVNMWDLFFSSSEDNFTNDLNGKEITSDTNEAEENISLDLIQYYLTFNFPNEPEN 521  
 QY 61 ISTEINSSDIIGOLELMPNIEERFPNGKYEIDKYMFMHYLRAQEFHGKSRALNSVNE 120  
 DB 522 ISTEINSSDIIGOLELMPNIEERFPNGKYEIDKYMFMHYLRAQEFHGKSRALNSVNE 581  
 QY 121 ALLNPSRVYTFPSSDYVKKVKNKATEAMFLGWVEOLVYDFDETSEVSTTDKIADITITII 180  
 DB 582 ALLNPSRVYTFPSSDYVKKVKNKATEAMFLGWVEOLVYDFDETSEVSTTDKIADITITII 641  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 DB 642 PYIGPALNIGNMLYKDDFVGALIFSGA 668  
 RESULT 14  
 AAW56015  
 ID AAW56015 standard; Protein; 894 AA.  
 XX  
 AC AAW56015;  
 XX  
 DT 27-JUL-1998 (first entry)  
 XX  
 DE Recombinant botulinum neurotoxin type A 23H423/A (Q2B, N26K, A27Y).  
 XX  
 KW Botulinum; recombinant; Clostridium botulinum; neurotoxin;  
 KW immunogen; detection; tetanus; non-toxic; toxin.  
 XX  
 OS Synthetic.  
 OS

OS Clostridium botulinum.  
XX MO9807864-A1.  
XX 26-FEB-1998.  
XX  
XX  
XX 22-AUG-1997; 97WO-GB02273.  
XX  
XX 13-DEC-1996; 96GB-0025996.  
XX 23-AUG-1996; 96GB-0017671.  
XX  
XX (MICR-) MICROBIOLOGICAL RES AUTHORITY.  
XX (SPEY-) SPEYWOOD LAB LTD.  
XX Foster KA, Quinn CP, Shone CC;  
XX  
XX WPI; 1998-169168/15.  
XX N-PSDB; AAV26287.  
XX  
XX Recombinant neurotoxin polypeptides - used to develop therapeutic  
PT agents, immunogens or as non-toxic standards for the detection of  
PT neurotoxins  
PS  
PS Example 1; Page 39-42; 137pp; English.  
XX  
XX The present sequence represents a recombinant neurotoxin protein from  
CC the present invention. The present invention describes recombinant  
CC neurotoxin proteins which comprise a first and second domain, where  
CC the first domain is adapted to cleave one or more vesicle or  
CC plasma-membrane associated proteins essential to exocytosis, and where  
CC the second domain is adapted: (a) to translocate the protein into a  
CC cell; (b) to increase the solubility of the protein compared to the  
CC solubility of the first domain on its own, or (c) both to translocate  
CC the protein into a cell and to increase the solubility of the protein  
CC compared to the solubility of the first domain on its own, the protein  
CC being free of clostridial neurotoxin (CN) and free of CN precursor that  
CC can be converted into toxin by proteolytic action. The recombinant  
CC proteins can be used as therapeutic agents for targeting cells  
CC expressing a relevant substrate. The products can also be used as  
CC immunogens and as non-toxic standards for the assessment and development  
CC of in vitro assays for the detection of functional botulinum or tetanus  
CC neurotoxins either in foodstuffs or in environmental samples.  
CC  
XX Sequence 894 AA;  
SQ  
Query Match 100.0%; Score 1071; DB 19; Length 894;  
Best Local Similarity 100.0%; Pred. No. 9.8e-99;  
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 IKVNMMDLFFSPSEDNFNNDLNKGEITSPTNIEAEENISIDLIOQYYLTFNPNNEPN 60  
DB 478 IKVNMMDLFFSPSEDNFNNDLNKGEITSPTNIEAEENISIDLIOQYYLTFNPNNEPN 537  
QY 61 ISENLSSDIIGOLELMPNIEERFPNGKRYELDKYTMFHYLRAQEFHKSRIALTNSVNE 120  
DB 538 ISENLSSDIIGOLELMPNIEERFPNGKRYELDKYTMFHYLRAQEFHKSRIALTNSVNE 597  
QY 121 ALLNPSRYTFFSSDYKVKVKATPAAMFLGWEOVLVDFDETSEVSTDKIADITITII 180  
DB 598 ALLNPSRYTFFSSDYKVKVKATPAAMFLGWEOVLVDFDETSEVSTDKIADITITII 657  
QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
DB 658 PYIGPALNIGNMLYKDDFVGALIFSGA 684  
RESULT 15  
ID AAW56012  
XX AAW56012 standard; Protein: 907 AA.  
XX  
XX AAW56012;  
XX  
DT 27-JUL-1998 (first entry)

XX  
DE Recombinant botulinum neurotoxin type A LfXa/3H423/A-CtxA 14.  
XX Botulinum; recombinant; Clostridium botulinum; neurotoxin;  
KW Immunogen; detection; tetanus; non-toxic; toxin.  
XX  
XX Synthetic.  
OS Clostridium botulinum.  
XX MO9807864-A1.  
XX  
XX 26-FEB-1998.  
XX  
XX 22-AUG-1997; 97WO-GB02273.  
XX  
XX 13-DEC-1996; 96GB-0025996.  
XX 23-AUG-1996; 96GB-0017671.  
XX  
XX (MICR-) MICROBIOLOGICAL RES AUTHORITY.  
XX (SPEY-) SPEYWOOD LAB LTD.  
XX Foster KA, Quinn CP, Shone CC;  
XX  
XX WPI; 1998-169168/15.  
XX N-PSDB; AAV26284.  
XX  
XX Recombinant neurotoxin polypeptides - used to develop therapeutic  
PT agents, immunogens or as non-toxic standards for the detection of  
PT neurotoxins  
PS  
PS Example 1; Page 77-79; 137pp; English.  
XX  
XX The present sequence represents a recombinant neurotoxin protein from  
CC the present invention. The present invention describes recombinant  
CC neurotoxin proteins which comprise a first and second domain, where  
CC the first domain is adapted to cleave one or more vesicle or  
CC plasma-membrane associated proteins essential to exocytosis, and where  
CC the second domain is adapted: (a) to translocate the protein into a  
CC cell; (b) to increase the solubility of the protein compared to the  
CC solubility of the first domain on its own, or (c) both to translocate  
CC the protein into a cell and to increase the solubility of the protein  
CC compared to the solubility of the first domain on its own, the protein  
CC being free of clostridial neurotoxin (CN) and free of CN precursor that  
CC can be converted into toxin by proteolytic action. The recombinant  
CC proteins can be used as therapeutic agents for targeting cells  
CC expressing a relevant substrate. The products can also be used as  
CC immunogens and as non-toxic standards for the assessment and development  
CC of in vitro assays for the detection of functional botulinum or tetanus  
CC neurotoxins either in foodstuffs or in environmental samples.  
CC  
XX Sequence 907 AA;  
SQ  
Query Match 100.0%; Score 1071; DB 19; Length 907;  
Best Local Similarity 100.0%; Pred. No. 1e-98;  
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 IKVNMMDLFFSPSEDNFNNDLNKGEITSPTNIEAEENISIDLIOQYYLTFNPNNEPN 60  
DB 462 IKVNMMDLFFSPSEDNFNNDLNKGEITSPTNIEAEENISIDLIOQYYLTFNPNNEPN 521  
QY 61 ISENLSSDIIGOLELMPNIEERFPNGKRYELDKYTMFHYLRAQEFHKSRIALTNSVNE 120  
DB 522 ISENLSSDIIGOLELMPNIEERFPNGKRYELDKYTMFHYLRAQEFHKSRIALTNSVNE 581  
QY 121 ALLNPSRYTFFSSDYKVKVKATPAAMFLGWEOVLVDFDETSEVSTDKIADITITII 180  
DB 582 ALLNPSRYTFFSSDYKVKVKATPAAMFLGWEOVLVDFDETSEVSTDKIADITITII 641  
QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
DB 642 PYIGPALNIGNMLYKDDFVGALIFSGA 668

Search completed: March 13, 2003, 11:39:09  
Job time : 41.7752 secs

---



R:DasGupta, B.R.; Dekleva, M.L.  
 Biochimie 72, 661-664, 1990  
 A:Title: Botulinum neurotoxin type A: sequence of amino acids at the N-terminus and aro  
 A:Reference number: A60025; MUID:91120847; PMID:2126206  
 A:Accession: A60025  
 A:Molecule type: protein  
 A:Residues: 2-6:445-453, 'X', 455-457 <DASL>  
 R:DasGupta, B.R.; Foley, J.; Niece, R.  
 Biochemistry 26, 4162, 1987  
 A:Title: Partial sequence of the light chain of botulinum neurotoxin type A.  
 A:Reference number: A27000  
 A:Accession: A27000  
 A:Molecule type: protein  
 A:Residues: 2-47 <DAS2>  
 R:Bliz, T.; Blasi, J.; Yamasaki, S.; Baumeister, A.; Link, E.; Suedhof, T.C.; Jahn, R.;  
 J. Biol. Chem. 269, 1617-1620, 1994  
 A:Title: Proteolysis of SNAP-25 by types E and A botulinial neurotoxins.  
 A:Reference number: A49708; MUID:94124495; PMID:8294407  
 A:Contents: annotation  
 A:Comment: Botulinum neurotoxins inhibit neurotransmitter release from cholinergic synap  
 C:Genetics:  
 A:Gene: atx; botA  
 C:Function:  
 A:Description: catalyzes hydrolysis of an Asn-Arg peptide bond in synaptosomal-associate  
 C:Superfamily: tetanus toxin  
 C:Keywords: disulfide bond; hydrolase; metalloprotease; neurotoxin; transmembrane prot  
 F:2-444/Product: bontoxylisin A light chain #status experimental <LGHT>  
 F:445-1296/Product: bontoxylisin A heavy chain #status experimental <HVT>  
 F:223,227/Binding site: zinc (His) #status predicted  
 F:224/Active site: Glu #status predicted

Query Match 100.0%; Score 1071; DB 1; Length 1296;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-77;  
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNMNDFEPPSEDNFTNDLKGEEITSDTNEAAEENISLDLQQYVLTFFNDEPEN 60  
 |||||||  
 Db 455 IKVNMNDFEPPSEDNFTNDLKGEEITSDTNEAAEENISLDLQQYVLTFFNDEPEN 514  
 QY 61 ISTEENSSDITIGOLELMPNIEFPNGKKYELDKYTFMFLRAOEFHGKSRILATNSVNE 120  
 |||||||  
 Db 515 ISTEENSSDITIGOLELMPNIEFPNGKKYELDKYTFMFLRAOEFHGKSRILATNSVNE 574  
 QY 121 ALLNPSRVYTFEPPSSDYKKVKNKATEAMFLGWEOQLVYDFDETSEVSTDKADIITIII 180  
 |||||||  
 Db 575 ALLNPSRVYTFEPPSSDYKKVKNKATEAMFLGWEOQLVYDFDETSEVSTDKADIITIII 634  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
 |||||||  
 Db 635 PYIGPALNIGNMLYKDDFVGALIFSGA 661

RESULT 2  
 I40645  
 botulinum neurotoxin type A - Clostridium botulinum  
 C:Species: Clostridium botulinum  
 C:Date: 12-Aug-1996 #sequence\_revision 12-Aug-1996 #text\_change 16-Jul-1999  
 C:Accession: I40645  
 R:Willems, A.; East, A.K.; Lawson, P.A.; Collins, M.D.  
 Res. Microbiol. 144, 547-556, 1993  
 A:Title: Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A  
 A:Reference number: I40645; MUID:94143603; PMID:8310180  
 A:Accession: I40645  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Residues: 1-1296 <RES>  
 A:Cross-References: EMBL:X73423; NID:g507070; PIDN:CAA51824.1; PID:g507071  
 C:Superfamily: tetanus toxin  
 C:Keywords: neurotoxin

Query Match 85.7%; Score 918; DB 2; Length 1296;  
 Best Local Similarity 85.4%; Pred. No. 2.4e-65;  
 Matches 176; Conservative 12; Mismatches 18; Indels 0; Gaps 0;

QY 1 IKVNMNDFEPPSEDNFTNDLKGEEITSDTNEAAEENISLDLQQYVLTFFNDEPEN 60  
 |||||||  
 Db 455 IKVNMNDFEPPSEDNFTNDLKGEEITSDTNEAAEENISLDLQQYVLTFFNDEPEN 514  
 QY 61 ISTEENSSDITIGOLELMPNIEFPNGKKYELDKYTFMFLRAOEFHGKSRILATNSVNE 120  
 |||||||  
 Db 515 ISTEENSSDITIGOLELMPNIEFPNGKKYELDKYTFMFLRAOEFHGKSRILATNSVNE 574  
 QY 121 ALLNPSRVYTFEPPSSDYKKVKNKATEAMFLGWEOQLVYDFDETSEVSTDKADIITIII 180  
 |||||||  
 Db 575 ALLNPSRVYTFEPPSSDYKKVKNKATEAMFLGWEOQLVYDFDETSEVSTDKADIITIII 634  
 QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 206  
 |||||||  
 Db 635 PYIGPALNIGNMLYKDDFVGALIFSGA 660

RESULT 3  
 S33411  
 botulinum neurotoxin type F - Clostridium baratii  
 C:Species: Clostridium baratii  
 C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 16-Jul-1999  
 C:Accession: S33411; S31860  
 R:Thompson, D.E.; Hutson, R.A.; East, A.K.; Allaway, D.; Collins, M.D.; Richardson, P  
 FEMS Microbiol. Lett. 108, 175-182, 1993  
 A:Title: Nucleotide sequence of the gene coding for Clostridium baratii type F neuroto  
 A:Reference number: S33411; MUID:93252228; PMID:8486245  
 A:Accession: S33411  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-1268 <THO>  
 A:Cross-References: EMBL:X68262; NID:949138; PIDN:CAA48329.1; PID:949139  
 C:Superfamily: tetanus toxin  
 C:Keywords: neurotoxin

Query Match 38.0%; Score 407.5; DB 2; Length 1268;  
 Best Local Similarity 44.0%; Pred. No. 1.8e-24;  
 Matches 95; Conservative 39; Mismatches 61; Indels 21; Gaps 7;

QY 1 IKVNMNDFEPPSEDNFTNDLKGEEITSDTNEAAEENISLDLQQYVLTFFNDEPEN 59  
 |||||  
 Db 436 IKVNMNDFEPPSEDNFTNDLKGEEITSDTNEAAEENISLDLQQYVLTFFNDEPEN 487  
 QY 60 NISIEENSSDITIGOLELMPNIEFPNGKKYELDKYTFMFLRAOEFHGKSR 111  
 |||||  
 Db 488 --AIPNLSRLNTTAQNDSDYVPKYD--SNGTSEIKEYTVDKLNFVYQAOKAPGESGA 543  
 QY 112 IATNNSVNEALLNPSRVYTFEPPSSDYKKVKNKATEAMFLGWEOQLVYDFDETSEVSTTD 171  
 |||||  
 Db 544 ISLTSSVNTALLDASKRVYTFEPPSSDYKVPVQAALFTSMIOQVINDFTTATQKSTID 603  
 QY 172 KIADITIIPIYIGPALNIGNMLYKDDFVGALIFSGA 207  
 |||||  
 Db 604 KIADISLIPIYVIGALNIGNEVOKGNFKRAIELLGA 639

RESULT 4  
 S39791  
 neurotoxin - Clostridium botulinum  
 C:Species: Clostridium botulinum  
 C:Date: 07-Oct-1994 #sequence\_revision 01-Dec-1995 #text\_change 16-Jul-1999  
 C:Accession: S39791  
 R:Campbell, K.; Collins, M.D.; East, A.K.  
 Biochim. Biophys. Acta 1216, 487-491, 1993  
 A:Title: Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridiu  
 A:Reference number: S39791; MUID:94092745; PMID:8268233  
 A:Accession: S39791  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-1297 <CAM>  
 A:Cross-References: EMBL:X74162; NID:9441275; PIDN:CAA52275.1; PID:9441276  
 C:Superfamily: tetanus toxin



```
06      427 TEINNGEI EEVASSENSNDONTNTBKEIDDTVTSSNNYE-----NDI.DOVTLNENSE 478
```

OY 56 NEPEHISSTENSSDIIGOLELMPNIERPPNG----KKYEELKRYTFHYLRQOEFGHSR 111  
:  
Db 479 SAP-GLSBEKSLNTITQND-AATPKD--SNCSDEIGHDVNELNVEFFLELDQAKPEGENN 534  
:  
OY 112 IALNSVNEALLNPBSRVYTFSSDYVKRKVRKATEAMFLGVWEDLYDFETSESVSTTD 171  
:  
Db 535 VMLTSIDTALLEOPKRITYTFSSFEFINNVNKPVCAALFVSMTIOQLVDFTEANQKSTVD 594  
:  
OY 172 KIADITIIIPYIAPALNIGNMILXKDDEFVALIFSGA 207  
|||||:~||| ||||| | ~ || ||  
Db 595 KIDISTIVPYIATALNIGNEAQKNFKDALELLGA 630

RESULT 7  
A48940  
botlotoxylisin (EC 3.4.2.4, 69) B precursor - Clostridium botulinum  
N:Alternate names: botulinum neurotoxin type B (BoNT/B)  
C:Species: Clostridium botulinum  
C:date: 19-Dec-1993 #sequence revision 18-Nov-1994 #text change 18-Jun-1999  
C:Accession: A48940; S48105; S21575; A42871; S07155; S08562; S07128; S08573; S08574  
R:Melan, S.M.; Elmore, M.J.; Bodsworth, N.J.; Brehm, J.K.; Atkinson, T.; Minton, N.P.  
Appl. Environ. Microbiol. 58, 2345-2354, 1992  
A:title: Molecular cloning of the Clostridium botulinum structural gene encoding the toxin  
A:Reference number: A48940; MUID:92384550; PMID:1514783  
A:Accession: A48940  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-1291 <MB>  
A:CROSS-references: EMBL:X70817; NID:g144734; PIDN:AAA23211.1; PID:g144735  
A:Experimental source: type B, Danish  
A>Note: sequence extracted from NCBI backbone (NCBIN:112080, NCBP:112081); this publication  
R:Campbell, K.D.; Collins, M.D.; East, A.K.  
J. Clin. Microbiol. 31, 2255-2262, 1993  
A:title: Gene probes for identification of the botulinum neurotoxin gene and specific id  
A:Reference number: S48103; MUID:94013372; PMID:8408542  
A:Accession: S48105  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 634-994 <CM>  
A:CROSS-references: EMBL:X70817; NID:g407782; PIDN:CAA50148.1; PID:g407783  
A:Experimental source: proteolytic type B, strain NCTC 7273  
R:Szabo, E.A.; Pemberton, J.M.; Desmarchelier, P.M.  
submitted to the EMBL Data Library, April 1992  
A:description: Partial amino acid sequence of botulinum neurotoxin type B and comparisid  
A:Reference number: S21575  
A:Accession: S21575  
A:Molecule type: DNA  
A:Residues: 36-217, 'G', 219-224, 'S', 226-246 <SZ>  
A:CROSS-references: EMBL:Z11934; NID:940383; PIDN:CAA77991.1; PID:940384  
R:Kurazono, H.; Mochida, S.; Blinz, T.; Eiselt, U.; Quanz, M.; Grebenstein, O.; Wernars, K  
J. Biol. Chem. 267, 14721-14729, 1992  
A:title: Minimal essential domains specifying toxicity of the light chains of tetanus tcd  
A:Reference number: A42871; MUID:92340509; PMID:1634516  
A:Accession: A42871  
A:Status: nucleic acid sequence not shown  
A:Molecule type: mRNA  
A:Residues: 1-313, 'S', 315-451 <KR>  
A:Experimental source: strain OKra  
A>Note: sequence extracted from NCBI backbone (NCBIP:109365)  
R:Dasgupta, B.R.; Datta, A.  
Biochimie 70, 811-817, 1988  
A:title: Botulinum neurotoxin type B (strain 657): partial sequence and similarity with  
A:Reference number: S07155; MUID:89000987; PMID:3139097  
A:Accession: S07155  
A:Molecule type: protein  
A:Residues: 2-29, 'M', 31-45 <DS>  
A:Accession: S08562  
A:Molecule type: protein  
A:Residues: 442-463, 'R', 465-467 <DA>  
R:Schmidt, J.J.; Sathymoorthy, V.; Dasgupta, B.R.  
Arch. Biochem. Biophys. 238, 544-548, 1985  
A:title: Partial amino acid sequences of botulinum neurotoxins types B and E.  
A:Reference number: S07148; MUID:85197963; PMID:3888113

A:Accession: S07128  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 2-16 <SCH1>  
A:Accession: S08573  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 2-17 <SCH2>  
A:Accession: S08574  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 442-459 <SCH3>  
R:Schiano, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; de Laureto, P.P.; DasGupta, R.  
A:Title: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolysis of syntaxin  
A:Reference number: S27125; MUID:93063293; PMID:1331807  
A:Contents: annotation  
C:Comment: Botulinum neurotoxins inhibit neurotransmitter release from cholinergic synapses  
C:Genetics:  
A:Gene: botX/b  
C:Function:  
A:Description: catalyzes hydrolysis of a Gln-Phe peptide bond in synaptobrevin 2  
C:Superfamily: tetanus toxin  
C:Keywords: hydrolyase; metalloproteinase; neurotoxin; transmembrane protein; zinc  
F:2-441/Product: botcoxilysin B light chain #status experimental <LcHT>  
F:442-1291/Product: botcoxilysin B heavy chain #status experimental <HVT>  
F:230-234/Binding site: zinc (His) #status predicted  
F:231/Active site:Glu #status predicted

Query Match

Best Local Similarity 39.4%; Pred. No. 3.6e-21;  
Matches 87; Conservative 39; Mismatches 62; Indels 33; Gaps 4.

QY 1 IKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTTFNFDNEPEN 60

Db 447 IDVDNEDLFFIADKNSFSDDLKNERIEYNT-----QSNYIENDF---PIN 489

QY 61 ISIENSSDIIGQLEL-----MPNIERFPNGKKYELDKYTMFHYLRAOEFE 106

Db 490 ELI--LDTDLISKIELPSENTESLTDNFVDPVYEKQPAIKKIFTDENTIFQYLLYSQTFP 54/

```

107 HGKSRALTNSVNEALLNPSRVYTFESSDYKKVNKATEAAM:LGWVEQLVYDFIDEISE 166
QY

```

DB 348 LDIRDISLSSFDLALLFSNKVSEFSMDYIKTKANKVVEAGLEAGWVKQIVNDFVIEANK 00/

18/ VSTIDKADITIIIP IGFALNIGNMELNDDFVGALIFSGA 20/

DD 008 SNMMDLADJSLVFIQHEALNVOHNEANONE EUNOF EIRGA 070

## RESULT 8

non-proteolytic botulinum neurotoxin type B precursor - *Clostridium botuli*

```
C;Date: 12-Aug-1996 #sequence_revision 12-Aug-1996 #text_change 16-Jul-1999
```

R; Hutson, R.A.; Collins, M.D.; East, A.K.; Thompson, D.E.  
 Data: Microbiol 38 101-110 1004

A;Title: Nucleotide sequence of the gene coding for non-proteolytic clostr

A;Accession: I40631  
A;Status: preliminary. translated from GB/EMBL/DDBJ

```
A: molecule type: DNA
A: Residues: 1-1291 <RES>
```

A;Cross-references: EMBL:X/1343; NID:g296148; P1DN:CAAS0482.1; PID:g296143  
R;Campbell, K.D.; Collins, M.D.; East, A.K.

J. Clin. Microbiol. 31, 2255-2262, 1993

A;Accession: S48103  
A;Reference Number: 340103/2; Field: 0400072

A; molecule type: DNA





```

QY 3 VNNMFFSPSEDNFTLNKNGEITSDTNEAEENISLDDIOQYLTFFNNDNEPNIS 62
Db 458 VKNDLPLPGIDISVDKDTIFLRKIDINETEVIYIPDNVSVD---QVILS---KNTSEHQ 511
QY 63 IENLSSDIIGOLELMPNTER-FPNGKRYELDKYTFHFHRAQEFHGSKRIALFNVSVEA 121
Db 512 LDLIYPSIDSESELPGENQVFIYDNRRQNVDSLNYYYLLESOQLSDNVEDTFFHSIEEA 571
QY 122 LANSRVYTFPFFSSDYVKVKNKATEAMFLGWEOQLVDFDETSESVSTYDKIADITITIIIP 181
Db 572 LDNSAKVYTFPEPT-LANKVNAGVOGGLFLMANADVVEDEFTNIIIRKDLTIDSVSAILIP 630
QY 182 YIGPALNTGNMLKDDFFGALIFSG 206
Db 631 YIGPALNTSIVSRKGNTEAPVTS 655

```

RESULT 14

botulinum neurotoxin type C1 precursor - Clostridium botulinum phage (type C, strain C-  
C:Species: Clostridium botulinum phage  
C:Date: 10-Mar-1994 #sequence-revision 07-Apr-1994 #text-change 23-Mar-2001  
C:Accession: S11291, A35396; S22166; A49777  
R:Hauser, D.; Eklund, M.W.; Kunzono, H.; Blatz, T.; Niemann, H.; Gill, D.M.; Boquet, P.;  
Nucleic Acids Res. 18, 4924, 1990  
A:Title: Nucleotide sequence of Clostridium botulinum C1 neurotoxin.  
A:Reference number: S11291; PMID:90370487; PMID:2204031  
A:Accession: S11291  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-84, 'P', 86-1291 <TAS>  
A:Cross-references: EMBL:X53751; NID:G14905; PIDD:CAA37780.1; PID:G14906  
R:Kimura, K.; Fujii, N.; Tsuzuki, K.; Murakami, T.; Indoh, T.; Yokosawa, N.; Takeshi, K  
Biochem. Biophys. Res. Commun. 171, 1304-1311, 1990  
A:Title: The complete nucleotide sequence of the gene coding for botulinum type C-1 toxin  
A:Reference number: A35396; PMID:91024998; PMID:2222445  
A:Accession: A35396  
A:Status: preliminary; not compared with conceptual translation  
A:Molecule type: DNA  
A:Residues: 1-669, 'R', 671-1291 <TS1>  
R:Tsuzuki, K.; Kimura, K.; Fujii, N.; Yokosawa, N.; Oguma, K.  
Submitted to the EMBL Data Library, December 1991  
A:Description: Nucleotide sequence of the gene for one of the components of hemagglutinin  
A:Reference number: S22163  
A:Accession: S22166  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-1291 <TS2>  
A:Cross-references: EMBL:X62389; NID:9558175; PIDD:CAA44263.1; PID:940390  
R:Kimura, K.; Fujii, N.; Tsuzuki, K.; Murakami, T.; Indoh, T.; Yokosawa, N.; Oguma, K.  
Appl. Environ. Microbiol. 57, 1168-1172, 1991  
A:Title: Cloning of the structural gene for Clostridium botulinum type C-1 toxin and whc  
A:Reference number: A49777; PMID:91282468; PMID:2059039  
A:Accession: A49777  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-607 <TS3>  
A:Cross-references: GB:D90210  
A:Superfamily: tetanus toxin  
A:Keywords: neurotoxin

24	Query Match	Score 263;	DB 2;	Length 1291;
	Best Local Similarity	31.2%;	Pred. No. 7e-13;	
Matches	64;	Conservative	39;	Mismatches 94; Indels 8; Gaps 4;

  

QY	3	VNNDDLFSPSPEDNTN	LNGEELTSPN	IEAEANISLD	LQOYLTFNFNDNEPENS	62
DB	458	VKNDDLPRTIGDISDKT	TLFLRKDINETE	EVYYIDNVSD--	OYILS--KNTSEHQ	511
QY	63	IENSSDIIIGOLELMPN	IER-PPNGCKYELDK	YTFHYLRQAEFEHGS	RIALATNSVNEA	121
DB	512	LDLILPSPIDSESLIE	PGNQVFFDMRTON	VDLNSYYLESQ	SLDNDVEDFTFTSR	571

[illegible]

RESULT 15

hypothetical protein [imported] - Buchnera sp. (strain APS)  
C:Species: Buchnera sp.  
C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 02-Mar-2001  
C:Accession: A84977  
R:Shigenobu, S.; Watanabe, H.; Hattori, M.; Sakaki, Y.; Ishikawa, H.  
Nature 407, 81-86, 2000  
A:Title: Genome sequence of the endocellular bacterial symbiont of aphids Buchnera sp.  
A:Reference number: A84930; MUID:20445173; PMID:10993077  
A:Accession: A84977  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-246 <STO>  
A:Cross-references: GB:AF000398; GSPDB:GNO0144  
A:Experimental source: strain APS  
C:Genetics:  
A:Gene: yf10; BU402

Query Match	10.0%	Score 107;	DB 2;	Length 246;
Best Local Similarity	21.8%	Pred. No. 0.24;		
Matches 44;	Conservative 40;	Mismatches 74;	Indels 44;	Gaps 8;

[illegible]

Search completed: March 13, 2003, 11:41:44  
Job time : 21.1066 secs

**THIS PAGE BLANK (uspto)**



```

QY 60 NISINLSDDIGOL-----ELMPNTEREPNG-----KKYELDQYTMFHYRAOEFHGKSR 111
Db 488 --AIPNLSRLLINTAONDSIYPKKD--SNGISEIKETIVDLINFFYLIAOKAPBGESA 543
QY 112 IALTNSVNEALLNPSRYVTFFSSDYVKVKNKTEAAMELGWVQOLVYDFTDTSSTVD 171
Db 544 ISLTSSVMTALADKAYVTFFSSDFTINMKFPVQAALFISWIOQYVINDTTEATOKSTVD 603
QY 172 KIADITTIIPYIGPALNTGNMLYKDFGALFFSGA 207
Db 604 KIADISLIVPYGIALNTGNENQKGNFKFALIELLGA 639

RESULT 2
Q9FAR6 PRELIMINARY: PRT: 1255 AA.
AC Q9FAR6;
DT 01-MAR-2001 (TREMBLrel. 16, Created)
DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
DE Type E botulinum toxin.
GN BONT/E.
OS Clostridium butyricum.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
OC Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_TaxID:1492;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BL 6340/ATCC 43755/BL 5520/Kz 147;
RX MEDLINE=20509829; PubMed=11055954;
RA Wang X., Maegawa T., Karasawa T., Kozaki S., Tsukamoto K., Gyobu Y.,
RA Yanakawa K., Oguna K., Sakaguchi Y., Nakamura S.;
RT "Genetic Analysis of Type E Botulinum Toxin-Producing Clostridium
RT butyricum Strains.";
RL Appl. Environ. Microbiol. 66:4992-4997(2000).
DR EMBL; AB039264; BABI2249.1; -.
DR HSSP; P10845; 3BPA.
DR InterPro; IPR000395; Bontoxilysin.
DR InterPro; IPR000130; Zn_MTPeptide.
DR Pfam; PF01742; Peptidase_M27; 1.
DR PRINTS; PRO0760; BONTOXILYSIN.
DR ProDom; PD001963; Bontoxilysin; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
DR DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
SQ SEQUENCE 1255 AA; 143918 MW; 1B557B9D5CD8BAD CRC64;

Query Match 35.0%; Score 374.5; DB 2; Length 1255;
Best local similarity 38.9%; Pred. No. 9.2e-20;
Matches 84; Conservative 51; Mismatches 60; Indels 21; Gaps

QY 1 IKVNWMDLFFSESENFNTD-LNKGEI-----TSDTINFAEENISLDLQOYVLFNFD 55
Db 430 IEINNGEELFEVASSESYNDNINFTKREIDYTSNNTE-----NDLDYILNFNSE 481
QY 56 NEPENISIEBSSDIIGOLELMPNTEREPNG-----KKYELDQYTMFHYRAOEFHGKSR 111
Db 482 SAP-GLSPEKILNLTIQND-AVIRPKYD--SNGTSDIEOHVDNELNFFYLDQAQVDEGENN 537
QY 112 IALTNSVNEALLNPSRYVTFFSSDYVKVKNKTEAAMELGWVQOLVYDFTDTSSTVD 171
Db 538 VNLTSIDTALLEQPKIITYFFSSSEFINNNKRVQAALFPGWIOQVAVDFTTEANOKSTVD 597
QY 172 KIADITTIIPYIGPALNTGNMLYKDFGALFFSGA 207
Db 598 KIADISLIVPYGIALNTGNENQKGNFKFALIELLGA 633

RESULT 3
Q9K395 PRELIMINARY: PRT: 1251 AA.
AC Q9K395;
DT 01-OCT-2000 (TREMBLrel. 15, Created)
DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update)

```

DE 01-DEC-2001 (TrEMBLrel. 19, last annotation update)  
DT Type E botulinum toxin.  
GN BONT/7.  
OS *Clostridium butyricum*.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
OX NCBI\_Taxid=1492;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=LCL 095;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (LCL 095) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=LCL 155;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Gyobu Y., Yamakawa K  
RT "C. butyricum (LCL 155) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1899;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (KZ 1899) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [4]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1897;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (KZ 1897) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [5]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1898;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (KZ 1898) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [6]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1886;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (KZ 1886) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [7]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1887;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (KZ 1887) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [8]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1889;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (KZ 1889) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [9]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1890;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RT "C. butyricum (KZ 1890) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [10]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KZ 1891;



RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Katasawa T.,  
RT "C. butyricum (K2 1891) gene for type E botulinum toxin";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
RN [11]  
RP SEQUENCE FROM N.A.  
RC STRAIN=LCL 063;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Katasawa T.,  
RT "C. butyricum (LCL 063) gene for type E botulinum toxin";  
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AB037714; BAB03522.1;  
DR EMBL: AB037704; BAB03512.1;  
DR EMBL: AB037705; BAB03513.1;  
DR EMBL: AB037706; BAB03514.1;  
DR EMBL: AB037707; BAB03515.1;  
DR EMBL: AB037708; BAB03516.1;  
DR EMBL: AB037709; BAB03517.1;  
DR EMBL: AB037710; BAB03518.1;  
DR EMBL: AB037711; BAB03519.1;  
DR EMBL: AB037712; BAB03520.1;  
DR EMBL: AB037713; BAB03521.1;  
DR HSSP: P10845; 3BTA.  
DR MEROPS: M27.002;  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_Mtpeptidse.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRINTS: PR00760; BONTOXILYSIN.  
DR PRODOM: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
SQ SEQUENCE 1251 AA; 143751 MW; 2021F4E427070296 CRC64;

Query Match 34.4%; Score 368.5; DB 2; Length 1251;  
Best Local Similarity 38.4%; Pred. No. 2.6e-19;  
Matches 83; Conservative 51; Mismatches 61; Indels 21; Gaps 7;

QY 1 IKVNMWDLFFSPEDNFNDLNKGEEL---TSDPTNEAEENISLDLQYLYTFNFD 55  
DB 427 IEINNGELFEVASENSYNDNINPKIEDPYTSNNNE-----NDLQVILNFSE 478  
QY 56 NEPEIETSIENSSDITIGLELMPNIERPNC---KTELDKTYMFHYLRAOEFHGKSR 111  
DB 479 SAP-GLSDEKLTLTIOND-AVYIPKD--SNGSTDEQHDVNELVNFYLDQKVEGENN 534  
QY 112 IALFNSVEALLNPSRVYTFPSSDYVKKNTAEAMFLGWEOLYVDFETSEVSTTD 171  
DB 535 VNLSSIDTALIEQPKITFFSSSEITNNVKNKPVQALFVSWIQVLVDFTEANOKSTVD 594  
QY 172 KIADITIIPIYIPALNIGNMLYKDDFVGALIFSGA 207  
DB 595 KIADISIVPIYIGLALNIGNEAKGNFKDALELLGA 630

## RESULT 4

ID 0933K0 PRELIMINARY; PRT: 1291 AA.  
AC 0933K0;  
DT 01-DEC-2001 (TREMblrel. 19, Created)  
DT 01-DEC-2001 (TREMblrel. 19, Last sequence update)  
DT 01-MAR-2002 (TREMblrel. 20, Last annotation update)  
DE Type B cryptic neurotoxin.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
OX NCBI\_TaxID=1491;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=593; AND 588;  
RA Kima N., Ferreira J.L., Baumstark B.R.;  
RT "Characterization of six type A strains of Clostridium botulinum that  
contain type B toxin gene sequences."  
RL Submitted (Aug-2000) to the EMBL/GenBank/DBJ databases.  
EMBL: AF300466; AAL11499.1;

DR EMBL: AF300465; AAL11498.1;  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_Mtpeptidse.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRODOM: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
KW Neurotoxin.  
SQ SEQUENCE 1291 AA; 150843 MW; 7AC1737B0FA5A151 CRC64;

Query Match 34.3%; Score 367.5; DB 2; Length 1291;  
Best Local Similarity 38.3%; Pred. No. 3.2e-19;  
Matches 85; Conservative 40; Mismatches 62; Indels 35; Gaps 3;

QY 1 IKVNMWDLFFSPEDNFNDLNKGEITSPTNIEAEENISLDLQYLYTFNFDNPE 59  
DB 447 IDVDNEDLFFADKNKSFSDLSKNRIAYNTQNTIENDPFSINEL----- 492  
QY 60 NISIEISSLITIGOLEL-----MPNIERPNGKKYELDKTYMFHYLRAOEF 105  
DB 493 -----LDTDISKIELPSENTESLDFNVYVPYVKQPAIKKLTEDNTIFQYLSQTF 546  
QY 106 EHGSRIALTNSVNEALLNPSRVYTFPSSDYVKKNTAEAMFLGWEOLYVDFETDTS 165  
DB 547 PLDIRDISLTSFDDALLFSNKVYSFESMDYIKTANKVVEAGLFAGWVKQIYNDVEIAN 606  
QY 166 EVSTDKTADITIIPIYIPALNIGNMLYKDDFVGALIFSGA 207  
DB 607 KSTIMDKTADISLIVPIYIGLALNIGNETAKGNFENAFELIAG 648

## RESULT 5

ID 093G71 PRELIMINARY; PRT: 1291 AA.  
AC 093G71;  
DT 01-DEC-2001 (TREMblrel. 19, Created)  
DT 01-DEC-2001 (TREMblrel. 19, Last sequence update)  
DT 01-MAR-2002 (TREMblrel. 20, Last annotation update)  
DE Neurotoxin type B.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
OX NCBI\_TaxID=1491;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=1436;  
RA Kima N., Ferreira J.L., Baumstark B.R.;  
RT "Characterization of six type A strains of Clostridium botulinum that  
contain type B toxin gene sequences."  
RL Submitted (Aug-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AF295926; AK97132.1;  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_Mtpeptidse.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRODOM: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
SQ SEQUENCE 1291 AA; 150824 MW; D7CA07BAE2B8CD2 CRC64;

Query Match 34.2%; Score 366.5; DB 2; Length 1291;  
Best Local Similarity 38.5%; Pred. No. 3.8e-19;  
Matches 85; Conservative 41; Mismatches 62; Indels 33; Gaps 3;

QY 1 IKVNMWDLFFSPEDNFNDLNKGEITSPTNIEAEENISLDLQYLYTFNFDNPE 60  
DB 447 IDVDNEDLFFADKNKSFSDLSKNRIAYNT-----QNNYITNDP-----S 487  
QY 61 ISIENTSSDITIGOLEL-----MPNIERPNGKKYELDKTYMFHYLRAOEF 106  
DB 488 INELLIDLTLSKIELPSENTESLDFNVYVPYVKQPAIKKLTEDNTIFQYLSQTF 547  
QY 107 HGSRIALTNSVNEALLNPSRVYTFPSSDYVKKNTAEAMFLGWEOLYVDFETDTS 166  
DB 548 LDIRDISLTSFDDALLFSNKVYSFESMDYIKTANKVVEAGLFAGWVKQIYNDVEIAN 607



OX NCBI\_TaxID=1491;  
 [1]  
 RN SEQUENCE FROM N.A.  
 RC STRAIN-EKUND 178 ATCC25765;  
 RX MEDLINE-9412659; PubMed-7764370;  
 RA Hutson R.A., Collins M.D., East A.K., Thompson D.E.;  
 RT "Nucleotide sequence of the gene coding for non-proteolytic  
 RT Clostridium botulinum type B neurotoxin: comparison with other  
 RT Clostridial neurotoxins."  
 RL Curr. Microbiol. 28:101-110(1994).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE THAT CLEAVES SYNAPOBREVIN-2.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N- AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: SECRETED.  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- SIMILARITY: HIGH WITH OTHER BOTULINUM NEUROTOXINS AND WITH TETANUS  
 CC NEUROTOXIN.  
 CC -1- SIMILARITY: TO OTHER ZINC METALLOPROTEINASES IN THE ACTIVE SITE  
 CC REGION.  
 CC EMBL: X71343; CA50482.1; -.  
 DR HSSP: P10845; 3B7A.  
 DR MEROPS: M27.002; -.  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_Mrpeptidase.  
 DR Pfam: PF01742; Peptidase\_M27; 1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR PRODOM: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
 DR Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; zinc.  
 SQ SEQUENCE 1291 AA; 150513 MW; 71BCAF23D69FAA CRC64;  
 Query Match 33.4%; Score 357.5; DB 2; Length 1291;  
 Best Local Similarity 38.5%; Pred. No. 1.8e-18;  
 Matches 85; Conservative 41; Mismatches 62; Indels 33; Gaps 4;  
 OY 1 IKVNMMDLFFSPSEDNFTNDLNKGEITSDTNEIAEENISLDLQOYYLTFNFPNEPN 60  
 DB 447 IDVDNENLFFADKNSFSDLSKNERVEXT-----QNNYIGDF--PIN 489  
 OY 61 ISIENLSSDIIGOLEL-----MNIERFPNGKKYELDKYTMFHYLRAQEF 106  
 DB 490 ELI--LDYDLISKRIELPSENTESLTFDENVDPVYEKQAPKVFIDENTIFQYLVSQTFP 547  
 OY 107 HGKSIATLNSVNEALNLPKRYTFFSSDYKVKVAKATEAMFLGWEOLYVDFDEFISE 166  
 DB 548 LNIKIDSLTSSFDALLVSSKYSFSSMDYKTKANKVVEAGLFAQWVKQIVDFVEIANK 607  
 OY 167 VSTDKIDIDITIIIPYIGPALNIGMNLKDDFVGLIFSGA 207  
 DB 608 SSTMDKIDISLIVPYIGLALNVGDEFTAKGNFESAPEIAGS 648  
 RESULT 9  
 O9ZAJ5 PRELIMINARY; PRT; 1280 AA.  
 AC O9ZAJ5.  
 DT 01-MAY-1999 (TREMBLrel. 10, Created)  
 DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)  
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)  
 DE Bont protein.  
 GN BONT.  
 OS Clostridium botulinum.  
 OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
 OC Clostridiales; Clostridiaceae; Clostridium.  
 OX NCBI\_TaxID=1491;

RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-CDC 3281;  
 RX MEDLINE-98440323; PubMed-9767710;  
 RA Santos-Buelga J., Collins M.D., East A.K.;  
 RT "Characterization of the genes encoding the Botulinum neurotoxin  
 RT complex in a strain of Clostridium botulinum producing type B & F  
 RT neurotoxins."  
 RL Curr. Microbiol. 37:312-318(1998).  
 DR EMBL: Y13631; CA473972.1; -.  
 DR HSSP: P10845; 3B7A.  
 DR MEROPS: M27.002; -.  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_Mrpeptidase.  
 DR Pfam: PF01742; Peptidase\_M27; 1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR PRODOM: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
 SQ SEQUENCE 1280 AA; 147487 MW; D0F748976BEC222C CRC64;  
 Query Match 32.4%; Score 347.5; DB 2; Length 1280;  
 Best Local Similarity 37.7%; Pred. No. 1e-17;  
 Matches 80; Conservative 50; Mismatches 69; Indels 13; Gaps 7;  
 OY 1 IKVNMMDLFFSPSEDNFTNDLNKGEITSDTNEIAEENISLDLQOYYLTFNFPNEPN 59  
 DB 446 IYNNKRELFFVASESSYNESEDINTPKELDTTNLNNNTR-NLD--EYILDYNSSETIQ 501  
 OY 60 NISIESSLSDIIGOLELMPNIEIRFPNG---KKYELDYTMFHYLRAQEFHGKSRIALT 115  
 DB 502 -ISNRTLWT-LVQDNSYVPRVD--SNGTSEIEEXDYVDFENFVFLHAQKVPGEINISLT 557  
 OY 116 NSVNEALLNPSKRYTFFSSDYKVKVAKATEAMFLGWEOLYVDTDETSEKSTDKAD 175  
 DB 558 SSIDALLSESKVYTFEFSSEFIDTINKPVNALFLDWMKSVIRDPTEATOKSTVDKAD 617  
 OY 176 ITIIPYIGPALNIGMNLKDDFVGLIFSGA 207  
 DB 618 ISLIVPYIGLALNIVYIEAKGNFEAPFELGA 649  
 RESULT 10  
 O9KW88 PRELIMINARY; PRT; 173 AA.  
 AC O9KW88.  
 DT 01-OCT-2000 (TREMBLrel. 15, Created)  
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)  
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)  
 DE Botulinum neurotoxin type E (Fragment).  
 GN BONT/E.  
 OS Clostridium botulinum.  
 OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
 OC Clostridiales; Clostridiaceae; Clostridium.  
 OX NCBI\_TaxID=1491;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-164-1;  
 RX MEDLINE-20575211; PubMed-11133447;  
 RA Kimura B., Kawasaki S., Nakano H., Fujii T.;  
 RT "Rapid, Quantitative PCR Monitoring of Growth of Clostridium botulinum  
 RT Type E in Modified-Atmosphere-Packaged Fish."  
 RL Appl. Environ. Microbiol. 67:206-216(2001).  
 DR EMBL: AB040128; BAB07890.2; -.  
 DR HSSP: P10845; 3B7A.  
 DR Neurotoxin.  
 GN Neurotoxin.  
 FT NON\_TER 1 1  
 FT NON\_TER 173 173  
 SQ SEQUENCE 173 AA; 19121 MW; 42F5822DE3B01F1F CRC64;  
 Query Match 31.1%; Score 333; DB 2; Length 173;  
 Best Local Similarity 35.7%; Pred. No. 1.1e-17;  
 Matches 71; Conservative 49; Mismatches 47; Indels 32; Gaps 5;



RA Kimura B., Kawasaki S., Nakano H., Fujii T.;  
RT "Type B, Quantitative PCR Monitoring of Growth of Clostridium botulinum  
RT Type B in Modified-Atmosphere-Packaged Fish."  
RL Appl. Environ. Microbiol. 67:206-216(2001).  
DR EMBL: AB040126; BAB07888.2; -;  
DR HSSP: P10845; 3BTA.  
KW Neurotoxin.

FT NON\_TER 1 1  
FT NON\_TER 173 173  
SQ SEQUENCE 173 AA; 19137 MW; 4178024F5BC4BF1F CRC64;

Query Match 30.8%; Score 330; DB 2; Length 173;  
Best Local Similarity 35.7%; Pred. No. 1.8e-17;  
Matches 71; Conservative 48; Mismatches 48; Indels 32; Gaps 5;

OY 13 SDNFNDLNKGEITSDNINFAA----EENISLDLQOYLTFNFDNENPISINSS 68  
DB 1 SNNNYENDL--DQVILNFNSESAPGLSDPKLNLITQNDAYIP-KYDS-----NGTS 48  
OY 69 DIIGOLELMPNIEFPGNGKYEIDKTYMFMHYLAQEFEGKSRIALTNGVNEALNPSRV 128  
DB 49 DI-----BOHDVNEINVFYIDAKVPEGENNVNLTSSIDRALLEQPKI 92  
OY 129 YTFSSDYVKVKNKATEAMFLGWVQOLVYDFTDETSEVSTDKIADITIIPIYIGPALN 188  
DB 93 YTFSSSEFINNVNKKPYQALFVGWIOQVLDFTTEANQESTVDKIADISIVPYKGLALN 152  
OY 189 IGNMLYKDDFVGALIFSGA 207  
DB 153 IGNEAKGNFKDALLELGA 171

RESULT 14  
O93N27 PRELIMINARY; PRT; 1310 AA.

AC O93N27;  
DT 01-DEC-2001 (TREMBlrel. 19, Created)  
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)  
DT 01-MAR-2002 (TREMBlrel. 20, Last annotation update)  
DE Tetanus toxin (Fragment).  
OS Clostridium tetani.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
OX NCBI\_TaxID=1513;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Shumin Z., Dianliang L.;  
RT "Cloning and sequence analysis of tetanus toxin gene."  
RT Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AF389424; AAK72964.2; -;  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR001064; Crystallin.  
DR InterPro: IPR000130; Zn\_MpPeptidase.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRODOM: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00225; CRYSTALLIN\_BETAGAMMA; UNKNOWN\_1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
FT NON\_TER 1 1  
FT NON\_TER 1310 1310  
SQ SEQUENCE 1310 AA; 150316 MW; 9EADDCC914418EA50 CRC64;

Query Match 29.3%; Score 314; DB 2; Length 1310;  
Best Local Similarity 33.2%; Pred. No. 3.4e-15;  
Matches 74; Conservative 44; Mismatches 67; Indels 38; Gaps 4;

OY 1 IKVNMNDLFSSSEDNFTDLNKGEEITSDNIEAENISLDLQOYLTFNFDNENPEN 60  
DB 469 IKIKNEDLFIKKNSEFSEPPDEIVSYNTKKNPLNFVYSLDKILDY----- 517  
OY 61 ISEINSSDIIGOLELMPNIEFPGNGK-----YELDKYMEHYLRQ 103  
DB 518 ----MLQSKI-----TLPNDRTTPYTKGIPVAPEKYSNAASTLEIHNDIDNTIYQYLAQ 568

OY 104 EFEGKSRIALTNGVNEALNPSRVYTFSSDYVKVKNKATEAMFLGWVQOLVYDFTDE 163  
DB 569 KSTTITQRTIMTNSVDDALLNSIKIXSYFP-SISKVNGAGQILFLQVNRDIDFTNE 627  
OY 164 TSEVSTTDKIADITIIPIYIGPALNIGNMLYKDDFVGALIFSG 206  
DB 628 SSQKTTIDKISDVSTIVPYIGPALNIVKQYEGNFGALETTG 670

RESULT 15  
O9LBR1 PRELIMINARY; PRT; 1285 AA.

AC O9LBR1;  
DT 01-OCT-2000 (TREMBlrel. 15, Created)  
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)  
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)  
DE Neurotoxin.  
GN NT.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
OX NCBI\_TaxID=1491;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=D-4947;  
RA Sagane Y., Watanabe T., Kouguchi H., Yamamoto T., Takizawa J.,  
RA Kawabe T., Murekami F., Muroga A., Nakatsuka M., Ohyana T.;  
RT "Characterization of the Progenitor Toxin Components Produced by  
RT Clostridium botulinum Type D Strain 4947."  
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AB037920; BAA90661.1; -;  
DR HSSP: P10845; 3BTA.  
DR MEROPS: M27.002; -;  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_MpPeptidase.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRINTS: PR00760; BONTOXILYSIN.  
DR PRODOM: PD001963; BONTOXILYSIN; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
SQ SEQUENCE 1285 AA; 147352 MW; B63AFA487D570680 CRC64;

Query Match 28.3%; Score 303.5; DB 2; Length 1285;  
Best Local Similarity 33.2%; Pred. No. 2e-14;  
Matches 72; Conservative 38; Mismatches 80; Indels 27; Gaps 4;

OY 1 IKVNMNDLFSSSEDNFTDLNKGEEITSDNIEAENISLDLQOYLTFNFDNENPEN 60  
DB 451 IOVKNNLTPLYVADKDSISOEIFESQITDETENVNSDNFSID---ESIIDAKVPTNPEA 507  
OY 61 ISEINSSDIIGOLELMPNIEFPGNGKYEIDKTYMFMHYLAQEFEGHK 109  
DB 508 VD-----PLLPVNMNEPLNVGPEEEVYDITRKVDVLYNSYYLLEKQKLSNV 555  
OY 110 SRIALTNGVNEALNPSRVYTFSSDYVKVKNKATEAMFLGWVQOLVYDFTDETSEVST 169  
DB 556 ENTTLTSVEALGYNKIKYTFELPS-LAKVKNGVAGALFLMNAANVDEFTTNINKKOT 614  
OY 170 TKDIADITIIPIYIGPALNIGNMLYKDDFVGALIFSG 206  
DB 615 LDKISDVSAIIPYIGPALNIGNSALGNFKQAFATAG 651

Search completed: March 13, 2003, 11:40:11  
Job time : 35.5202 secs

**THIS PAGE BLANK (USPTO)**



```

XX The present sequence represents a fragment of the Clostridium botulinum
CC neurotoxin (BoNT). It was produced by amplifying overlapping fragments
CC of the BoNT gene. The amplified fragments were cloned expressed to
CC identify immunogenic polypeptides which are capable of giving rise to
CC protective antibodies. The BoNT polypeptide fragment are useful as
CC vaccines, for immunizing against botulism, and as diagnostic agents
CC to identify protective antibodies.
XX
SQ Sequence 140 AA:

Query Match 100.0%; Score 727; DB 22; Length 140;
Best Local Similarity 100.0%; Pred. No. 1.2e-77;
Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LNSSLYRGTFRIKKYASGKNDIVRNDRYINVVYKKERYLATNASQAGYEKILSL 60
DB 1 LNSSLYRGTFRIKKYASGKNDIVRNDRYINVVYKKERYLATNASQAGYEKILSL 60
OY 61 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOFNNIAKLVA5MWYNR 120
DB 61 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOFNNIAKLVA5MWYNR 120
OY 121 QIERSSRTLCGSWEFTIPVD 140
DB 121 QIERSSRTLCGSWEFTIPVD 140

RESULT 2
AAV77144
ID AAV77144 standard; Protein; 206 AA.
XX
AC AAV77144;
XX
DT 08-MAY-2000 (first entry)
XX
DE Botulinum neurotoxin serotype A (BoNTA) C-terminal subfragment AsubHc2.
XX
KW Botulinum neurotoxin; heavy chain; BoNT; serotype A;
KW C-terminal subfragment; Hc; botulism; VEE;
KW Venezuelan equine encephalitis virus replicon; vaccine; diagnosis;
KW drug screening.
XX
OS Clostridium botulinum.
OS Synthetic.
XX
PN WO200002524-A2.
XX
PD 20-JAN-2000.
XX
PF 09-JUL-1999; 99WO-US15570.
XX
PR 10-JUL-1998; 98US-0092416.
XX
PR 12-MAY-1999; 99US-0133870.
XX
PA (USME-) US MEDICAL RES INST INFECTIOUS DISEASES.
XX
PI Lee JS, Pushko P, Smith JF, Parker M, Dertzbaugh MT, Smith L;
XX
XX MPI: 2000-160827/14.
XX
DR N-PSDB; AA287222.
XX
PT Novel Botulinum neurotoxin vaccine comprising a fragment from botulinum
PT toxin serotypes A-G, is used for inducing an immune response against
PT botulinum -
XX
PS Disclosure; Page 53; 54pp; English.
XX
CC The invention relates to novel vaccines that induce a protective immune
CC response against botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F
CC and G (BoNTA-BoNTG). The vaccine of the invention is novel recombinant
CC DNA construct comprising a vector, and at least one nucleic acid
CC fragment comprising a C-terminal heavy chain fragment (Hc) from BoNT

```

```

CC serotypes A-G. In preferred embodiments of the invention, the vector is a
CC Venezuelan equine encephalitis virus (VEE) replicon vector. Use of this
CC vector results in the production of large amounts of a protein encoded by
CC a sequence cloned into the replicon. The constructs are used to produce
CC vaccines against botulism. The proteins can also be used as diagnostic
CC tools for the diagnosis of botulism. The transformed host cells can be
CC used to analyse the effectiveness of drugs and agents which inhibit toxin
CC effects. The vaccine currently used against botulism is dangerous
CC and expensive to produce, and contains formalin, which is very painful
CC for the recipient. Also, the vaccine is incomplete, in that only 5 of
CC the 7 serotypes are represented in the formulation. The novel vaccine
CC overcomes these problems, as it is easily purified, and available in
CC large quantities. It is also expressed in the lymph nodes for a better
CC immune response. The present sequence represents BoNTA heavy chain
CC C-terminal subfragment AsubHc2, comprising residues 234 to 438 of the
CC BoNTA Hc fragment plus an initial methionine, and was used in the present
CC invention.
XX
SQ Sequence 206 AA:

Query Match 100.0%; Score 727; DB 21; Length 206;
Best Local Similarity 100.0%; Pred. No. 2.2e-77;
Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LNSSLYRGTFRIKKYASGKNDIVRNDRYINVVYKKERYLATNASQAGYEKILSL 60
DB 60 LNSSLYRGTFRIKKYASGKNDIVRNDRYINVVYKKERYLATNASQAGYEKILSL 119
OY 61 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOFNNIAKLVA5MWYNR 120
DB 120 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOFNNIAKLVA5MWYNR 179
OY 121 QIERSSRTLCGSWEFTIPVD 140
DB 180 QIERSSRTLCGSWEFTIPVD 199

RESULT 3
AAB36303
ID AAB36303 standard; Protein; 382 AA.
XX
AC AAB36303;
XX
DT 15-FEB-2001 (first entry)
XX
DE BoNT/A protoxin heavy chain C-terminal neural cell binding domain.
XX
KW Human; procholecystokinin; CCK A receptor; CCK B receptor;
KW pancreatitis; antiinflammatory.
XX
OS Clostridium botulinum.
XX
PN WO200061192-A2.
XX
PD 19-OCT-2000.
XX
PF 06-APR-2000; 2000WO-US09142.
XX
PR 08-APR-1999; 99US-0288326.
XX
PA (ALUR ) ALLERGAN SALES INC.
XX
PI Steward LE, Sachs G, Aoki KR;
XX
XX MPI: 2000-679416/66.
XX
PT New composition for treating acute pancreatitis, comprises a pancreatic
PT cell surface marker binding element, a translocation element that
PT transfers polypeptide across vesicular membrane, and a therapeutic
PT element -
XX
PS Example 1; Page 29; 50pp; English.
XX

```



CC The present invention describes a composition (I) for treating acute  
 CC pancreatitis. (I) comprises a first element containing a binding element  
 CC that binds to a pancreatic cell surface marker, a second element  
 CC containing a translocation element that facilitates polypeptide transfer  
 CC across the vesicular membrane, and a third element containing a  
 CC therapeutic element that inhibits enzyme secretion in pancreatic cell  
 CC cytoplasm. Also described is a method for making a therapeutic  
 CC polypeptide having a binding element selective for cholecystokinin (CCK)  
 CC receptor by expressing within a host cell a recombinant chimeric  
 CC polypeptide comprising an extein containing a therapeutic element and a  
 CC translocation element, and an intein located to the carboxy terminal  
 CC of extein having a cysteine, serine or threonine at its amino terminus,  
 CC and contacting the extein with a synthetic peptide comprising a CCK  
 CC amino acid sequence containing an amidated phenylalanine at a natural  
 CC C-terminus, and a cysteine, serine or threonine at its N-terminus, and  
 CC a nucleophilic reagent able to cause cleavage of the intein to form a  
 CC peptide bond between the extein C-terminus and synthetic peptide  
 CC N-terminus through the formation of an activated ester or thio ester  
 CC intermediate. (I) has antiinflammatory activity and prevents accumulation  
 CC of pancreatic digestive enzymes, and prevents exocytic fusion of vesicles  
 CC containing secretory enzymes of pancreas. (I) is useful for treating  
 CC acute pancreatitis. The present sequence represents the Clostridium  
 CC botulinum BONT/A prototoxin heavy chain C-terminal neural cell binding  
 CC domain, which is given in the exemplification of the present invention.  
 CC  
 XX SQ Sequence 382 AA:

Query Match 100.0%; Score 727; DB 21; Length 382;  
 Best Local Similarity 100.0%; Pred. No. 5.6e-77;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LNSSLYRGKFKFIKKYASGNKDNIVNRNRYTINVVYKKEVRLATNASOAGYEKLSAL 60  
 DB 236 LNSSLYRGKFKFIKKYASGNKDNIVNRNRYTINVVYKKEVRLATNASOAGYEKLSAL 295  
 OY 61 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNNGNDIGFIGHQFNNTAKLIVASWMYNR 120  
 DB 296 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNNGNDIGFIGHQFNNTAKLIVASWMYNR 355  
 OY 121 QIERSRRTIGCSWEFIPVD 140  
 DB 356 QIERSRRTIGCSWEFIPVD 375

## RESULT 4

ID AAB04083 standard; protein; 415 AA.

AC AAB04083;

DT 11-APR-2001 (first entry)

DE Botulinum toxin C fragment sequence (serotype A).

KW Botulinism; toxin; neurotoxin; heavy chain; recombinant expression;  
 KW recombinant vector; antigen; immune response; vaccine; bacterium;  
 KW infection.

OS Clostridium botulinum.

PN WO200067700-A2.

PD 16-NOV-2000.

PF 12-MAY-2000; 2000WO-US12890.

XX 12-MAY-1999; 99US-0133865.

PR 12-MAY-1999; 99US-0133866.

PR 12-MAY-1999; 99US-0133867.

PR 12-MAY-1999; 99US-0133868.

PR 12-MAY-1999; 99US-0133869.

PR 12-MAY-1999; 99US-0133873.

PR 29-JUL-1999; 99US-0146192.

XX (USSA ) US ARMY MEDICAL RES & MATERIAL COMMAND.  
 PA Smith LA, Byrne MP, Middlebrook JL, Lapenotiere H;  
 PI WPI: 2001-016048/02.

PT New nucleic acids encoding the carboxy- or amino-terminal portions of  
 PT the heavy chain of botulinum neurotoxin of serotype A-G, useful as  
 PT vaccine against botulinism

XX Example 7: Page 36; 73pp; English.

CC Botulin neurotoxins are translated as a single 150 kDa polypeptide  
 CC chain and then posttranslationally nicked, forming a dichain which  
 CC consisting of a 100 kDa heavy chain and a 50 kDa light chain which  
 CC remain linked by a disulfide bond. Nucleic acids encoding the  
 CC carboxy-terminal (HC) or amino-terminal (HN) portion of the heavy  
 CC chain of botulinum neurotoxin (BONT) can be used in recombinant  
 CC expression vectors and expressed in transformed cells to produce  
 CC peptide antigens useful for eliciting an immune response to give  
 CC protective immunity against botulinum neurotoxin, which causes  
 CC botulinism. The nucleic acids are expressible in a recombinant  
 CC organisms such as Escherichia coli or Pichia pastoris. The use  
 CC of recombinant nucleic acids are advantageous since it eliminates  
 CC the need to culture large quantities of hazardous toxin-producing  
 CC bacterium. Production yield from the genetically engineered product  
 CC is also high and cost of production is lower. The nucleic acids can  
 CC be derived from Clostridium botulinum serotypes A-G.

SQ Sequence 415 AA:

Query Match 100.0%; Score 727; DB 22; Length 415;  
 Best Local Similarity 100.0%; Pred. No. 6.3e-77;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LNSSLYRGKFKFIKKYASGNKDNIVNRNRYTINVVYKKEVRLATNASOAGYEKLSAL 60  
 DB 269 LNSSLYRGKFKFIKKYASGNKDNIVNRNRYTINVVYKKEVRLATNASOAGYEKLSAL 328  
 OY 61 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNNGNDIGFIGHQFNNTAKLIVASWMYNR 120  
 DB 329 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNNGNDIGFIGHQFNNTAKLIVASWMYNR 388  
 OY 121 QIERSRRTIGCSWEFIPVD 140  
 DB 389 QIERSRRTIGCSWEFIPVD 408

## RESULT 5

ID AAY77142 standard; protein; 432 AA.

AC AAY77142;

DT 08-MAY-2000 (first entry)

DE Native botulinum neurotoxin serotype A (BONTA) C-terminal fragment (HC).

KW Botulinum neurotoxin; heavy chain; BONT; serotype A;  
 KW C-terminal fragment; HC; Venezuelan equine encephalitis virus replicon;  
 KW VEE; botulinism; vaccine; diagnosis; drug screening.

OS Clostridium botulinum.

PN WO200002524-A2.

PD 20-JAN-2000.

XX Key Location/Qualifiers

XX FT Misc-difference 432

XX XX /note= "Apparently encoded by GCATGCGGAG AAAGGCCACT G"

```

XX PF 09-JUL-1999; 99WO-US15570.
XX PR 10-JUN-1998; 98US-0092416.
XX PR 12-MAY-1999; 99US-0133870.
XX PA (USME-) US MEDICAL RES INST INFECTIOUS DISEASES.
XX PI Lee JS, Pushko P, Smith JF, Parker M, Dertbaugh MT, Smith L;
XX DR WPI: 2000-160827/14.
XX DR N-PSDB; AAZ87220.
XX PT Novel Botulinum neurotoxin vaccine comprising a fragment from botulinum
PT toxin serotypes A-G, is used for inducing an immune response against
PT botulinum -
PS PS
PS XX Example 3; Page 52; 54pp; English.
CC CC The invention relates to novel vaccines that induce a protective immune
CC response against botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F
CC and G (BoNTA-BoNTG). The vaccine of the invention is novel recombinant
CC DNA construct comprising a vector, and at least one nucleic acid
CC fragment comprising a C-terminal heavy chain fragment (Hc) from BoNT
CC serotypes A-G. In preferred embodiments of the invention, the vector is a
CC Venezuelan equine encephalitis virus (VEE) replicon vector. Use of this
CC vector results in the production of large amounts of a protein encoded by
CC a sequence cloned into the replicon. The constructs are used to produce
CC vaccines against botulinism. The proteins can also be used as diagnostic
CC tools for the diagnosis of botulinism. The transformed host cells can be
CC used to analyse the effectiveness of drugs and agents which inhibit toxin
CC effects. The vaccine currently used against botulinism is dangerous
CC and expensive to produce, and contains formalin, which is very painful
CC for the recipient. Also, the vaccine is incomplete, in that only 5 of
CC the 7 serotypes are represented in the formulation. The novel vaccine
CC of overcomes these problems, as it is easily purified, and available in
CC large quantities. It is also expressed in the lymph nodes for a better
CC immune response. The present sequence represents the native BoNTA heavy
CC chain C-terminal fragment (Hc) used in an exemplification of the present
CC invention.
CC XX
SQ Sequence 432 AA;
Query Match 100.0%; Score 727; DB 21; Length 432;
Best Local Similarity 100.0%; Pred. No. 6.7e-77;
Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 INSSLYRGKFFIKKYASGNKDNIYRNNDRVYINVVKKREYRLATNAAQGEKLTSL 60
Db 292 IINSLLYRGKTFIKKYASNKNNDIYRNNDRVYINVVKKREYRLATNAAQGEKLTSL 351
OY 61 ELIPDVGNLSQVVVMKSKNDGITNCKNMALQNNNGNDIGFIFGHQFNNTAKLVASWMYNR 120
Db 352 ELIPDVGNLSQVVVMKSKNDGITNCKNMALQNNNGNDIGFIFGHQFNNTAKLVASWMYNR 411
OY 121 QIERSSRTLGCSWEFIPVD 140
Db 412 QIERSSRTLGCSWEFIPVD 431
RESULT 6
AAB04089
ID AAB04089 standard; Protein; 434 AA.
XX AC AAB04089;
XX DT 11-APR-2001 (first entry)
XX DE Botulinism toxin heavy chain C-terminal sequence (serotype A).
XX KW Botulinism; toxin; neurotoxin; heavy chain; recombinant expression;
XX recombinant vector; antigen; immune response; vaccine; bacterium;
XX infection.

```

OS	Synthetic.
OS	Clostridium botulinum.
XX	
PN	MO20067700-A2.
XX	
PD	16-NOV-2000.
PF	12-MAY-2000; 2000WO-US12890.
PR	
XX	12-MAY-1999; 99US-0133865.
PR	12-MAY-1999; 99US-0133866.
PR	12-MAY-1999; 99US-0133867.
PR	12-MAY-1999; 99US-0133868.
PR	12-MAY-1999; 99US-0133869.
PR	12-MAY-1999; 99US-0133873.
XX	29-JUL-1999; 99US-0146192.
PA	(USSA ) US ARMY MEDICAL RES & MATERIAL COMMAND.
XX	
PI	Smith LA, Byrne MP, Middlebrook JL, Lapenotiere H;
XX	
DR	WPI; 2001-016048/02.
DR	N-PSDB; AAA54483.
XX	
PT	New nucleic acids encoding the carboxy- or amino-terminal portions of
PT	the heavy chain of botulinum neurotoxin of serotype A-G, useful as
PT	vaccine against botulism
XX	
PS	Disclosure; Fig 2b; 73pp; English.
XX	
CC	Botulism neurotoxins are translated as a single 150 kDa polypeptide
CC	chain and then posttranslationally nicked, forming a dichain
CC	consisting of a 100 kDa heavy chain and a 50 kDa light chain which
CC	remain linked by a disulfide bond. Nucleic acids encoding the
CC	carboxy-terminal (HC) or amino-terminal (HN) portion of the heavy
CC	chain of botulinum neurotoxin (BoNT) can be used in recombinant
CC	expression vectors and expressed in transformed cells to produce
CC	peptide antigens useful for eliciting an immune response to give
CC	protective immunity against botulinum neurotoxin, which causes
CC	botulism. The nucleic acids are expressible in a recombinant
CC	organisms such as Escherichia coli or Pichia pastoris. The use
CC	of recombinant nucleic acids are advantageous since it eliminates
CC	the need to culture large quantities of hazardous toxin-producing
CC	bacterium. Production yield from the genetically engineered product
CC	is also high and cost of production is lower. The nucleic acids can
CC	be derived from Clostridium botulinum serotypes A-G.
XX	
SO	Sequence 434 AA:
Query Match	100.0%; Score 727; DB 22; Length 434;
Best Local Similarity	100.0%; Pred. No. 6,7e-77;
Matches 140; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
OY	1 UNSSYLRCGRKFLIKKYASGNKDNIYRNRDRIYINVVKKKEVRLATMNSQAVEKITLSAL 60
DB	288 UNSSYLRCGRKFLIKKYASGNKDNIYRNRDRIYINVVKKKEVRLATMNSQAVEKITLSAL 347
OY	61 ETPDVGNLSQVVMKSKNDGITNCKKNMLQDNNGNDIGFIFGHFPNNIAKLVASNWYNR 120
DB	348 ETPDVGNLSQVVMKSKNDGITNCKKNMLQDNNGNDIGFIFGHFPNNIAKLVASNWYNR 407
OY	121 QIERSSRTLGCSEWFIPYDD 140
DB	408 QIERSSRTLGCSEWFIPYDD 427
RESULT 7	:
AAB04090	
ID	AAB04090 standard; Protein: 435 AA.
XX	
AC	AAB04090; :
XX	
DT	11-APR-2001 (first entry)

XX Botulism toxin heavy chain C-terminal sequence (serotype A).  
 DE AAB04088  
 XX ID AAB04088 standard; Protein; 437 AA.  
 KW Botulism; toxin; neurotoxin; heavy chain; recombinant expression;  
 KM recombinant vector; antigen; immune response; vaccine; bacterium;  
 XX infection.  
 XX Synthetic.  
 OS Clostridium botulinum.  
 XX WO200067700-A2.  
 PN 16-NOV-2000.  
 XX 12-MAY-2000; 2000WO-US12890.  
 PF 12-MAY-1999; 99US-0133865.  
 XX 12-MAY-1999; 99US-0133866.  
 PR 12-MAY-1999; 99US-0133867.  
 XX 12-MAY-1999; 99US-0133868.  
 PR 12-MAY-1999; 99US-0133869.  
 XX 12-MAY-1999; 99US-0133870.  
 PR 12-MAY-1999; 99US-0133871.  
 XX 29-JUL-1999; 99US-0146192.  
 PR (USSA ) US ARMY MEDICAL RES & MATERIAL COMMAND.  
 PA Smith LA, Byrne MP, Middlebrook JL, Lapenotiere H;  
 XX WPI: 2001-016048/02.  
 DR N-PSDB; AAA54484.  
 XX New nucleic acids encoding the carboxy- or amino-terminal portions of  
 PT the heavy chain of botulinum neurotoxin of serotype A-G, useful as  
 PT vaccine against botulism  
 XX Disclosure: Fig 3b; 73pp; English.  
 PS Botulism neurotoxins are translated as a single 150 kDa polypeptide  
 CC chain and then posttranslationally nicked, forming a dichain  
 CC consisting of a 100 kDa heavy chain and a 50 kDa light chain which  
 CC remain linked by a disulfide bond. Nucleic acids encoding the  
 CC carboxy-terminal (HC) or amino-terminal (HN) portion of the heavy  
 CC chain of botulinum neurotoxin (BoNT) can be used in recombinant  
 CC expression vectors and expressed in transformed cells to produce  
 CC protective antigens useful for eliciting an immune response to give  
 CC botulism. The nucleic acids are expressible in a recombinant  
 CC organisms such as Escherichia coli or Pichia pastoris. The use  
 CC of recombinant nucleic acids are advantageous since it eliminates  
 CC the need to culture large quantities of hazardous toxin-producing  
 CC bacterium. Production yield from the genetically engineered product  
 CC is also high and cost of production is lower. The nucleic acids can  
 CC be derived from Clostridium botulinum serotypes A-G.  
 XX Sequence 435 AA;  
 SQ  
 Query Match 100.0%; Score 727; DB 22; Length 435;  
 Best Local Similarity 100.0%; Pred. No. 6.8e-77;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 8  
 AAB04088  
 ID AAB04088 standard; Protein; 437 AA.  
 KW Botulism; toxin; neurotoxin; heavy chain; recombinant expression;  
 KM recombinant vector; antigen; immune response; vaccine; bacterium;  
 XX infection.  
 XX Synthetic.  
 OS Clostridium botulinum.  
 XX WO200067700-A2.  
 PN 16-NOV-2000.  
 XX 12-MAY-2000; 2000WO-US12890.  
 PF 12-MAY-1999; 99US-0133865.  
 XX 12-MAY-1999; 99US-0133866.  
 PR 12-MAY-1999; 99US-0133867.  
 XX 12-MAY-1999; 99US-0133868.  
 PR 12-MAY-1999; 99US-0133869.  
 XX 12-MAY-1999; 99US-0133870.  
 PR 29-JUL-1999; 99US-0146192.  
 XX (USSA ) US ARMY MEDICAL RES & MATERIAL COMMAND.  
 PA Smith LA, Byrne MP, Middlebrook JL, Lapenotiere H;  
 XX WPI: 2001-016048/02.  
 DR N-PSDB; AAA54482.  
 XX New nucleic acids encoding the carboxy- or amino-terminal portions of  
 PT the heavy chain of botulinum neurotoxin of serotype A-G, useful as  
 PT vaccine against botulism  
 XX Claim 3; Fig 1b; 73pp; English.  
 PS Botulism neurotoxins are translated as a single 150 kDa polypeptide  
 CC chain and then posttranslationally nicked, forming a dichain  
 CC consisting of a 100 kDa heavy chain and a 50 kDa light chain which  
 CC remain linked by a disulfide bond. Nucleic acids encoding the  
 CC carboxy-terminal (HC) or amino-terminal (HN) portion of the heavy  
 CC chain of botulinum neurotoxin (BoNT) can be used in recombinant  
 CC expression vectors and expressed in transformed cells to produce  
 CC peptide antigens useful for eliciting an immune response to give  
 CC protective immunity against botulinum neurotoxin, which causes  
 CC botulism. The nucleic acids are expressible in a recombinant  
 CC organisms such as Escherichia coli or Pichia pastoris. The use  
 CC of recombinant nucleic acids are advantageous since it eliminates  
 CC the need to culture large quantities of hazardous toxin-producing  
 CC bacterium. Production yield from the genetically engineered product  
 CC is also high and cost of production is lower. The nucleic acids can  
 CC be derived from Clostridium botulinum serotypes A-G.  
 XX Sequence 437 AA;  
 SQ  
 Query Match 100.0%; Score 727; DB 22; Length 437;  
 Best Local Similarity 100.0%; Pred. No. 6.8e-77;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 351 EIPDVGNLSQVVMKSKNDGITNKCKMNLQDNNNGNDIGFIGHQFNNTAKLIVASMWYNR 410  
 OY 121 QIERSSRTLGCSEWFIIPVD 140  
 DB 411 QIERSSRTLGCSEWFIIPVD 430

RESULT 9  
 AAR95008  
 ID AAR95008 standard; Protein; 438 AA.

XX AAR95008;  
 XX  
 DT 07-JUL-1996 (first entry)  
 XX  
 DE Type A neurotoxin C fragment.

XX Toxin; neurotoxin; fusion protein; antitoxin; vaccine; immunogen;  
 KW Clostridium botulinum.

XX Synthetic.

OS  
 PN WO9612802-A1.

XX  
 PD 02-MAY-1996.

XX  
 PF 23-OCT-1995; 95WO-US13737.

XX  
 PR 07-JUN-1995; 95US-0480604.

XX  
 PR 24-OCT-1994; 94US-0329154.

XX  
 PR 16-MAR-1995; 95US-0405496.

XX  
 PR 14-APR-1995; 95US-0422711.

XX  
 PA (OPHT-) OPHIDIAN PHARM INC.

XX  
 PI Pirca JR, Kink JA, Padhye NV, Stafford DC, Thalley BS;

XX  
 PI Williams JA;

XX  
 DR WPI: 1996-230603/23.

XX  
 DR N-PSDB; AAT9245.

XX  
 PT Fusion proteins comprising non-toxin protein and part of toxin -

XX  
 PT useful to form anti-toxins against Clostridium botulinum type A, and

XX  
 PT C. difficile type toxins, and to treat C. difficile intoxication,

XX  
 PT paritc. diarrhoea

XX  
 PS Claim 5; Page 336-38; 434pp; English.

XX  
 CC The heavy chain C fragment (AAR95008) of Clostridium botulinum type

XX  
 CC A neurotoxin (see also AAR95010) was produced by expression of a

XX  
 CC synthetic gene (AAT9245) in Escherichia coli. The C fragment

XX  
 CC comprises the C-terminal portion of the type A neurotoxin heavy

XX  
 CC chain. It is pref. produced as a fusion protein with a

XX  
 CC polyhistidine affinity tag or maltose binding protein, and is

XX  
 CC used to produce avian antitoxin against C. botulinum type A

XX  
 CC or as an immunogen in vaccine compsns. (see also AAR95009).

OY Sequence 438 AA:  
 SQ

Query Match 100.0%; Score 727; DB 17; Length 438;  
 Best Local Similarity 100.0%; Pred. No. 6.8e-77;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 412 QIERSSRTLGCSEWFIIPVD 431

RESULT 10  
 AAW68389  
 ID AAW68389 standard; Protein; 438 AA.

XX AAW68389;  
 XX  
 DT 07-DEC-1998 (first entry)

XX Clostridium botulinum toxin A fragment C.

XX Antitoxin; vaccine; neurotoxin; toxin A; intoxication; immunogen;

KW botulism.

XX Clostridium botulinum serotype A.

OS Key Location/Qualifiers

XX FT Misc-difference 1..2

XX FT note="vector-derived amino acid residues"

XX PN WO9808540-A1.

XX  
 PD 05-MAR-1998.

XX  
 PF 28-AUG-1997; 97WO-US15394.

XX  
 PR 28-AUG-1996; 96US-0704159.

XX  
 PA (OPHT-) OPHIDIAN PHARM INC.;

XX  
 PI Thalley BS, Williams JA;

XX  
 DR WPI: 1998-230234/20.

XX  
 DR N-PSDB; AAV30571.

XX  
 PT Host cell containing recombinant expression vector encoding

XX  
 PT Clostridium botulinum type B or E toxin - useful to treat humans

XX  
 PT and other animals at risk of intoxication with clostridial toxin

XX  
 PS Example 22; Page 262-263; 428pp; English.

XX  
 CC This is the amino acid sequence of Clostridium botulinum serotype A

XX  
 CC toxin C-fragment expressed by a DNA sequence (see AAV30571) in plasmid

XX  
 CC PalterBot. Recombinant C-fragment proteins have been produced in

XX  
 CC Escherichia coli as fusion proteins with either maltose binding

XX  
 CC protein or Clostridium difficile type A toxin (see AAW68387). The

XX  
 CC invention relates to recombinant proteins derived from C. botulinum

XX  
 CC toxins. Methods are provided which allow for the isolation of

XX  
 CC soluble recombinant toxin proteins free of significant endotoxin

XX  
 CC contamination. Preferred hosts for production of the recombinant

XX  
 CC proteins are E. coli, insect cells and yeast cells. The recombinant

XX  
 CC toxin proteins are used as immunogens for the production of vaccines

XX  
 CC and antitoxins that are useful in the treatment of humans and

XX  
 CC animals at risk of intoxication with clostridial toxin.

OY Sequence 438 AA:  
 SQ

Query Match 100.0%; Score 727; DB 19; Length 438;  
 Best Local Similarity 100.0%; Pred. No. 6.8e-77;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 412 QIERSRRTLGCSWEFIIPVD 431

# RESULT 11

ID AAY77134 standard; Protein; 438 AA.

XX AAY77134;

DT 08-MAY-2000 (first entry)

XX Synthetic botulinum neurotoxin serotype A (BoNTA) C-terminal fragment.

DE Botulinum neurotoxin; heavy chain; BoNT; serotype A;

KM C-terminal fragment; Venezuelan equine encephalitis virus replicon;

XX VEE; botulism; vaccine; diagnosis; drug screening.

OS Clostridium botulinum.

XX Synthetic.

PN WO200002524-A2.

XX 20-JAN-2000.

XX 09-JUL-1999; 99WO-US15570.

XX 10-JUL-1998; 98US-0092416.

PR 12-MAY-1999; 99US-0133870.

XX (USME-) US MEDICAL RES INST INFECTIOUS DISEASES.

XX Lee JS, Pushko P, Smith JF, Parker M, Dertzbaugh MT, Smith L;

XX WPI: 2000-160827/14.

DR N-PSDB; AA87212.

XX Novel Botulinum neurotoxin vaccine comprising a fragment from botulinum

PT toxin serotypes A-G, is used for inducing an immune response against

PR botulinum -

XX Claim 22; Page 54; 54pp; English.

XX The invention relates to novel vaccines that induce a protective immune

CC response against botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F

CC and G (BoNTA-BoNTG). The vaccine of the invention is novel recombinant

CC DNA construct comprising a vector, and at least one nucleic acid

CC fragment comprising a C-terminal heavy chain fragment (Hc) from BoNT

CC serotypes A-G. In preferred embodiments of the invention, the vector is

CC a Venezuelan equine encephalitis virus (VEE) replicon vector. Use of

CC this vector results in the production of large amounts of a protein

CC encoded by a sequence cloned into the replicon. The constructs are used

CC to produce vaccines against botulism. The proteins can also be used as

CC diagnostic tools for the diagnosis of botulism. The transformed host

CC cells can be used to analyse the effectiveness of drugs and agents which

CC inhibit toxin effects. The vaccine currently used against botulism is

CC dangerous and expensive to produce, and contains formalin, which is very

CC painful for the recipient. Also, the vaccine is incomplete, in that only

CC 5 of the 7 serotypes are represented in the formulation. The novel

CC vaccine of overcomes these problems, as it is easily purified, and

CC available in large quantities. It is also expressed in the lymph nodes

CC for a better immune response. Sequences AAY77134-Y77139 represent

CC synthetic BoNT Hc fragments used in the present invention. The DNA

CC encoding these sequences had been optimised for codon usage for

CC expression in yeast.

XX Sequence 438 AA:

SO

Query Match 100.0%; Score 727; DB 21; Length 438;

Best Local Similarity 100.0%; Pred. No. 6,8e-77;

Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LNSSLYRGTKFLIKKRYASGNKNDIVRNDRVYINVVKNKKEYRLATNASQAGVEKILSAL 60

|||||

Db 292 LNSSLYRGTKFLIKKRYASGNKNDIVRNDRVYINVVKNKKEYRLATNASQAGVEKILSAL 351

OY 61 EIPDVGNTLSOVVYMKSKNOGITNKKMNLQDNNGNDIGFIGHQHNNTAKLVASWYNR 120

Db 352 EIPDVGNTLSOVVYMKSKNOGITNKKMNLQDNNGNDIGFIGHQHNNTAKLVASWYNR 411

OY 121 QIERSRRTLGCSWEFIIPVD 140

Db 412 QIERSRRTLGCSWEFIIPVD 431

# RESULT 12

AAW68391

XX AAW68391 standard; Protein; 445 AA.

AC AAW68391;

DT 07-DEC-1998 (first entry)

XX Clostridium botulinum toxin A fragment C (His-tagged).

DE Clostridium botulinum toxin A fragment C (His-tagged).

XX Antitoxin; vaccine; neurotoxin; toxin A; intoxication; immunogen;

KM botulism.

XX Clostridium botulinum serotype A.

OS Synthetic.

XX key

FT Location/Qualifiers

FT Peptide 1..7

XX /note="N-terminal histidine tag"

XX W09808540-A1.

XX 05-MAR-1998.

XX 28-AUG-1997; 97WO-US15394.

XX 28-AUG-1996; 96US-0704159.

XX (OPHI-) OPHIDIAN PHARM INC.

XX Thalley BS, Williams JA;

XX WPI: 1998-230234/20.

DR N-PSDB; AAW30576.

XX Host cell containing recombinant expression vector encoding

PT Clostridium botulinum type B or E toxin - useful to treat humans

PR and other animals at risk of intoxication with clostridial toxin

XX Example 29; Page 279-281; 428pp; English.

XX This is the amino acid sequence of a histidine-tagged fragment C

CC polypeptide of Clostridium botulinum serotype A toxin encoded by a

CC DNA sequence (see AAW30576) in plasmid pHisBot(syn). This vector

CC was used to express native soluble C fragment in *Escherichia coli*

CC host cells, with the recombinant C fragment being purified on a

CC poly-histidine binding affinity resin. The invention relates

CC to recombinant proteins derived from C. botulinum toxins. Methods

CC are provided which allow the isolation of soluble recombinant

CC proteins that are free of significant endotoxin contamination.

CC Preferred hosts for production of recombinant proteins are *E. coli*,

CC insect cells and yeast cells. The recombinant toxins are used as

CC immunogens for the production of vaccines and antitoxins that are

CC useful in the treatment of humans and animals at risk of

CC intoxication with clostridial toxin.

XX Sequence 445 AA:

SO

Query Match 100.0%; Score 727; DB 19; Length 445;

Best Local Similarity 100.0%; Pred. No. 7e-77;

Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LNSSLYRGTFEIIKKYASGKNKDNIVRNNDRVYINVVYKNEYRLATNASQAGVEKILISAL 60  
 DB 299 LNSSLYRGTFEIIKKYASGKNKDNIVRNNDRVYINVVYKNEYRLATNASQAGVEKILISAL 358  
 QY 61 EIPDVGNLSQVYVWYKSKNDGKITNCKKMNLDNNNGNDIGTGFHFQFNNAIKLVASMMYNR 120  
 DB 359 EIPDVGNLSQVYVWYKSKNDGKITNCKKMNLDNNNGNDIGTGFHFQFNNAIKLVASMMYNR 418  
 QY 121 QIERSSRTLGCSEFEIPYVD 140  
 DB 419 QIERSSRTLGCSEFEIPYVD 438

## RESULT 13

AAR95009 standard; Protein; 462 AA.

AAR95009;

07-JUL-1996 (first entry)

Type A neurotoxin C fragment-polyhistidine tag fusion phisBot.

Toxin; neurotoxin; fusion protein; antitoxin; vaccine; immunogen;  
 Clostridium botulinum; polyhistidine; vector; PETHisa; phisBot.

Synthetic.

Location/Qualifiers

Key 1..21  
 Peptide /label= Polyhistidine\_tag  
 FT 22..462  
 FT /label= C-fragment

MO9612802-A1.

02-MAY-1996.

23-OCT-1995; 95WO-US13737.

07-JUN-1995; 95US-0480604.

24-OCT-1994; 94US-0329154.

16-MAR-1995; 95US-0405496.

14-APR-1995; 95US-0422711.

(OPHI-) OPHIDIAN PHARM INC.

Thalley BS, Williams JA;

WPI; 1996-230603/23.

N-PADB; AAT29246.

Fusion proteins comprising non-toxin protein and part of toxin

useful to form anti-toxins against Clostridium botulinum type A, and

C. difficile type toxins, and to treat C. difficile intoxication,

partic. diarrhoea

Claim 7; Page 340-342; 434pp. English.

phisBot fusion protein (AAR95009), the product of a nucleotide

sequence (AAT29246) in vector PETHisa, comprises a polyhistidine

affinity tag and fragment C (see also AAR95008) of the Clostridium

botulinum type A neurotoxin. The phisBot protein was expressed

in Escherichia coli as a soluble protein and was purified by

metal chelate affinity chromatography to obtain a product free

of endotoxin contamination that may be useful as an immunogen

in vaccine compsns.

Sequence 462 AA;

Query Match 100.0%; Score 727; DB 17; Length 462;

Best Local Similarity 100.0%; Pred. No. 7.4e-77;

Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 LNSSLYRGTFEIIKKYASGKNKDNIVRNNDRVYINVVYKNEYRLATNASQAGVEKILISAL 60  
 DB 316 LNSSLYRGTFEIIKKYASGKNKDNIVRNNDRVYINVVYKNEYRLATNASQAGVEKILISAL 375  
 QY 61 EIPDVGNLSQVYVWYKSKNDGKITNCKKMNLDNNNGNDIGTGFHFQFNNAIKLVASMMYNR 120  
 DB 376 EIPDVGNLSQVYVWYKSKNDGKITNCKKMNLDNNNGNDIGTGFHFQFNNAIKLVASMMYNR 435  
 QY 121 QIERSSRTLGCSEFEIPYVD 140  
 DB 436 QIERSSRTLGCSEFEIPYVD 455

## RESULT 14

AAM68390 standard; Protein; 462 AA.

AAM68390;

07-DEC-1998 (first entry)

Clostridium botulinum toxin A fragment C (His-tagged).

Antitoxin; vaccine; neurotoxin; toxin A; intoxication; immunogen;  
 botulism.

Clostridium botulinum serotype A.

Synthetic.

Location/Qualifiers

Key 1..21  
 Peptide /note= "N-terminal histidine tag"

MO9808540-A1.

05-MAR-1998.

28-AUG-1997; 97WO-US15394.

28-AUG-1996; 96US-0704159.

(OPHI-) OPHIDIAN PHARM INC.

Thalley BS, Williams JA;

WPI; 1998-230234/20.

N-PADB; AAV30572 and AAV30575.

Host cell containing recombinant expression vector encoding

Clostridium botulinum type B or E toxin - useful to treat humans

and other animals at risk of intoxication with clostridial toxin

Example 24; Page 265-267; 428pp. English.

This is the amino acid sequence of a histidine-tagged fragment C

polypeptide of Clostridium botulinum serotype A toxin encoded by a

DNA sequence (see AAV30572) in plasmid phisBot, and by a DNA sequence

(see AAV30575) in phisBOTA. These vectors were used to express

native (i.e. non-fusion) soluble C fragment in Escherichia coli

host cells, with the recombinant C fragment being purified on a

poly-histidine binding affinity resin. The invention relates

to recombinant proteins derived from C. botulinum toxins. Methods

are provided which allow the isolation of soluble recombinant

proteins that are free of significant endotoxin contamination.

Preferred hosts for production of recombinant proteins are E. coli,

insect cells and yeast cells. The recombinant toxins are used as

immunogens for the production of vaccines and antitoxins that are

useful in the treatment of humans and animals at risk of

intoxication with clostridial toxin.

Sequence 462 AA;

Query Match 100.0%; Score 727; DB 17; Length 462;

Best Local Similarity 100.0%; Pred. No. 7.4e-77;

Query Match 100.0%; Score 727; DB 19; Length 462;  
 Best Local Similarity 100.0%; Pred. No. 7.4e-77;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LNSSLYRGKFTIKKAYASGNKDNIVRNDRYINVVYKKEKRLATNASOAGYEKILSL 60  
 DB 316 LNSSLYRGKFTIKKAYASGNKDNIVRNDRYINVVYKKEKRLATNASOAGYEKILSL 375

QY 61 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOPNNIAKLVAASWYNR 120  
 DB 376 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOPNNIAKLVAASWYNR 435

QY 121 QIERSSRTLGCSEWEIFPVD 140  
 DB 436 QIERSSRTLGCSEWEIFPVD 455

RESULT 15  
 AAY77140  
 ID AAY77140 standard; Protein; 837 AA.

AC AAY77140;  
 DT 08-MAY-2000 (first entry)  
 DE Native botulinum neurotoxin serotype A (BoNTA).  
 KM Botulinum neurotoxin; heavy chain; BoNT; serotype A;  
 KW Venezuelan equine encephalitis virus replicon;  
 VEE; botulism; vaccine; diagnosis; drug screening.  
 OS Clostridium botulinum.

EH Key Location/Qualifiers  
 FT Misc-difference 837 /note="Apparently encoded by GGATGGGAG AAAGCCACT G"  
 XX

MO200002524-A2.  
 PD 20-JAN-2000.  
 PF 09-JUL-1999; 99WO-US15570.  
 PR 10-JUL-1998; 98US-0092416.  
 PR 12-MAY-1999; 99US-0133870.  
 XX (USME-) US MEDICAL RES INST INFECTIOUS DISEASES.  
 PA  
 XX Lee JS, Pushko P, Smith JF, Parker M, Dertzbaugh MT, Smith L;  
 PI WPT. 2000-160827/14.  
 DR N-PSDB; AA87218.  
 XX Novel Botulinum neurotoxin vaccine comprising a fragment from botulinum  
 PT toxin serotypes A-G, is used for inducing an immune response against  
 PT botulinum -  
 XX  
 PS Example 3; Page 49; 54pp; English.  
 XX

CC The invention relates to novel vaccines that induce a protective immune  
 CC response against botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F  
 CC and G (BoNTA-BoNTG). The vaccine of the invention is novel recombinant  
 CC DNA construct comprising a vector, and at least one nucleic acid  
 CC fragment comprising a C-terminal heavy chain fragment (Hc) from BoNT  
 CC serotypes A-G. In preferred embodiments of the invention, the vector is a  
 CC Venezuelan equine encephalitis virus (VEE) replicon vector. Use of this  
 CC vector results in the production of large amounts of a protein encoded by  
 CC a sequence cloned into the replicon. The constructs are used to produce  
 CC vaccines against botulism. The proteins can also be used as diagnostic  
 CC tools for the diagnosis of botulism. The transformed host cells can be  
 CC used to analyse the effectiveness of drugs and agents which inhibit toxin  
 CC effects. The vaccine currently used against botulism is dangerous

CC and expensive to produce, and contains formalin, which is very painful  
 CC for the recipient. Also, the vaccine is incomplete, in that only 5 of  
 CC the 7 serotypes are represented in the formulation. The novel vaccine  
 CC of overcomes these problems, as it is easily purified, and available in  
 CC large quantities. It is also expressed in the lymph nodes for a better  
 CC immune response. The present sequence represents the native BoNTA heavy  
 CC chain used in an exemplification of the present invention.

SQ Sequence 837 AA:

Query Match 100.0%; Score 727; DB 21; Length 837;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-76;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LNSSLYRGKFTIKKAYASGNKDNIVRNDRYINVVYKKEKRLATNASOAGYEKILSL 60  
 DB 697 LNSSLYRGKFTIKKAYASGNKDNIVRNDRYINVVYKKEKRLATNASOAGYEKILSL 756

QY 61 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOPNNIAKLVAASWYNR 120  
 DB 757 EIPDVGNLSQVYVYMKSKNDGITNKCKMNLQDNGNDIGFIGHOPNNIAKLVAASWYNR 816

QY 121 QIERSSRTLGCSEWEIFPVD 140  
 DB 817 QIERSSRTLGCSEWEIFPVD 836

Search completed: March 13, 2003, 11:39:09  
 Job time : 26.2248 secs

**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.4.p5\_4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 13, 2003, 11:36:37 ; Search time 6.4553 Seconds

(without alignments)  
899.518 Million cell updates/sec

Title: US-09-917-791-22

Perfect score: 727

Sequence: 1 LNSSLYRGTKEFIKKYASGN.....OIERSSRTLCGSMFEIPYDD 140

Scoring table: BIOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_40.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	727	100.0	1295	1 BXA1_CLOBO	P10845 clostridium
2	671	92.3	1295	1 BXA2_CLOBO	Q45894 clostridium
3	258.5	35.6	1274	1 BXF_CLOBO	P30996 clostridium
4	199	27.4	1250	1 BXE_CLOBO	Q00496 clostridium
5	190	26.1	1250	1 BXE_CLOBO	P30995 clostridium
6	165.5	22.8	1290	1 BXH_CLOBO	P10844 clostridium
7	163	22.4	1314	1 TERX_CLOBO	P04958 clostridium
8	158.5	21.8	1296	1 BXG_CLOBO	Q60393 clostridium
9	100	13.8	1290	1 BXC1_CLOBO	P18640 clostridium
10	88.5	12.2	264	1 MURI_FUSNN	O87666 fusobacteri
11	79.5	10.9	1786	1 YCF1_ARATH	P56785 arabidopsis
12	79	10.9	765	1 Y008_HUMAN	Q15398 homo sapien
13	75	10.3	720	1 WGC_ECOLI	P76387 escherichia
14	74	10.2	1276	1 BXD_CLOBO	P19321 clostridium
15	73.5	10.1	682	1 NISP_LACIA	Q07596 lactococcus
16	73	10.0	556	1 MUTL_SYNY3	P73349 synechocyst
17	73	10.0	573	1 TLPC_BACSU	P33209 bacillus su
18	73	10.0	720	1 WGC_ECO57	O84719 escherichia
19	72.5	10.0	875	1 ZIPL_YEAST	P31111 saccharomyc
20	72	9.9	1177	1 Y307_MYCGB	P45749 mycoplasma
21	71.5	9.8	399	1 LODC_BUCAI	P57382 buchnera ap
22	71.5	9.8	721	1 PRTP_HSVJ1	P52385 human herpe
23	71.5	9.8	735	1 CIGB_DICDI	O94481 dictyosteli
24	71.5	9.8	1076	1 RPOB_ASTIO	P27059 astasia ion
25	71.5	9.8	1744	1 TMAA_XENIA	Q01550 xenopus lae
26	71.5	9.8	2339	1 RPCI_PLANA	P27625 plasmodium
27	71	9.8	266	1 TERM_BPPI2	P57306 buchnera ap
28	71	9.8	353	1 RPOA_MYCSP	P38018 mycoplasma
29	71	9.8	445	1 IT2A_MOUSE	P15091 mus musculu
30	71	9.8	445	1 IT2B_MOUSE	O91002 mus musculu
31	71	9.8	542	1 V155_FOWPV	O915a7 fowlpox vir
32	71	9.8	3079	1 IRA2_YEAST	P19158 saccharomyc
33	71	9.8			

## ALIGNMENTS

RESULT 1	ID	Sequence	Standard	PRT: 1295 AA.
AC	BXA1_CLOBO	P10845; P18639; P01561;		
DT	01-JUL-1988 (Rel. 11, Created)			
DT	01-JUL-1993 (Rel. 26, Last sequence update)			
DT	15-JUN-2002 (Rel. 41, Last annotation update)			
DE	Botulinum neurotoxin type A precursor (EC 3.4.24.69) (BONT/A)			
DE	chain; Botulinum neurotoxin A, heavy-chain).			
GN	BOTA OR BNA OR ATX.			
OS	Clostridium botulinum.			
OC	Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;			
OX	Clostridium.			
RN	[1]			
RE	SEQUENCE FROM N.A.			
RE	STRAIN=NCCT 2916;			
RE	MEDLINE=90235864; PubMed=2185020;			
RA	Thompson D.E., Brehm J.K., Oultram J.D., Swinfield T.-J.,			
RA	Shone C.C., Atkinson T., Mellington J., Milton N.P.;			
RT	"The complete amino acid sequence of the Clostridium botulinum type A			
RT	neurotoxin, deduced by nucleotide sequence analysis of the encoding			
RT	gene.";			
RT	Eur. J. Biochem. 189:73-81(1990).			
RE	[2]			
RE	SEQUENCE FROM N.A.			
RE	STRAIN=62A.			
RE	MEDLINE=90264400; PubMed=2160960;			
RA	Bhaz B., Kuatzone H., Wille M., Frevent J., Wernars K., Niemann H.;			
RT	"The complete sequence of botulinum neurotoxin type A and comparison			
RT	with other clostridial neurotoxins.";			
RT	J. Biol. Chem. 265:9153-9158(1990).			
RN	[3]			
RE	SEQUENCE OF 1-65 FROM N.A.			
RE	STRAIN=62A.			
RE	MEDLINE=97016817; PubMed=8863443;			
RA	East A.K., Bhandari M., Stacey J.M., Campbell K.D., Collins M.D.;			
RT	"Organization and phylogenetic interrelationships of genes encoding			
RT	components of the botulinum toxin complex in proteolytic Clostridium			
RT	botulinum types A, B, and F: evidence of chimeric sequences in the			
RT	gene encoding the nontoxic nonhemagglutinin component.";			
RT	Int. J. Syst. Bacteriol. 46:1105-1112(1996).			
RE	[4]			
RE	SEQUENCE OF 1-34 FROM N.A.			
RE	STRAIN=Hall;			
RE	MEDLINE=89350959; PubMed=2669749;			
RA	Betley M.J., Somers E., Dasgupta B.R.;			
RT	"Characterization of botulinum type A neurotoxin gene: delineation of			
RT	the N-terminal encoding region.";			
RT	Biochem. Biophys. Res. Commun. 162:1388-1395(1989).			
RN	[5]			
RE	SEQUENCE OF 1-18 FROM N.A.			
RE	STRAIN=Type A NIH;			
RE	MEDLINE=96096783; PubMed=8521962;			
RA	Fujita R., Fujinaga Y., Inoue K., Nakajima H., Kumon H., Oguma K.;			

RT "Molecular characterization of two forms of nontoxic-nonhemagglutinin  
RT components of Clostridium botulinum type A progenitor toxins.";  
RT FEBS Lett. 376:41-44(1995).  
RN [6]  
RP SEQUENCE OF 1-16.  
RX MEDLINE-84178501; PubMed-6370252;  
RA Schmidt J.J., Sattymoorthy V., Dasgupta B.R.;  
RT "Partial amino acid sequence of the heavy and light chains of  
RT botulinum neurotoxin type A.";  
RL Biochem. Biophys. Res. Commun. 119:900-904(1984).  
RN [7]  
RP SEQUENCE OF 1-46.  
RA Dasgupta B.R., Foley J., Niece R.;  
RT "Partial sequence of the light chain of botulinum neurotoxin type A.";  
RL Biochemistry 26:4162-4162(1987).  
RN [8]  
RP SEQUENCE OF 1-5 AND 444-456.  
RX MEDLINE-91120847; PubMed-2126206;  
RA Dasgupta B.R., Dekleva M.L.;  
RT "Botulinum neurotoxin type A: sequence of amino acids at the  
RT N-terminus and around the nicking site.";  
RL Biochimie 72:661-664(1990).  
RN [9]  
RP SEQUENCE OF 448-464 AND 872-895.  
RX MEDLINE-89024662; PubMed-3178218;  
RA Sattymoorthy V., Dasgupta B.R., Foley J., Niece R.L.;  
RT "Botulinum neurotoxin type A: cleavage of the heavy chain into two  
RT halves and their partial sequences.";  
RL Arch. Biochem. Biophys. 266:142-151(1988).  
RN [10]  
RP SEQUENCE OF 448-482.  
RX MEDLINE-85285016; PubMed-3896784;  
RA Shone C.C., Hambleton P., Mellin J.;  
RT "Inactivation of Clostridium botulinum type A neurotoxin by trypsin  
RT and purification of two tryptic fragments. Proteolytic action near  
RT the COOH-terminus of the heavy subunit destroys toxin-binding  
RT activity.";  
RL Eur. J. Biochem. 151:75-82(1985).  
RN [11]  
RP IDENTIFICATION OF SUBSTRATE.  
RX MEDLINE-94063091; PubMed-8243676;  
RA Schiavo G., Santucci A., Dasgupta B.R., Mehta P.P., Jontes J.,  
RT Bentenati F., Wilson M.C., Montecucco C.;  
RT "Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct  
RT COOH-terminal peptide bonds.";  
RL FEBS Lett. 335:99-103(1993).  
RN [12]  
RP IDENTIFICATION OF SUBSTRATE.  
RX MEDLINE-94124495; PubMed-8294407;  
RA Binz T., Biasi J., Yamasaki S., Baumeister A., Link E., Suedhof T.C.,  
RT Jahn R., Niemann H.;  
RT "Proteolysis of SNAP-25 by types E and A botulinum neurotoxins.";  
RL J. Biol. Chem. 269:1617-1620(1994).  
RN [13]  
RP MUTAGENESIS OF GLU-261, PHE-265 AND TYR-365.  
RX MEDLINE-21556941; PubMed-11700044;  
RA Rigoni M., Caccin P., Johnson E.A., Montecucco C., Rossetto O.;  
RT "Site-directed mutagenesis identifies active-site residues of the  
RT light chain of botulinum neurotoxin type a.";  
RL Biochem. Biophys. Res. Commun. 288:1231-1237(2001).  
RN [14]  
RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS).  
RA MEDLINE-98455071; PubMed-9783750;  
RT Lacy D.B., Tepp W., Cohen A.C., Dasgupta B.R., Stevens R.C.;  
RT "Crystal structure of botulinum neurotoxin type A and implications  
RT for toxicity.";  
RL Nat. Struct. Biol. 5:898-902(1998).  
CC -I- FUNCTION: Inhibits acetylcholine release. The botulinum toxin  
CC binds with high affinity to peripheral neuronal presynaptic  
CC membrane, is then internalized by receptor-mediated endocytosis.  
CC The C-terminus of the heavy chain (H) is responsible for the  
CC adherence of the toxin to the cell surface while the N-terminus  
CC mediates transport of the light chain from the endocytic vesicle

CC to the cytosol. After translocation, the light chain (L)  
CC hydrolyzes the 197-Gln-I-Arg-198 bond in SNAP-25, thereby blocking  
CC neurotransmitter release. Inhibition of acetylcholine release  
CC results in flaccid paralysis, with frequent heart or respiratory  
CC failure.  
CC -I- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
CC detected action on small molecule substrates.  
CC -I- SUBUNIT: Disulfide-linked heterodimer of a light chain (L) and a  
CC heavy chain (H).  
CC -I- SUBCELLULAR LOCATION: Secreted.  
CC -I- PHARMACEUTICAL: Available under the name BOTOX (Allergan) for  
CC the treatment of strabismus and blepharospasm associated with  
CC dystonia and cervical dystonia. Also used for the treatment of  
CC hemifacial spasm and a number of other neurological disorders  
CC characterized by abnormal muscle contraction.  
CC -I- MISCELLANEOUS: There are seven antigenically distinct forms of  
CC botulinum neurotoxin: types A, B, C1, D, E, F, and G.  
CC -I- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
CC -I- DATABASE: NAME=BOTOX product information Web site;  
CC WWW="http://www.botox.com/index.jsp?hp&productinfo".  
CC -I- DATABASE: NAME=protein Spotlight;  
CC NOTE=Issue 19 of February 2002:  
CC WWW="http://www.expasy.org/spotlight/articles/split019.html".  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
CC -----  
DR EMBL: X52066; CAA36289.1; -  
DR EMBL: M30196; AAA23262.1; -  
DR EMBL: X92973; CAA63551.1; -  
DR EMBL: D67030; BAA11051.1; -  
DR EMBL: M27892; AAA23269.1; -  
DR PIR: A35294; BTCLAB.  
DR PIR: S09492; S09492.  
DR PDB: 3BTA; 01-OCT-99.  
DR MEROPS: M27.002; -  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_MTPeptidase.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRINTS: PR00760; BONTOXILYSIN.  
DR PRODOM: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc;  
KW Pharmacological: 3D-structure.  
FT INIT\_MET 0 0  
FT CHAIN 1 447 BOTULINUM NEUROTOXIN A, LIGHT-CHAIN.  
FT CHAIN 448 1295 BOTULINUM NEUROTOXIN A, HEAVY-CHAIN.  
FT METAL 222 222 ZINC (CATALYTIC).  
FT ACT\_SITE 223 223 ZINC (CATALYTIC).  
FT METAL 226 226 ZINC (CATALYTIC).  
FT METAL 261 261 ZINC (CATALYTIC).  
FT DISULFID 429 453 INTERCHAIN.  
FT DISULFID 1234 1279 POTENTIAL.  
FT TRANSMEM 626 646 POTENTIAL.  
FT TRANSMEM 655 675 POTENTIAL.  
FT VARIANT 26 26 V -> A.  
FT MUTAGEN 261 261 E -> A: DRASTIC DECREASE IN ENZYMATIC  
FT MUTAGEN 265 265 ACTIVITY.  
FT MUTAGEN 365 365 F -> A: DECREASE IN ENZYMATIC ACTIVITY.  
FT CONFLICT 1 1 Y -> A: DECREASE IN ENZYMATIC ACTIVITY.  
FT CONFLICT 479 479 P -> Q (IN REF. 1).  
FT CONFLICT 479 479 E -> P (IN REF. 9).  
FT CONFLICT 875 875 T -> L (IN REF. 8).  
FT CONFLICT 891 891 S -> K (IN REF. 8).  
SQ SEQUENCE 1295 AA; 149322 MW; 858342F754662579 CRC64;

Query Match

100.0%; Score 727; DB 1; Length 1295;

Best Local Similarity 100.0%, Pred. No. 2.8e-59;  
Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LNSSLYRGKFKFIKKYASGNKDNIVRNDRYINVVYKKKRYLATNNAQAVEKILSL 60  
DB 1149 LNSSLYRGKFKFIKKYASGNKDNIVRNDRYINVVYKKKRYLATNNAQAVEKILSL 1208

OY 61 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNGNDIGFHFQFNNTAKLVASMWYR 120  
DB 1209 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNGNDIGFHFQFNNTAKLVASMWYR 1268

OY 121 QIERSRRTGCSWEFIPVD 140  
DB 1269 QIERSRRTGCSWEFIPVD 1288

RESULT 2  
BXA2\_CLOBO STANDARD; PRT: 1295 AA.

AC 045894; P77780;  
DT 15-JUN-2002 (Rel. 41, Created)  
DT 15-JUN-2002 (Rel. 41, Last sequence update)  
DE 15-JUN-2002 (Rel. 41, Last annotation update)  
DE Botulinum neurotoxin type A precursor (BC 3.4.24.69) (BONT/A)  
DE (Bontoxilysin A) (BOTOX) [contains: Botulinum neurotoxin A, light-chain; Botulinum neurotoxin A, heavy-chain].  
GN BOTA OR BNA OR ATX.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
OC Clostridium.  
OX NCBI\_TaxID=1491;  
RN [1]

RP SEQUENCE FROM N.A.  
RC STRAIN-Kyoto-F;  
RX MEDLINE=94143603; PubMed=8310180;  
RA Williams A., East A.K., Lawson P.A., Collins M.D.;  
RT "Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins.";  
RT Res. Microbiol. 144:547-556(1993).  
RN [2]

RP SEQUENCE OF 1-65 FROM N.A.  
RC STRAIN-Kyoto-F;  
RX MEDLINE=97016817; PubMed=8863443;  
RA East A.K., Bhandari M., Stacey J.M., Campbell K.D., Collins M.D.;  
RT "Organization and phylogenetic interrelationships of genes encoding components of the botulinum toxin complex in proteolytic Clostridium botulinum types A, B, and F: evidence of chimeric sequences in the gene encoding the nontoxic nonhemagglutinin component.";  
RT Int. J. Syst. Bacteriol. 46:1105-1112(1996).  
CC -1- FUNCTION: Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane, is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-1-Arg-198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure (by similarity).  
CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on small molecule substrates.  
CC -1- SUBUNIT: Disulfide-linked heterodimer of a light chain (L) and a heavy chain (H) (by similarity).  
CC -1- SUBCELLULAR LOCATION: Secreted.  
CC -1- MISCELLANEOUS: There are seven antigenically distinct forms of botulinum neurotoxin: Types A, B, C1, D, E, F, and G.  
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see [http://www.isb-sib.ch/announce/or\\_send\\_an\\_email\\_to\\_license@sib.ch](http://www.isb-sib.ch/announce/or_send_an_email_to_license@sib.ch)).

CC -----  
CC EMBL: X73423; CAA51824.1; -;  
CC EMBL: X87974; CAA61234.1; -;  
CC HSSP: P10845; 3BTA.  
CC MEROPS: M27.002; -;  
CC InterPro: IPR000395; Bontoxilysin.  
CC InterPro: IPR000130; Zn\_MTPeptide.  
CC Pfam: PF01742; Peptidase\_M27; 1.  
CC ProDom: PD001963; Bontoxilysin; 1.  
CC PROSITE: PS00142; ZINC\_PROTEASE; FALSE NEG.  
CC Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.  
CC INIT\_MET 0  
CC CHAIN 1 447  
CC CHAIN 448 1295  
CC METAL 222 222  
CC ACT\_SITE 223 223  
CC METAL 226 226  
CC DISULFID 429 453  
CC DISULFID 1234 1279  
CC TRANSMEM 626 646  
CC TRANSMEM 655 675  
CC POTENTIAL.  
SQ SEQUENCE 1295 AA; 149279 MW; 5DA04A13D98D6372 CRC64;

Query Match 92.3%; Score 671; DB 1; Length 1295;  
Best Local Similarity 90.7%; Pred. No. 4.1e-54;  
Matches 127; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

OY 1 LNSSLYRGKFKFIKKYASGNKDNIVRNDRYINVVYKKKRYLATNNAQAVEKILSL 60  
DB 1149 LNSTLEGKFKFIKKYASGNEDNIVRNDRYINVVYKKKRYLATNNAQAVEKILSL 1208

OY 61 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNGNDIGFHFQFNNTAKLVASMWYR 120  
DB 1209 EIPDVGNLSQVYVYVMSKNDGITNCKMNLQDNGNDIGFHFQFNNTAKLVASMWYR 1268

OY 121 QIERSRRTGCSWEFIPVD 140  
DB 1269 QVKAASRTGCSWEFIPVD 1288

RESULT 3  
BXF\_CLOBO STANDARD; PRT: 1274 AA.

AC P30996;  
DT 01-JUL-1993 (Rel. 26, Created)  
DT 15-JUN-1993 (Rel. 26, Last sequence update)  
DE 15-JUN-2002 (Rel. 41, Last annotation update)  
DE Botulinum neurotoxin type F precursor (BC 3.4.24.69) (BONT/F)  
DE (Bontoxilysin F).  
GN BOTF.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
OC Clostridium.  
OX NCBI\_TaxID=1491;  
RN [1]

RP SEQUENCE FROM N.A.  
RC STRAIN-ATCC 23387;  
RX MEDLINE=93012902; PubMed=1398040;  
RA East A.K., Richardson F.T., Allaway D., Collins M.D.,  
RA Roberts T.A., Thompson D.E.;  
RT "Sequence of the gene encoding type F neurotoxin of Clostridium botulinum.";  
RT FEWS Microbiol. Lett. 75:225-230(1992).  
RN [2]

RP SEQUENCE OF 1-64 FROM N.A.  
RC STRAIN-Hobbs FT10;  
RX MEDLINE=94297488; PubMed=7764998;  
RA East A.K., Collins M.D.;



RX MEDLINE=94124495; PubMed=8294407;  
 RA Bin Z., Blas J., Yamasaki S., Baumeister A., Link E., Suedhof T.C.,  
 RA Jahn R., Niemann H.,  
 RA "Proteolysis of SNAP-25 by types E and A botulinum neurotoxins.",  
 RL J. Biol. Chem. 269:1617-1620(1994).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE THAT CATALYZES THE HYDROLYSIS OF THE 180-ARG-1-ILE-  
 CC 181 BOND IN SNAP-25.  
 CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
 CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
 CC detected action on small molecule substrates.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: X62089; CAA43999.1; -;  
 DR EMBL: X62583; CAA44558.1; -;  
 DR PIR: A60027; A60027.  
 DR PIR: B35294; B35294.  
 DR PIR: JH0257; JH0257.  
 DR PIR: S08575; S08575.  
 DR PIR: S18111; S18111.  
 DR PIR: S21178; S21178.  
 DR HSSP: F10845; 3BTA.  
 DR MEROPS: M27.002; -;  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_Mpeptide.  
 DR Pfam: PF01742; Peptidase\_M27; 1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR PRODOM: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
 KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.  
 FT INIT\_MET 0  
 FT CHAIN 1 421 BOTULINUM NEUROTOXIN E, LIGHT-CHAIN.  
 FT CHAIN 422 1250 BOTULINUM NEUROTOXIN E, HEAVY-CHAIN.  
 FT METAL 211 211 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT METAL 212 212 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT ACT\_SITE 212 212 BY SIMILARITY.  
 FT METAL 215 215 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT DISULFID 411 425 INTERCHAIN (PROBABLE).  
 FT CONFLICT 176 176 C -> G (IN REF. 2).  
 FT CONFLICT 197 197 R -> S (IN REF. 2 AND 3).  
 FT CONFLICT 339 339 R -> A (IN REF. 2).  
 FT CONFLICT 772 772 I -> L (IN REF. 2).  
 FT CONFLICT 962 963 FE -> LQ (IN REF. 2).  
 FT CONFLICT 966 966 R -> A (IN REF. 2).  
 FT CONFLICT 1194 1194 N -> NN (IN REF. 2).  
 FT SEQUENCE 1250 AA; 143712 MW; D9FCE2DDDA041EB4 CRC64;  
 Query Match 27.4%; Score 199; DB 1; Length 1250;  
 Best Local Similarity 37.4%; Pred. No. 1.3e-10;  
 Matches 52; Conservative 19; Mismatches 52; Indels 16; Gaps 6;  
 Oy 1 LNSSLYRGTKFIKKY-ASGNKDNIVRNNDRYIVVY-KKEYVLAINASAGYEKILS 58  
 Db 1116 LANRLYSIKYKIQVNNSSNDNLVRRNDQVYINFAVSKTHPLPLVADTAITNKEK--- 1172

Oy 59 ALEIPDVGN-LSQVVMKSKNDQGITNCKKNIADNNGNDIGFGEHQFNINIAKLVASNW 117  
 Db 1173 TIKISSSGKRFQVYVYNNM-----VGNCTMFKNKNNNGNIIQLGF-----KADIVYASTW 1222  
 Oy 118 VNRQIERSRTLGCSWEFT 136  
 Db 1223 YTHNRDHTNSNGCFWNFT 1241  
 RESULT 5  
 BSE.CLOBU  
 ID BSE.CLOBU STANDARD; PRT; 1250 AA.  
 AC P30995;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-JUL-1993 (Rel. 26, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Botulinum neurotoxin type E precursor (EC 3.4.24.69) (BONT/E)  
 DE (Bontoxilysin E).  
 OS Clostridium/butyricum.  
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
 OC Clostridium.  
 OX NCBI\_TaxID=1492;  
 OX [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=ATCC 43181, and ATCC 43755;  
 RX MEDLINE=92181428; PubMed=1543481;  
 RA Poulet S., Hauser D., Quanz M., Niemann H., Popoff M.R.;  
 RT "Sequences of the botulinum neurotoxin E derived from Clostridium  
 RT botulinum type E (strain Beluga) and Clostridium butyricum (strains  
 RT ATCC 43181 and ATCC 43755).";  
 RL Biochem. Biophys. Res. Commun. 183:107-113(1992).  
 RN [2]  
 RP SEQUENCE OF 1-251 FROM N.A.  
 RC STRAIN=BL6340;  
 RX MEDLINE=91237316; PubMed=2033376;  
 RA Fujii N., Kimura K., Murakami T., Indoh T., Tsuzuki K.,  
 RA Yokosawa N., Yashiki T., Oguma K.;  
 RT "Cloning of a DNA fragment encoding the 5'-terminus of the botulinum  
 RT type E toxin gene from Clostridium butyricum strain BL6340.";  
 RL J. Gen. Microbiol. 137:519-525(1991).  
 RN [3]  
 RP SEQUENCE OF 1-48.  
 RC STRAIN=5262;  
 RA Gimenez J., Foley J., Dasgupta B.R.;  
 RT "Neurotoxin type E from Clostridium botulinum and C. butyricum;  
 RT partial sequence and comparison.";  
 RL FASEB J. 2:A1750-A1750(1988).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE.  
 CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
 CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
 CC detected action on small molecule substrates.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL: X62088; CAA43998.1; -  
 DR EMBL: X53180; CAA37321.1; -  
 DR PIR: JH0256; JH0256.  
 DR PIR: S16145; S16145.  
 DR HSSP: P10845; 3BTA.  
 DR MEROPS: M27.002; -  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_MTPeptide.  
 DR Pfam: PF01742; Peptidase\_M27; 1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR PRODOM: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
 DR Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; zinc.  
 KW INIT MET 0 0  
 FT CHAIN 1 421 BOTULINUM NEUROTOXIN E, LIGHT-CHAIN.  
 FT CHAIN 422 1250 BOTULINUM NEUROTOXIN E, HEAVY-CHAIN.  
 FT METAL 211 211 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT ACT\_SITE 212 212 BY SIMILARITY.  
 FT METAL 215 215 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT DISULFID 411 425 INTERCHAIN (PROBABLE).  
 FT CONFLICT 229 229 K -> M (IN REF. 2).  
 SO SEQUENCE 1250 AA; 143265 MW; 8171B5B2C2312857 CRC64;  
 Query Match 26.1%; Score 190; DB 1; Length 1250;  
 Best Local Similarity 37.7%; Pred. No. 8, 9e-10;  
 Matches 52; Conservative 19; Mismatches 53; Indels 14; Gaps 6;  
 QY 1 LNSLRGKFKITKKY-ASGNKDNIVRNDRYINVVYKKEKRLATNMQAGVEKILSA 59  
 DB 1116 LARLISGIVKIVRVNNSSTNDLVKNDQVYINFA-SKTHLLPLVADTATNK-EKT 1173  
 QY 60 LEIPDGN-LSQVYVSKNDGKITKCKANLQDNGNDIGFQHFQNNIAKLVSANWY 118  
 DB 1174 IKSSSGNRRNQVYVNS-----VGNCTNFKNNNGNNGIGLGF-----KADIVVASWV 1223  
 QY 119 NQIERSSRTLCGSEWT 136  
 DB 1224 YTHMRDNTNGNPFNFI 1241  
 RESULT 6  
 BXB\_CLOBO STANDARD; PRT; 1290 AA.  
 ID BXB\_CLOBO STANDARD; PRT; 1290 AA.  
 AC P10844; P10843;  
 DT 01-JUL-1989 (Rel. 11, Created)  
 DT 01-JUL-1993 (Rel. 26, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Botulinum neurotoxin type B precursor (EC 3.4.24.69) (BONT/B)  
 DE (Bontoxilysin B).  
 GN BOTB.  
 OS Clostridium botulinum.  
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
 OC Clostridium.  
 OX NCBI\_TaxID=1491;  
 OX [1]  
 RN SEQUENCE FROM N.A.  
 RX MEDLINE=92384550; PubMed=1514783;  
 RA Whelan N.P.; Elmore M.J.; Bodsworth N.J.; Brehm J.K.; Atkinson T.,  
 Minton N.P.;  
 RT "Molecular cloning of the Clostridium botulinum structural gene  
 encoding the type B neurotoxin and determination of its entire  
 nucleotide sequence."  
 RT Appl. Environ. Microbiol. 58:2345-2354(1992).  
 RL [2]  
 RN SEQUENCE OF 35-245 FROM N.A.  
 RC STRAIN=NCOTC 7273;  
 RA Szabo E.A., Pemberton J.M., Desmarchelier P.M.;  
 RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE OF 633-993 FROM N.A.  
 RC STRAIN=NCOTC 7273; PubMed=8408542;  
 RX MEDLINE=9401372; PubMed=8408542;  
 RA Campbell K., East A.K., Collins M.D.;

RT "Gene probes for identification of the botulinum neurotoxin gene and  
 RT specific identification of neurotoxin types B, E, and F.";  
 RL J. Clin. Microbiol. 31:2255-2262(1993).  
 RN [4]  
 RP SEQUENCE OF 1-44 AND 441-466.  
 RC STRAIN=657;  
 RX MEDLINE=89000987; PubMed=3139097;  
 RA Dasgupta B.R., Datta A.;  
 RT "Botulinum neurotoxin type B (strain 657): partial sequence and  
 RT similarity with tetanus toxin.";  
 RL Biochimie 70:811-817(1998).  
 RN [5]  
 RP SEQUENCE OF 1-16 AND 441-458.  
 RC STRAIN=OKRA;  
 RX MEDLINE=85197963; PubMed=3888113;  
 RA Schmidt J.J., Sathyanarayanan V., Dasgupta B.R.;  
 RT "Partial amino acid sequences of botulinum neurotoxins types B and  
 RT E.";  
 RL Arch. Biochem. Biophys. 238:544-548(1985).  
 RN [6]  
 RP IDENTIFICATION AS ZINC-PROTEASE.  
 RX MEDLINE=93054694; PubMed=1429690;  
 RA Schiavo G., Rossetto O., Santucci A., Dasgupta B.R., Montecucco C.;  
 RT "Botulinum neurotoxins are zinc proteases.";  
 RL J. Biol. Chem. 267:23479-23483(1992).  
 RN [7]  
 RP IDENTIFICATION OF SUBSTRATE.  
 RX MEDLINE=93063293; PubMed=1331807;  
 RA Schiavo G., Benfenati F., Poulain B., Rossetto O., de Laureto P.P.,  
 RA Dasgupta B.R., Montecucco C.;  
 RT "Tetanus and botulinum-B neurotoxins block neurotransmitter release  
 RT by proteolytic cleavage of synaptobrevin.";  
 RL Nature 359:832-835(1992).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE THAT CLEAVES THE 76-GLN-1-PHE-77 BOND OF  
 CC SYNAPTOSOMAL-2.  
 CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
 CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. NO  
 CC detected action on small molecule substrates.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib.ch](mailto:license@sib.ch)).  
 CC -----  
 DR EMBL: M0186; AAA23211.1; -  
 DR EMBL: Z11934; CAA77991.1; -  
 DR EMBL: X70817; CAA50148.1; -  
 DR PIR: S07128; S07128.  
 DR PIR: S07155; S07155.  
 DR PIR: S08562; S08562.  
 DR PIR: S08573; S08573.  
 DR PIR: S08574; S08574.  
 DR PIR: A48940; A48940.  
 DR HSSP: P10845; 3BTA.  
 DR MEROPS: M27.002; -  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_MTPeptide.

DR Pfam: PF01742; Peptidase\_M27; 1.  
 DR PRINTS: PR00760; BONTOTOXILYSIN.  
 DR Prodom: PD001963; Bontotoxylysin: 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
 KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.  
 FT INIT\_MET 0  
 FT CHAIN 1 440 BOTULINUM NEUROTOXIN B, LIGHT-CHAIN.  
 FT METAL 441 1290 BOTULINUM NEUROTOXIN B, HEAVY-CHAIN.  
 FT ACT\_SITE 229 229 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT METAL 230 230 BY SIMILARITY.  
 FT METAL 233 233 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT DISULFID 436 445 INTERCHAIN (PROBABLE).  
 FT CONFLICT 29 29 T -> M (IN REF. 4).  
 FT CONFLICT 217 217 A -> G (IN REF. 2).  
 FT CONFLICT 224 224 A -> S (IN REF. 2).  
 FT CONFLICT 463 463 S -> R (IN REF. 4).  
 SQ SEQUENCE 1290 AA; 150670 MW; D21746E2C024DF43 CRC64;  
 Query Match 22.8%; Score 165.5; DB 1; Length 1290;  
 Best Local Similarity 28.7%; Pred. No. 1.7e-07;  
 Matches 43; Conservative 31; Mismatches 61; Indels 15; Gaps 5;  
 Oy 5 LYRGTFIKRYASGN--KDNIVRNNDVYINVVKNRYRLATNASQAGVEKLISALEI 62  
 Db 1138 LYIGKEFIIRKRSNSQINDIVRKEDYILDFENLQEMRYVYKYFKKEEKLFLAPI 1197  
 Oy 63 PDVGLSLGVVVMKSKNDGINKCKM--NLQDNNGNDIGFCIFQFNMA-----KL 112  
 Db 1198 SDSDEFYVTIQKEYDEP--TYSQCLPKKDESDDELGLIGHFYESGIVFEYKDYF 1256  
 Oy 113 VASNNYNNRQIERS--SRLGCSWEPFIPVD 140  
 Db 1257 CISKWKYKVKRKRPNLKLGCNMQPIPKDE 1286  
 RESULT 7  
 TETX.CLOTE  
 ID TETX.CLOTE STANDARD; PRT; 1314 AA.  
 AC P04958;  
 DT 13-AUG-1987 (Rel. 05, Last sequence update)  
 DT 13-AUG-1987 (Rel. 05, Last sequence update)  
 DT 15-JUL-1999 (Rel. 38, Last annotation update)  
 DE Tetanus toxin precursor (EC 3.4.24.68) (Tentoxylysin).  
 OS Clostridium tetani.  
 OG Plasmid.  
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
 OC Clostridium.  
 ON NCBI\_TaxID=1513;  
 OX [1]  
 RX SEQUENCE FROM N.A.  
 RX MEDLINE=87053814; PubMed=3536478;  
 RA Eisel U., Jarausch W., Goretzki K., Henschen A., Engels J.,  
 RA Weller U., Hudel W., Habermann E., Niemann H.;  
 RT "Tetanus toxin: Primary structure, expression in E. coli, and  
 RT homology with botulinum toxins.";  
 RL EMBO J. 5:2495-2502(1986).  
 RN [2]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN=CN3911;  
 RC MEDLINE=87040747; PubMed=3774547;  
 RA Fairweather N.F., Lyness V.A.;  
 RT "The complete nucleotide sequence of tetanus toxin.";  
 RL Nucleic Acids Res. 14:7809-7812(1986).  
 RN [3]  
 RP SEQUENCE OF 742-1314 FROM N.A.  
 RX MEDLINE=86085672; PubMed=3510187;  
 RA Fairweather N.F., Lyness V.A., Pickard D.J., Allen G., Thomson R.O.;  
 RT "Cloning, nucleotide sequencing, and expression of tetanus toxin  
 RT fragment C in Escherichia coli.";  
 RL J. Bacteriol. 165:21-27(1986).  
 RN [4]  
 RP PARTIAL SEQUENCE; AND DISULFIDE BONDS.  
 RX MEDLINE=90201034; PubMed=2108021;

RA Kriegstein K., Henschen A., Weller U., Habermann E.;  
 RT "Arrangement of disulfide bridges and positions of sulfhydryl groups  
 RT in tetanus toxin.";  
 RL Eur. J. Biochem. 186:39-45(1990).  
 RN [5]  
 RP PARTIAL SEQUENCE.  
 RX MEDLINE=92037649; PubMed=1935979;  
 RA Kriegstein K.G., Henschen A.H., Weller U., Habermann E.;  
 RT "Limited proteolysis of tetanus toxin. Relation to activity and  
 RT identification of cleavage sites.";  
 RL Eur. J. Biochem. 202:41-51(1991).  
 RN [6]  
 RP IDENTIFICATION AS ZINC-PROTEASE.  
 RX MEDLINE=93010948; PubMed=1396558;  
 RA Schiavo G., Poultain B., Rossetto O., Benfenati F., Tauc L.,  
 RA Montecucco C.;  
 RT "Tetanus toxin is a zinc protein and its inhibition of  
 RT neurotransmitter release and protease activity depend on zinc.";  
 RL EMBO J. 11:3577-3583(1992).  
 RN [7]  
 RP IDENTIFICATION OF SUBSTRATE.  
 RX MEDLINE=93063293; PubMed=1331807;  
 RA Schiavo G., Benfenati F., Poultain B., Rossetto O., de Laureto P.P.,  
 RA Dasgupta B.R., Montecucco C.;  
 RT "Tetanus and botulinum-B neurotoxins block neurotransmitter release  
 RT by proteolytic cleavage of synaptobrevin.";  
 RL Nature 359:832-835(1992).  
 RN [8]  
 RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 874-1314.  
 RX MEDLINE=97475217; PubMed=9334741;  
 RA Umland T.C., Wingert L.M., Swaminathan S., Furey W.F., Schmidt J.J.,  
 RA Sax M.;  
 RT "Structure of the receptor binding fragment HC of tetanus  
 RT neurotoxin.";  
 RL Nat. Struct. Biol. 4:788-792(1997).  
 CC -I- FUNCTION: TETANUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE THAT CATALYZES THE HYDROLYSIS OF THE 76-GLN-1-PHE-77  
 CC BOND OF SYNAPTOSOMAL-2.  
 CC -I- CATALYTIC ACTIVITY: HYDROLYSIS OF 76-GLN-1-PHE-77 BOND IN  
 CC SYNAPTOSOMAL-2.  
 CC -I- SUBUNIT: THE PRECURSOR POLYPEPTIDE IS SUBSEQUENTLY CLEAVED TO  
 CC YIELD SUBCHAINS L AND H. THESE REMAIN LINKED BY A DISULFIDE BRIDGE  
 CC AND ARE NON-TOXIC AFTER SEPARATION.  
 CC -I- MISCELLANEOUS: THE C-TERMINAL OF THE HEAVY CHAIN BINDS TO  
 CC GANGLIOSIDE RECEPTORS.  
 CC -I- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.ebi.ac.uk/announcements>  
 CC or send an email to [license@ebi.slb.ch](mailto:license@ebi.slb.ch)).  
 CC -----  
 CC EMBL; X04436; CAA28033.1; -;  
 DR EMBL; M12739; AAA23282.1; -;  
 DR EMBL; X06214; CAA29564.1; -;  
 DR PIR; A25689; BTCLTN  
 DR PDB; 1AF9; 29-APR-98.  
 DR PDB; 1ABD; 14-OCT-98.  
 DR MEROPS; M27.001; -;  
 DR InterPro; IPR000395; Bontotoxylysin.  
 DR InterPro; IPR000130; zn\_mtpeptidse.  
 DR Pfam; PF01742; Peptidase\_M27; 1.  
 DR PRINTS; PR00760; BONTOTOXILYSIN.  
 DR Prodom; PD001963; Bontotoxylysin: 1.  
 DR PROSITE; PS00142; ZINC\_PROTEASE; 1.  
 KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc; Plasmid;



```

KW 3D-structure. 0
FT INIT_MER 1 456
FT CHAIN 457 1314 TETANUS TOXIN LIGHT CHAIN.
FT CHAIN 232 232 TETANUS TOXIN HEAVY CHAIN.
FT METAL 233 233 ZINC (CATALYTIC) (BY SIMILARITY).
FT ACT_SITE 233 233 BY SIMILARITY.
FT METAL 236 236 ZINC (CATALYTIC) (BY SIMILARITY).
FT TRANSMEM 226 246 POTENTIAL.
FT TRANSMEM 669 689 POTENTIAL.
FT DISULFID 438 466 INTERCHAIN.
FT DISULFID 1076 1092
SQ SEQUENCE 1314 AA; 150550 MW; 134C3657133EF81D CRC64;

Query Match 22.4%; Score 163; DB 1; Length 1314;
Best Local Similarity 26.9%; Pred. No. 2.9e-07;
Matches 43; Conservative 26; Mismatches 49; Indels 42; Gaps 6;

QY 5 LVRGTFITIKKASGK-DNIYRNNDRVIYINVVKKEY-----RLA 45
DB 1168 LYNGLFIIKRTYPPNNEIDSFVSGDFIKLYVSYNNNEHVGYPRKGNMFNNIDRLIRVG 1227
QY 46 TNASQAGVEKILSALFIPVGNLSQYVVKSKNDGITNCKKNLQDNNNGNDIGFIFPH-104
DB 1228 YNAPGIPLKKEAVKLRDK-----TISVQLKLYDKKNASLGIVGTHN 1271
QY 105 -QFNNTAK--LIVASNMVNRQIERSSRTLCGSMFPIVDD 140
DB 1272 GQIGNDPNRDILIASNMVFNHLK--DKILGCDMVFYPTDE 1309

RESULT 8
BXCL_CLOBO ID BXCL_CLOBO STANDARD: PRT; 1296 AA.
AC 060393:
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Botulinum neurotoxin type G precursor (EC 3.4.24.69) (BONT/G)
DE (Bontoxillysin G).
GN BONTG.
OS Clostridium botulinum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=1491;
RN (1)
RP SEQUENCE FROM N.A.
RC STRAIN=113 / 30;
RX MEDLINE=94092745; PubMed=8268233;
RA Campbell K., Collins M.D., East A.K.;
RT "Nucleotide sequence of the gene coding for Clostridium botulinum
RT (Clostridium argentineense) type G neurotoxin: genealogical comparison
RT with other clostridial neurotoxins."
RL Biochim. Biophys. Acta 1216:487-491(1993).
CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER
CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED
CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD
CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT
CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC
CC ENDOPEPTIDASE.
CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the
CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No
CC detected action on small molecule substrates.
CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A
CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,
CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL
CC FORMATION AND TOXIN BINDING, RESPECTIVELY.
CC -1- SUBCELLULAR LOCATION: Secreted (By similarity).
CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF
CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

```

```

CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: X74162; CAA52275.1; -.
DR HSSP; P10845; 3BTA.
DR MEROPS; M27.002; -.
DR InterPro: IPR000395; Bontoxillysin.
DR InterPro: IPR000130; zn_MTPeptide.
DR Pfam: PF01742; Peptidase_M27; 1.
DR PRINTS; PR00760; BONTOXILYSIN.
DR ProDom; PD001963; Bontoxillysin; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; 1.
DR Neurotoxin; Hydrolase; Metalloprotease; Zinc.
FT INIT_MER 0
FT CHAIN 1 441
FT CHAIN 442 1296 BOTULINUM NEUROTOXIN G, LIGHT-CHAIN.
FT METAL 229 229 ZINC (CATALYTIC) (BY SIMILARITY).
FT ACT_SITE 230 230 BY SIMILARITY.
FT METAL 233 233 ZINC (CATALYTIC) (BY SIMILARITY).
FT DISULFID 435 449 INTERCHAIN (PROBABLE).
SQ SEQUENCE 1296 AA; 149013 MW; DC8E47E15F665C31 CRC64;

Query Match 21.8%; Score 158.5; DB 1; Length 1296;
Best Local Similarity 29.9%; Pred. No. 7.4e-07;
Matches 46; Conservative 28; Mismatches 59; Indels 21; Gaps 7;

QY 4 SLVRGTFITIKKASG---NKNIVRNNDRVIYIN-VVKNKEKRLTNASQAGVEKILS 59
DB 1143 NYLGLFIIKRTYPPNNEIDSFVSGDFIKLYVSYNNNEHVGYPRKGNMFNNIDRLIRVG 1202
QY 60 LEIPDVGNLSQYVVKSKNDGITNCKKNLQDNNNGNDIGFIFPH-----NN 108
DB 1203 APINDPTTYDVQLR-KYREKTTYNQI-LCEKDKRTGLGIGKFFVDGYWMDTYDN 1260
QY 109 IAKTVASNMVNRQIER--SSRTLCGSMFPIVDD 140
DB 1261 Y-FCISQWVLRIRISENINKLRIGCMWGFIPVDE 1292

RESULT 9
BXCL_CLOBO ID BXCL_CLOBO STANDARD: PRT; 1290 AA.
AC P18640:
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Botulinum neurotoxin type C1 precursor (EC 3.4.24.69) (BONT/C1)
DE (Bontoxillysin C1).
OS Clostridium botulinum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=1491;
RN (1)
RP SEQUENCE FROM N.A.
RC MEDLINE=90370487; PubMed=2204031;
RX Hauser D., Eklund M.W., Kurazono H., Binz T., Niemann H., Gili D.M.,
RA Boquet P., Popoff M.R.;
RT "Nucleotide sequence of Clostridium botulinum C1 neurotoxin."
RL Nucleic Acids Res. 18:4924-4924(1990).
RN (2)
RP SEQUENCE FROM N.A.
RC STRAIN=type C Stockholm / C-ST;
RX MEDLINE=91024998; PubMed=2222445;
RA Kimura K., Fujii N., Tsuzuki K., Murakami T., Indoh T.,
RA Yokosawa N., Takeshi K., Syuto B., Oguma K.;
RT "The complete nucleotide sequence of the gene coding for botulinum
RT type C1 toxin in the C-ST phage genome."
RL Biochem. Biophys. Res. Commun. 171:1304-1311(1990).
RN (3)
RP SEQUENCE OF 2-25.

```



CC	STRAIN-Type C Stockholm / C-SF;
RX	MEDLINE=86153072; PubMed=2450068;
RA	Tsuzuki K., Yokosawa N., Syuto B., Ohishi I., Fujii N., Kimura K.,
RT	Oguma K.,
RT	"Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, Cl, D, and E toxins and tetanus toxin."
RL	Infect. Immun. 56:898-902(1988).
RN	[4]
RP	IDENTIFICATION OF SUBSTRATE.
RX	MEDLINE=94038966; PubMed=7901002;
RA	Biasi J., Chapman E.R., Yamasaki S., Blinz T., Niemann H., John R.,
RT	"Botulinum neurotoxin Cl blocks neurotransmitter release by means of cleaving HPC-1/syntaxin."
RL	EMBO J. 12:4821-4828(1993).
CC	-1 FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC ENDOPEPTIDASE THAT CLEAVES SYNTAXIN.
CC	-1 CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. NO detected action on small molecule substrates.
CC	-1 SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY, WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDiate CHANNEL FORMATION AND TOXIN BINDING, RESPECTIVELY.
CC	-1 MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF BOTULINUM NEUROTOXIN: TYPES A, B, Cl, D, E, F, AND G.
CC	-1 MISCELLANEOUS: BOTULINDM TYPE CI NEUROTOXIN IS SYNTHESIZED BY C STRAIN OF CLOSTRIDIUM BOTULINUM WHICH CARRY THE APPROPRIATE BACTERIOPHAGE.
CC	-1 SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.
CC	-----
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between The Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/or send an email to license@isb-sib.ch).
CC	-----
DR	EMBL; X66433; CAAs4706.1; -
DR	EMBL; X72793; CAAs1313.1; -
DR	EMBL; X53751; CAAs3780.1; -
DR	EMBL; D90710; BAAl4235.1; -
DR	EMBL; X62389; CAAs44263.1; -
DR	PIR; S11291; S11291.
DR	PIR; A35396; A35396.
DR	PIR; A43503; A43503.
DR	HSSP; P10845; 3BTA.
DR	MEROPS; M27.002; -
DR	InterPro; IPR000395; Bontoxilysin.
DR	InterPro; IPR000130; Zn_MTPeptide.
DR	Pfam; PF01742; Peptidase_M27; 1.
DR	PRINTS; PR00760; BONTOXILYSIN.
DR	ProDom; PD001963; Bontoxilysin; 1.
DR	ProSITE; PS00142; ZINC_PROTEASE; 1.
KW	Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; zinc.
FT	INTL MET 0
FT	CHAIN 1 448
FT	CHAIN 449 1290
FT	METAL 228 228
FT	ACT_SITE 229 229
FT	METAL 232 232
FT	DISULFD 436 452
FT	CONFLICT 84 84
SO	SEQUENCE 1290 AA; 148734 MW; 71PBE379F97129E8 CRC64;
Query Match	13.8%; Score 100; DB 1; Length 1290;
Best Local Similarity	23.6%; Pred. NO. 0.18;

Qy	Matches	37;	Conservative	21;	Mismatches	77;	Indels	22;	Gaps	4;
Qy	2	NSSLYRGFTIKFIKKYASGKNDIVANNDRVYINVVYKNEYRL-----ATNASQAGV	53							
Db	1138	NNDFEGEKIIIRKIRGTNPIDTRVGGDILVFDMITINKKAVNLFMKNETMADHNSTEDI	1197							
Qy	54	EKLISALEIPVGNLSQVYVYVKKSKNDQITKNC-KMNLDNNNGNDIGTIGHQF-----	106							
Db	1198	YALGREDTKIDINDIIFQIOPMNNYVYASQIFPNSNGENISGICSIGYRFRLGGDW	1257							
Qy	107	---NNIAKLVASNMWNRROIERSRFTLGSWEPIFPD	140							
Db	1258	YRHNLVPTVYKOGNYASLLESTST-----THMGFVPVSE	1230							
RESULT 10										
ID	MURI_FUSNN	STANDARD:	PR:	264	AA.					
AC	Q8REB6;									
DT	15-JUN-2002 (Rel. 41, Created)									
DT	15-JUN-2002 (Rel. 41, Last sequence update)									
DT	15-JUN-2002 (Rel. 41, Last annotation update)									
DE	Glutamate racemase (EC 5.1.1.3).									
GN	MURI OR FN1161.									
OC	Fusobacterium nucleatum (subsp. nucleatum).									
OC	Bacteria; Fusobacteria; Fusobacterium.									
OX	NCHI_TaxID=76856;									
RN	[1]									
RP	SEQUENCE FROM N.A.									
RC	STRAIN-ATCC 25586;									
RX	MEDLINE-21886394; Pubmed=1189109;									
RA	Kapatral V., Anderson I., Ivanova N., Reznik G., Los T., Lykidis A.,									
RA	Babitchayya A., Bartman A., Gardner W., Grecklin G., Zhu L.,									
RA	Vasileva O., Chu L., Kogan Y., Chaga O., Goldsman E., Bernal A.,									
RA	Larsen N., D'Souza M., Malunas T., Pusch G., Haselkorn R.,									
RA	Forsteln M., Kyrides N., Overbeck R.,									
RT	"Genome sequence and analysis of the oral bacterium Fusobacterium									
RL	nucleatum strain ATCC 25586."									
RJ	J. Bacteriol. 184:2005-2018(2002).									
CC	-1- FUNCTION: Provides the (R)-glutamic acid required for cell wall									
CC	biosynthesis (By similarity).									
CC	-1- CATALYTIC ACTIVITY: L-glutamate -> D-glutamate.									
CC	-1- PATHWAY: Peptidoglycan biosynthesis.									
CC	-1- SIMILARITY: BELONGS TO THE ASPARTATE-GLUTAMATE RACEMASES FAMILY.									
CC	-1- This SWISS-PROT entry is copyright. It is produced through a collaboration									
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -									
CC	the European Bioinformatics Institute. There are no restrictions on its									
CC	use by non-profit institutions as long as its content is in no way									
CC	modified and this statement is not removed. Usage by and for commercial									
CC	entities requires a license agreement (See <a href="http://www.isb-sib.ch/announcement">http://www.isb-sib.ch/announcement</a>									
CC	or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ).									
CC										
DR	EMBL; AE010622; AAL95357.1;									
DR	PROSITE; PS00923; ASP_GLU_RACEMASE_1; 1.									
DR	PROSITE; PS00924; ASP_GLU_RACEMASE_2; 1.									
KW	Peptidoglycan synthetase; Cell wall; Isomerase; Complete proteome.									
SC	SEQUENCE 264 AA; 29882 MW; F69A0C16BEAB6AF9 CRC64;									
Qy	Query Match	12.2%;	Score 88.5;	DB 1;	Length 264;					
Qy	Best Local Similarity	26.7%;	Pred. No. 0.36;							
Qy	Matches	39;	Conservative	22;	Mismatches	54;	Indels	31;	Gaps	6;
Db	16	YASGKDNIVRNNDRVYINVVYKN--KEKRLATN-ASQAGVEKILSALEIPVGNLSQV	72							
Db	44	YSGGTRKELELDLTRLRIIDFVYKNNCKLIYACNASTRAIDYLRKESLPIGITTEGV	103							
Qy	73	VKRSKN-----DQGITKCKKMNLDNNNGNDIGTIGHQ-----ENN	108							
Db	104	KIASKNFTNKNKNIIVISTFTAESHGKYNKKAKMDSELVWKEIACTEFQMIETGMDTFDN	163							

DB 164 RREL--NKYSEIPKNDTLVIGCT 187

RESULT 11

YCF1\_ARATH

ID YCF1\_ARATH STANDARD; PRT; 1786 AA.

AC P56785;

DT 30-MAY-2000 (Rel. 39, Created)

DT 30-MAY-2000 (Rel. 39, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Hypothetical 213.7 kDa protein ycf1.

GN YCF1

OS Arabidopsis thaliana (Mouse-ear cress).

OC Chloroplast.

CC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

CC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;

CC eucosids II; Brassicales; Brassicaceae; Arabidopsis.

OX NCBI\_TaxID=3702;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=cv. Columbia;

RX MEDLINE=20039611; PubMed=10574454;

RA Sato S., Nakamura Y., Kaneko T., Asamizu E., Tabata S.;

RT "Complete structure of the chloroplast genome of Arabidopsis thaliana."

RL DNA Res. 6:283-290(1999).

CC -1- FUNCTION: NOT YET KNOWN.

CC -1- SIMILARITY: BELONGS TO THE YCF1 FAMILY.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation- the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).

CC -----

CC EMBL: AP000423; BAA84445.1; -

DR EMBL: AP000423; BAA84433.1; -

KW Chloroplast; Hypothetical protein.

SQ SEQUENCE 1786 AA; 213727 MW; CFFD2A4D76D7E5D CRC64;

Query Match 10.9%; Score 79.5; DB 1; Length 1786;

Best Local Similarity 25.5%; Pred. No. 20;

Matches 40; Conservative 26; Mismatches 58; Indels 33; Gaps 8;

OY 6 YRGTFRIKKYASGNKDNIVRNDRYINVVKN-----KEYRLATNASQAGVEKILS 58

DB 1103 FETSKTILDKYIKNEENGKKNTLYFISTINKLISNKKKMSYDLC-SLSQAYFFYKLS 1161

OY 59 ALEIPDVGNLSQV-----VMKSK-----NDQGI-----TNKCKKNLQDNGNDIG 99

DB 1162 QIKVSNFKKIAVLEYNICITSPFVKNKIKVFOEHGIFHYELKNTFLNSEVNQMKN-W 1220

OY 100 FIGFHQFN-----NIKLVASNNYRNQIERSRRLGCS 132

DB 1221 LRSQYQYNLPQISWRLVYQNMKNK-INKDSVLNPS 1256

RESULT 12

Y008\_HUMAN

ID Y008\_HUMAN STANDARD; PRT; 765 AA.

AC Q15398;

DT 15-JUL-1998 (Rel. 36, Created)

DT 15-JUL-1998 (Rel. 36, Last sequence update)

DT 15-JUN-2002 (Rel. 41, Last annotation update)

DE Hypothetical protein KIA0008.

GN KIA0008.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI\_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Bone marrow;

RX MEDLINE=96051387; PubMed=7584026;

RA Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarayashi Y.,

RA Sato S., Nagase T., Seki N., Ishikawa K.-I., Tabata S.;

RT "Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIA0001-KIA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1."

RL DNA Res. 1:27-35(1994).

RN [2]

RP SEQUENCE FROM N.A.

RC TISSUE=Eye, and Lung;

RA Strausberg R.;

RL Submitted (OCT-2001) to the EMBL/Genbank/DBJ databases.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation- the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).

CC -----

CC EMBL: D13633; BAA02797.1; -

DR EMBL: BC010658; AAH10658.1; -

DR EMBL: BC016276; AAH16276.1; -

DR InterPro: IPR005026; GKAP.

DR Pfam: PF03359; GKAP; 1.

KW Hypothetical protein

SQ SEQUENCE 765 AA; 85668 MW; 00AFF91A02387EAL CRC64;

Query Match 10.9%; Score 79; DB 1; Length 765;

Best Local Similarity 21.9%; Pred. No. 8;

Matches 32; Conservative 27; Mismatches 39; Indels 48; Gaps 8;

OY 20 MKDNIVRNDRYIN-----VKNKRYLA-----TNASQAGVEKILS--- 58

DB 309 HEEHVINKKEATYKNGLPKEVPSLERNGRIAPHGVPYFRN1LQSEFEKLSHCF 368

OY 59 -----ALEIPD-----VGNLSQVYVMSKSNQGITNKC--TMNLDNNGNDI-GF 100

DB 369 EMDRKLELDIPDAKDLIRAVGQTRLMKERKQFEGLVDCERYKGIKETTCTLDIGF 428

OY 101 ---IGF-----HGFNNIAKLVASNN 117

DB 429 WDMVSFOIEDVYHKFNKLLKLEESGV 454

RESULT 13

WZC\_ECOLI

ID WZC\_ECOLI STANDARD; PRT; 720 AA.

AC P76387; P71236; O08003; O08004;

DT 15-JUN-2002 (Rel. 41, Created)

DT 15-JUN-2002 (Rel. 41, Last sequence update)

DT 15-JUN-2002 (Rel. 41, Last annotation update)

DE Tyrosine-protein kinase wzc (EC 2.7.1.112).

GN WZC OR B2060.

OS Escherichia coli.

OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;

OC Escherichia.

OX NCBI\_TaxID=562;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=K12;

RX MEDLINE=96326333; PubMed=8759852;

RA Stevenson G., Andrianopoulos K., Hobbs M., Reeves P.R.;

RT "Organization of the Escherichia coli K-12 gene cluster responsible for production of the extracellular polysaccharide colanic acid.";

RL J. Bacteriol. 178:4885-4893(1996).

RN [2]

RP SEQUENCE FROM N.A.

RC STRAIN=K12 / MG1655;

RX MEDLINE=97426617; PubMed=9278503;  
 RA Blatner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,  
 RA Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,  
 RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,  
 RA Mau B., Shao Y.;  
 RT "The complete genome sequence of *Escherichia coli* K-12.";  
 RL Science 277:1453-1474(1997).  
 [3]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN-K12;  
 RC MEDLINE=97251358; PubMed=9097040;  
 RA Itoh T., Alba B., Baba T., Fujita K., Hayashi K., Inada T., Isono K.,  
 RA Kasai H., Kimura S., Kitagawa M., Kitagawa M., Makino K., Maki T.,  
 RA Mizobuchi K., Mori H., Mori T., Motomura K., Nakade S., Nakamura Y.,  
 RA Nashimoto H., Nishio Y., Oshima T., Saito N., Sempel G., Seki Y.,  
 RA Sivasubram S., Tagami H., Takeda J., Takemoto K., Wada C.,  
 RA Yamamoto Y., Horuchi T.;  
 RT "A 460-kb DNA sequence of the *Escherichia coli* K-12 genome  
 RT corresponding to the 40.1-50.0 min region on the linkage map.";  
 RL DNA Res. 3:379-392(1996).  
 [4]  
 RN CHARACTERIZATION  
 RP STRAIN-K12 / JM109;  
 RC MEDLINE=99287830; PubMed=10348860;  
 RA Vincent C., Doublet P., Grangeasse C., Vaganay E., Cozzone A.J.,  
 RA Duclos B.;  
 RT "Cells of *Escherichia coli* contain a protein-tyrosine kinase, Wzc, and  
 RT a phosphotyrosine-protein phosphatase, Wzb.";  
 RL J. Bacteriol. 181:3472-3477(1999).  
 [5]  
 RN CHARACTERIZATION  
 RP STRAIN-K12 / JM109;  
 RC MEDLINE=20545593; PubMed=11090276;  
 RA Vincent C., Duclos B., Grangeasse C., Vaganay E., Riberty M.,  
 RA Cozzone A.J., Doublet P.;  
 RT "Relationship between exopolysaccharide production and protein-  
 RT tyrosine phosphorylation in gram-negative bacteria.";  
 RL J. Mol. Biol. 304:311-321(2000).  
 [6]  
 RN CHARACTERIZATION AND MUTAGENESIS  
 RP STRAIN-K12 / JM109;  
 RC MEDLINE=21850696; PubMed=11751920;  
 RA Grangeasse C., Doublet P., Cozzone A.J.;  
 RT "Tyrosine phosphorylation of protein kinase Wzc from *Escherichia coli*  
 RT K12 occurs through a two-step process.";  
 RL J. Biol. Chem. 277:7127-7135(2002).  
 [7]  
 CC -1- FUNCTION: Required for the extracellular polysaccharide colanic  
 CC acid synthesis. The autophosphorylated form is inactive. Probably  
 CC involved in the export of colanic acid from the cell to medium.  
 CC -1- CATALYTIC ACTIVITY: ATP + a protein tyrosine = ADP + protein  
 CC tyrosine phosphate.  
 CC -1- ENZYME REGULATION: Dephosphorylated and activated by wzb.  
 CC -1- PATHWAY: Exopolysaccharide biosynthesis.  
 CC -1- SUBCELLULAR LOCATION: Inner membrane (Probable).  
 CC -1- PIM: Autophosphorylated. Seems to be phosphorylated through a  
 CC cooperative two-step mechanism. First, Tyr-569 is phosphorylated  
 CC in an intramolecular reaction that generates a significant  
 CC increase of protein kinase activity. Then Tyr-708, Tyr-710, Tyr-  
 CC 711, Tyr-713 and Tyr-715 are phosphorylated in an intermolecular  
 CC Tyr-569-dependent reaction.  
 CC -1- MISCELLANEOUS: Additional site-directed mutagenesis experiments  
 CC indicated that the tyrosine residues at positions 708, 710, 711,  
 CC 713 and 715 are phosphorylation sites, whereas tyrosine at  
 CC position 705 is not.  
 CC -1- SIMILARITY: BELONGS TO THE ETK/WZC FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC -----  
 DR EMBL: U38473; AAC78835.1;  
 DR EMBL: AE000296; AAC75121.1; ALT\_INIT.  
 DR EMBL: D90843; BAA15913.1;  
 DR EMBL: D90844; BAA15915.1;  
 DR PhosSite: P76387;  
 DR Ecocore: EGI3568; wzc.  
 KW Transferase: Tyrosine-protein kinase: Phosphorylation;  
 KW Exopolysaccharide synthesis; Transmembrane; Inner membrane;  
 KW Complete proteome.  
 FT DOMAIN 1 31 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 32 52 POTENTIAL.  
 FT DOMAIN 53 424 PERIPLASMIC (POTENTIAL).  
 FT TRANSMEM 425 445 POTENTIAL.  
 FT DOMAIN 446 720 CYTOPLASMIC (POTENTIAL).  
 FT MOD\_RES 569 569 PHOSPHORYLATION (AUTO-) (PROBABLE).  
 FT MOD\_RES 708 708 PHOSPHORYLATION (PROBABLE).  
 FT MOD\_RES 710 710 PHOSPHORYLATION (PROBABLE).  
 FT MOD\_RES 711 711 PHOSPHORYLATION (PROBABLE).  
 FT MOD\_RES 713 713 PHOSPHORYLATION (PROBABLE).  
 FT MOD\_RES 715 715 PHOSPHORYLATION (PROBABLE).  
 FT MUTAGEN 467 467 Y->E: NO LOSS OF AUTOPHOSPHORYLATION.  
 FT MUTAGEN 491 491 Y->F: NO LOSS OF AUTOPHOSPHORYLATION.  
 FT MUTAGEN 540 540 K->M: LOSS OF AUTOPHOSPHORYLATION.  
 FT MUTAGEN 569 569 Y->F: LOSS OF AUTOPHOSPHORYLATION.  
 FT MUTAGEN 636 636 Y->E: NO LOSS OF AUTOPHOSPHORYLATION.  
 FT MUTAGEN 668 668 Y->F: NO LOSS OF AUTOPHOSPHORYLATION.  
 SQ SEQUENCE 720 AA: 79343 MW: 86101735cEFB45 CRC64;  
 Query Match 10.3%; Score 75; DB 1; Length 720;  
 Best Local Similarity 25.6%; Pred. No. 19;  
 Matches 32; Conservative 20; Mismatches 55; Indels 18; Gaps 5;  
 QY 29 DRYVNVVYKKEVRLATNA-----SQAG---VEKILSALEIPDYGMLSGVYVYKSKND 79  
 Db 149 DQVFLNVLDNKNKNTLSSDGFSGFARGAQGMKKEGYTLMTVAIRHASPGEPTVK-YST 207  
 QY 80 QGITKCKKKNLQ-DNMGNDIGTIGF-----HGNNNAKLAVASWYNYRQTRSSRTIGC 131  
 Db 208 LGMNQLNSLTVTENGKADAGVLSLTGTGEDEQRIDILNSIARNYQDNTERKSAEASK 267  
 QY 132 SWEFT 136  
 Db 268 SLATL 272  
 RESULT 14  
 BOLD\_CLOBO STANDARD: PRT: 1276 AA.  
 ID BOLD\_CLOBO  
 AC P19321.  
 DT 01-NOV-1990 (Rel. 16, Created)  
 DT 01-NOV-1990 (Rel. 16, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Botulinum neurotoxin type D precursor (EC 3.4.24.69) (BONT/D)  
 DE (Bontoxilysin D).  
 GN BONT.  
 OS Clostridium botulinum.  
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
 OC Clostridium.  
 OX NCBI\_TaxID=1491;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-BVD/-3;  
 RX MEDLINE=91016853; PubMed=2216736;  
 RA Blinz T., Kurazono H., Popoff M.R., Eklund M.W., Sakaguchi G.,  
 RA Kozaki S., Krieglstein K., Henschen A., Gill D.M., Ntemann H.;  
 RT "Nucleotide sequence of the gene encoding Clostridium botulinum  
 RL neurotoxin type D.";  
 RN Nucleic Acids Res. 18:5556-5556(1990).  
 [2]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN-CB16;  
 RX MEDLINE=93042276; PubMed=1420572;

RA Sunagawa H., Ohyama T., Watanabe T., Inoue K.;  
 RT "The complete amino acid sequence of the Clostridium botulinum type D  
 RT neurotoxin, deduced by nucleotide sequence analysis of the encoding  
 RT phage d-16 phi genome.";  
 RL J. Vet. Med. Sci. 54:905-913(1992).  
 RN [3]  
 RC PARTIAL SEQUENCE.  
 RC STRAIN-D-SA, and D-1873;  
 RX MEDLINE-89339741; PubMed-2668193;  
 RA Morishita K., Syuto B., Kubo S., Oguma K.;  
 RT "Molecular diversity of neurotoxins from Clostridium botulinum type D  
 RT strains.";  
 RL Infect. Immun. 57:2886-2891(1989).  
 RN [4]  
 RP IDENTIFICATION OF SUBSTRATE.  
 RX MEDLINE-94230352; PubMed-8175689;  
 RA Yamasaki S., Baumeister A., Binz T., Blas J., Link E., Cornille F.,  
 RT Rogues B., Fyfe E.M., Stedhof T.C., Jahn R., Niemann H.;  
 RT Cleavage of members of the synaptobrevin/VAMP family by types D and  
 RL F botulinum neurotoxins and tetanus toxin.";  
 J. Biol. Chem. 269:12764-12772(1994).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE THAT CLEAVES THE 60-LYS-1-LEU-61 BOND OF  
 CC SYNAPTOSOMALIN-1 AND -2.  
 CC -1- CATALYTIC ACTIVITY: limited hydrolysis of proteins of the  
 CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
 CC detected action on small molecule substrates.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N- AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- MISCELLANEOUS: BOTULINUM TYPE D NEUROTOXIN IS SYNTHESIZED BY D  
 CC STRAIN OF CLOSTRIDIUM BOTULINUM WHICH CARRY THE APPROPRIATE  
 CC BACTERIOPHAGE.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement. (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 DR EMBL; X54254; CAA38175.1; -  
 DR EMBL; S49407; AAB24244.1; -  
 DR PIR: S11455; S11455.  
 DR HSSP: P10845; 3BTA.  
 DR MEROPS; M27.002; -  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_MTPeptidase.  
 DR Pfam: PF01742; Peptidase\_M27; 1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR ProDom: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
 KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.  
 FT CHAIN 1 442  
 FT METAL 1276  
 FT ACT\_SITE 229 230 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT METAL 230 233 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT METAL 233 233 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT DISULFID 437 450 INTERCHAIN (PROBABLE).  
 FT VARIANT 15 16 ND -> PV (IN STRAIN D-SA).  
 FT VARIANT 17 18 ND -> LQ (IN STRAIN D-1873).  
 FT VARIANT 452 452 K -> Q (IN STRAIN D-SA).  
 FT VARIANT 457 457 R -> T (IN STRAIN D-SA).  
 FT VARIANT

FT VARIANT 457 457 R -> F (IN STRAIN D-1873).  
 FT VARIANT 462 462 A -> D (IN STRAIN D-1873).  
 FT VARIANT 489 489 K -> N (IN STRAIN CB16).  
 FT VARIANT 644 644 N -> K (IN STRAIN CB16).  
 FT VARIANT 1122 1122 O -> R (IN STRAIN CB16).  
 FT SEQUENCE 1276 AA; 146871 MW; C1EC50F6C8233E2 CRC64;  
 Query Match 10.2%; Score 74; DB 1; Length 1276;  
 Best local Similarity 21.9%; Pred. No. 45;  
 Matches 30; Conservative 18; Mismatches 39; Indels 50; Gaps 5;  
 QY 3 SSILRGTKFLIKKYGASGNDIVRNNDVYINVVANKEKRLATN-----ASQAGYEKIL 57  
 DB 1127 SKLYTGNPTIKSVSDKNPYSRILNDGNTILHMLYNSRKMYILRDYITATGG----- 1181  
 QY 58 SALEIPDVGNLSQVVMVMSKNDGINTCKMN-----LDDNGN-DIGIFGHQFNNTA 110  
 DB 1182 -----ECSQNCVYALKLDSNLGNIGIGIF-----SIK 1208  
 QY 111 KLVASWYNRQIERSSR 127  
 DB 1209 NIVSKNKYCQIFSSFR 1225  
 RESULT 15  
 NISP\_LACLA STANDARD; PRT; 682 AA.  
 ID NISP\_LACLA  
 AC 007596;  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Nisin leader peptide processing serine protease nisp precursor  
 DE (EC 3.4.21.-).  
 GN NISP.  
 OS Lactococcus lactis (subsp. lactis) (Streptococcus lactis).  
 OC Bacteria; Firmicutes; Lactobacillales; Streptococcaceae; Lactococcus.  
 OX NCBI\_TaxID=1360;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-NIZO R5;  
 RX MEDLINE-93239683; PubMed-8478324;  
 RA van der Meer J.R., Polman J., Beerthuyzen M.M., Smeets R.J.,  
 RA Kuipers O.P., de Vos W.M.;  
 RT "Characterization of the Lactococcus lactis nisin A operon genes  
 RT nisp, encoding a subtilisin-like serine protease involved in  
 RT precursor processing, and nlsr, encoding a regulatory protein  
 RT involved in nisin biosynthesis.";  
 RL J. Bacteriol. 175:2578-2586(1993).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-6F3;  
 RX MEDLINE-94213458; PubMed-8161176;  
 RA Engelke G., Gutowski-Eckel Z., Klesau P., Siegers K.,  
 RA Hammelmann M., Ertlan K.-D.;  
 RT "Regulation of nisin biosynthesis and immunity in Lactococcus lactis  
 RT 6F3.";  
 RL Appl. Environ. Microbiol. 60:814-825(1994).  
 RN [3]  
 RP 3D-STRUCTURE MODELING.  
 RX MEDLINE-95357326; PubMed-7630881;  
 RA Stezen R.J., Rollemma H.S., Kuipers O.P., de Vos W.M.;  
 RT "Homology modelling of the Lactococcus lactis leader peptidase Nisp  
 RT and its interaction with the precursor of the lantibiotic nisin.";  
 RL Protein Eng. 8:117-125(1995).  
 CC -1- FUNCTION: CLEAVES THE LANTIBIOTIC NISIN PRECURSOR PEPTIDE.  
 CC -1- PATHWAY: Nisin biosynthesis; last step.  
 CC -1- SUBCELLULAR LOCATION: Attached to the cell wall peptidoglycan by  
 CC an amide bond (potential).  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S8.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL: L11061; AAA25200.1; -  
 DR EMBL: X76884; CAA54210.1; -  
 DR HSSP: P29600; 1GCI.  
 DR MEROPS: S08.059; -  
 DR InterPro: IPR001699; Gram\_pos\_anchor.  
 DR InterPro: IPR000209; Peptidase\_S8.  
 DR Pfam: PF00082; Peptidase\_S8; 1.  
 DR PRINTS: PR00723; SUBTILISIN.  
 DR PROSITE: PS00136; SUBTILASE\_ASP; 1.  
 DR PROSITE: PS00137; SUBTILASE\_HIS; 1.  
 DR PROSITE: PS00138; SUBTILASE\_SER; FALSE\_NEG.  
 DR PROSITE: PS50847; GRAM\_POS\_ANCHORING; FALSE\_NEG.  
 KM Hydrolyase; Serine protease; Cell wall; Peptidoglycan-anchor; Zymogen;  
 KW Signal.  
 FT SIGNAL 1 22 POTENTIAL.  
 FT PROPEP 23 195 POTENTIAL.  
 FT CHAIN 196 655 NISIN LEADER PEPTIDE PROCESSING SERINE  
 FT PROPEP 656 682 PROTEASE NISP.  
 FT ACT\_SITE 259 259 REMOVED BY SORTASE (POTENTIAL).  
 FT ACT\_SITE 306 306 CHARGE RELAY SYSTEM (BY SIMILARITY).  
 FT ACT\_SITE 512 512 CHARGE RELAY SYSTEM (BY SIMILARITY).  
 FT SITE 652 656 CHARGE RELAY SYSTEM (BY SIMILARITY).  
 FT MOD\_RES 655 655 LPXTG SORTING SIGNAL (POTENTIAL).  
 FT CONFLICT 500 500 AMIDE-LINKED TO CELL WALL (POTENTIAL).  
 SQ SEQUENCE 682 AA: 74767 MW: 74767 MM: D5F29313F2983EC9 CRC64;

Query Match 10.1%; Score 73.5; DB 1; Length 682;  
 Best Local Similarity 25.2%; Pred. No. 25;

Matches 37; Conservative 22; Mismatches 51; Indels 37; Gaps 8;

OY 12 IIRKYASGNKDNIVR-----NNDRYVINV-----YKNREYRLATNASQAGYEKILS 58  
 DB 525 VYDKYGIKPNQKRLNNSPEVNGNRV-LNIYDLNCKKKAFLDTDKGD-----D 577  
 OY 59 ALEIDVGNLSOV-VVMKSKNDGITNKCKMNLQDNGNDIGFIGHFQFNNTAKLVASNM 117  
 DB 578 AINHKSMENLKESRDTMKQEDKEIORNTNNNFSIKN-----DFHNISKEYISVD 627  
 OY 118 Y--NFOIERSRLGC---SWEFIPV 138  
 DB 628 YNINQMANNNRNSRGAVSYRQOEIILPV 654

Search completed: March 13, 2003, 11:40:38  
 Job time : 8.45533 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.4.p5\_4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

## OM protein - protein search, using sw model

Run on: March 13, 2003, 11:31:47 ; Search time 20.9798 seconds  
(without alignments)  
1374.968 Million cell updates/sec

Title: US-09-917-791-22

Perfect score: 727

Sequence: 1 LNSSLYRGTRFKTIKKYASGN.....QIERSRRLGCSWEPIPYDD 140

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPREMBL\_21:\*  
1: sp.archaea:\*  
2: sp.bacteria:\*  
3: sp.fungi:\*  
4: sp.human:\*  
5: sp.invertebrate:\*  
6: sp.mammal:\*  
7: sp.mnc:\*  
8: sp.organelle:\*  
9: sp.phage:\*  
10: sp.plant:\*  
11: sp.todent:\*  
12: sp.virus:\*  
13: sp.vertebrate:\*  
14: sp.unclassified:\*  
15: sp.virus:\*  
16: sp.bacteriap:\*  
17: sp.archaeap:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	341	46.9	72	2	Q9R540
2	282.5	38.9	1268	2	Q45851
3	277.5	38.2	1278	2	Q57236
4	260.5	35.8	1280	2	Q9ZAJ5
5	205	28.2	1251	2	Q9K395
6	197.5	27.2	1255	2	Q9FAR6
7	169.5	23.3	1291	2	Q08077
8	162	22.3	1291	2	Q9LA13
9	161.5	22.2	441	2	Q9X708
10	160.5	22.1	1291	2	Q93G71
11	160.5	22.1	1291	2	Q933K0
12	160.5	22.1	1291	2	Q9ZAJ8
13	160	22.0	1310	2	Q93N27
14	110	13.1	315	16	Q97F01
15	100	13.8	1291	2	Q93HT3
16	95	13.1	1285	2	Q91BR1

17	95	13.1	1285	2	Q45967	Q45967 clostridium
18	88.5	12.2	264	16	Q8REB6	Q8REB6 fuscobacteri
19	88	12.1	408	15	Q11572	Q11572 human immun
20	87.5	12.0	204	15	Q9D980	Q9D980 human immun
21	86.5	11.9	401	15	Q11575	Q11575 human immun
22	85.5	11.8	467	16	Q97N26	Q97N26 clostridium
23	85	11.7	1593	5	Q8T177	Q8T177 dictyosteli
24	84.5	11.6	848	15	Q9WC60	Q9WC60 human immun
25	83	11.4	245	16	Q8RDM8	Q8RDM8 fuscobacteri
26	83	11.4	408	15	Q11570	Q11570 human immun
27	83	11.4	409	15	Q11571	Q11571 human immun
28	83	11.4	1483	3	Q96UL6	Q96UL6 diaporthe a
29	83	11.4	4550	5	Q77336	Q77336 plasmodium
30	82.5	11.3	479	10	Q9M6B4	Q9M6B4 nicotiana t
31	82	11.3	255	16	Q8XK40	Q8XK40 clostridium
32	82	11.3	408	15	Q11567	Q11567 human immun
33	81.5	11.2	235	2	Q93D91	Q93D91 streptococc
34	81.5	11.2	408	15	Q11574	Q11574 human immun
35	81.5	11.2	1077	1	Q977Q4	Q977Q4 methanosarc
36	81.5	11.2	1869	12	Q8V2H2	Q8V2H2 camelpox vi
37	81.5	11.2	1869	12	Q8QXZ7	Q8QXZ7 camelpox vi
38	81	11.1	336	12	Q91M09	Q91M09 lumpey skin
39	81	11.1	1301	5	Q8W5K5	Q8W5K5 plasmodium
40	81	11.1	1484	3	Q8TGV4	Q8TGV4 diaporthe p
41	80	11.0	1122	3	Q8X1C2	Q8X1C2 photopsis s
42	79.5	10.9	214	15	Q74058	Q74058 human immun
43	79.5	10.9	233	16	Q92C15	Q92C15 listeria in
44	79.5	10.9	307	16	Q8XK10	Q8XK10 clostridium
45	79.5	10.9	1807	5	Q8WSL1	Q8WSL1 plasmodium

## ALIGNMENTS

RESULT 1									
Q9R540		PRELIMINARY:		PRT:		72 AA.			
AC	Q9R540:								
DT	01-MAY-2000 (TREMBLrel. 13, Created)								
DT	01-MAY-2000 (TREMBLrel. 13, Last sequence update)								
DT	01-OCT-2000 (TREMBLrel. 15, Last annotation update)								
DE	Neurotoxin heavy chain 18 kDa fragment (Fragment).								
OS	Clostridium botulinum.								
OC	Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;								
OC	Clostridiales; Clostridiaceae; Clostridium.								
OX	NCBI_TaxID=1491;								
RN	[1]								
RP	SEQUENCE.								
RP	MEDLINE=94000342; PubMed=8397793;								
RA	Gimenez J.A., Dasgupta B.R.;								
RT	"Botulinum type A neurotoxin digested with pepsin yields 132, 97, 72,								
RT	45, 42, and 18 kD fragments."								
RT	J. Protein Chem. 12:351-363(1993).								
DR	HSP; P10845; 3BPA.								
SQ	SEQUENCE 72 AA; 8165 MW; 87A959576A615E18 CRC64;								
Query Match									
Best Local Similarity		46.9%;	Score 341;	DB 2;	Length 72;				
Matches 69;		Conservative	0;	Mismatches 1;	Indels	0;	Gaps	0;	
OY	1 LNSSLYRGTRFKTIKKYASGNKDINVRNDRVYINVVKKKEYRLATNASQAVEKLSAL 60								
DB	3 LNSSLYRGTRFKTIKKYASGNKDINVRNDRVYINVVKKKEYRLATNASQAVEKLSAL 62								
OY	61 EIPDVGNLSQ 70								
DB	63 EIPDVGNLSQ 72								
RESULT 2									
ID	Q45851	PRELIMINARY:		PRT:		1268 AA.			
AC	Q45851:								

DT 01-NOV-1996 (TREMBlrel. 01, Created)  
DT 01-NOV-1996 (TREMBlrel. 01, last sequence update)  
DT 01-DEC-2001 (TREMBlrel. 19, last annotation update)  
DE Neurotoxin type F.  
GN BONT/F.  
OS Clostridium baratii.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
ON NCBI\_TaxId=1561;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=93252228; PubMed=8486245;  
RA Thompson D.E., Hutson R.A., East A.K., Allaway D., Collins M.D.,  
RA Richardson P.T.;  
RT "Nucleotide sequence of the gene coding for Clostridium baratii type F  
neurotoxin: Comparison with other clostridial neurotoxins.";  
RL FEMS Microbiol. Lett. 108:175-182(1993).  
DR EMBL: X68262; CAA48329.1; -.  
DR HSSP: P10845; 3BTA.  
DR MEROPS: M27.002; -.  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_MTpeptidse.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRINTS: PR00760; BONTOXILYSIN.  
DR PRODOM: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
SQ SEQUENCE 1268 AA; 145513 MW; 963040091AC15ED2 CRC64;

Query Match 38.9%; Score 282.5; DB 2; Length 1268;  
Best Local Similarity 45.3%; Pred. No. 1.5e-17;  
Matches 63; Conservative 19; Mismatches 44; Indels 13; Gaps 5;

QY 2 NSSLYRGTFEIIKKVAS---GNKDNIVRNNDRYIYVYVVKNEKRYLATNASQAGVERILS 58  
DB 1131 NARLYGVEVILIKVSTDSNTDNFVRKNDYIYVYVGSNSRYQLADYSTGAVERTIK 1190  
QY 59 ALEIIPVG-NLSGVYVVKSKNDGKITNCKMNIQDNNGNDIGTIGFHOENNIKLVASNW 117  
DB 1191 LRRISNYSNYSNMQIIMDS----IGDNCTMNFKNYNGNDIGLGFH-LNN--LVASSW 1241  
QY 118 YNRQIERSRSLGCSWEFI 136  
DB 1242 YKNIINRNTRNNGCEWSFI 1260

## RESULT 3

ID 057236 PRELIMINARY; PRT: 1278 AA.  
AC 057236; Q45863;  
DT 01-NOV-1996 (TREMBlrel. 01, Created)  
DT 01-NOV-1996 (TREMBlrel. 01, last sequence update)  
DT 01-JUN-2001 (TREMBlrel. 17, last annotation update)  
DE Botulinum neurotoxin type F (BONT/F protein).  
GN BONT/F.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
ON NCBI\_TaxId=1491;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX STRAIN=NCCTC 10281;  
RA Hutson R.A., Collins M.D.;  
RL Submitted (Aug-1995) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RA Elmore M.J., Bodsworth N.J., Whelan S.M., Minton N.P.;  
RL Submitted (Aug-1994) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP SEQUENCE OF 635-1000 FROM N.A.  
RX STRAIN=NCCTC 1028;  
RA MEDLINE=94013372; PubMed=8408542;  
RX Campbell K., East A.K., Collins M.D.;  
RT "Gene probes for identification of the botulinum neurotoxin gene and

RT specific identification of neurotoxin types B, E, and F.";  
RL J. Clin. Microbiol. 31:2255-2262(1993).  
RN [4]

RP SEQUENCE OF 1-27 FROM N.A.  
RX STRAIN=LANCELAND;  
RX MEDLINE=98404102; PubMed=9732534;  
RA East A.K., Bhandari M., Hieim S., Collins M.D.;  
RT "Analysis of the botulinum neurotoxin type F gene clusters in  
RT proteolytic and nonproteolytic Clostridium botulinum and Clostridium  
RT baratii";  
RL Curr. Microbiol. 37:262-268(1998).  
DR EMBL: X61714; CAA57358.1; -.  
DR EMBL: L35496; AAA23210.1; -.  
DR EMBL: X70821; CAA50152.1; -.  
DR EMBL: X99064; CAA67512.1; -.  
DR HSSP: P10845; 3BTA.  
DR MEROPS: M27.002; -.  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_MTpeptidse.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRINTS: PR00760; BONTOXILYSIN.  
DR PRODOM: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
KW Neurotoxin.  
SQ SEQUENCE 1278 AA; 147073 MW; A1BE1318431D6918 CRC64;

Query Match 38.2%; Score 277.5; DB 2; Length 1278;  
Best Local Similarity 44.6%; Pred. No. 4.5e-17;  
Matches 62; Conservative 19; Mismatches 45; Indels 13; Gaps 4;

QY 2 NSSLYRGTFEIIKKVAS---GNKDNIVRNNDRYIYVYVVKNEKRYLATNASQAGVERILS 58  
DB 1140 NTRLYGVEVILIKRKNSTDSNTDNFVRKNDLAYIYVVDORDEVRYLYADISIAKPEKIK 1199  
QY 59 ALEIIPVG-NLSGVYVVKSKNDGKITNCKMNIQDNNGNDIGTIGFHOENNIKLVASNW 117  
DB 1200 LIFTSNNSNLGQIYVDS----IGNCTMNFQNNNGNIGLGFHSNN--LVASSW 1250  
QY 118 YNRQIERSRSLGCSWEFI 136  
DB 1251 YNNIKRNTSSNCGFWSFI 1269

## RESULT 4

ID 092A75 PRELIMINARY; PRT: 1280 AA.  
AC 092A75;  
DT 01-MAY-1999 (TREMBlrel. 10, Created)  
DT 01-MAY-1999 (TREMBlrel. 10, last sequence update)  
DT 01-DEC-2001 (TREMBlrel. 19, last annotation update)  
DE Bont protein.  
GN BONT.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
ON NCBI\_TaxId=1491;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX STRAIN=CDC 3281;  
RX MEDLINE=98440323; PubMed=9767710;  
RA Santos-Bueiga J., Collins M.D., East A.K.;  
RT "Characterization of the genes encoding the Botulinum neurotoxin  
RT complex in a strain of clostridium botulinum producing type B & F  
RT neurotoxins";  
RL Curr. Microbiol. 37:312-318(1998).  
DR EMBL: Y13631; CAA73972.1; -.  
DR HSSP: P10845; 3BTA.  
DR MEROPS: M27.002; -.  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; Zn\_MTpeptidse.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR PRINTS: PR00760; BONTOXILYSIN.  
DR PRODOM: PD001963; Bontoxilysin; 1.



DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
SQ SEQUENCE 1280 AA; 147487 MW; D0F748976EBC222C CRC64;  
Query Match 35.8%; Score 260.5; DB 2; Length 1280;  
Best Local Similarity 42.9%; Pred. No. 1.7e-15;  
Matches 60; Conservative 19; Mismatches 48; Indels 13; Gaps 4;  
OY 1 LNSSLYRGTFILIKRYAS--GNKDNIVRNNDRYINWVYKNEKRYLATNASQAGYEKIL 57  
DB 1142 LNKLYEGEYIIRKNAPIDISWDFVRKNDLAYINVDHGEYLDLYDISTTKEKIL 1201  
OY 58 SALEIFDVG-NLSQVYVYKSKNDGITTNCCKNLQDNNGNDIGFIFGHQFNNTAKLVASN 116  
DB 1202 KLIRTSNPNDLSGQIIVMDS-----IGNCTMNFQNDGNSIGLIGFHSDD---LVASS 1252  
OY 117 WYNROIESSRTLCGSWEFI 136  
DB 1253 WYNNHRRNTSSNGCFWSPF 1272  
RESULT 5  
OY 09K395 PRELIMINARY; PRT; 1251 AA.  
AC 09K395;  
DT 01-OCT-2000 (TREMBLrel. 15, Created)  
DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update)  
DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)  
DE Type E botulinum toxin.  
GN BONT/E.  
OS Clostridium butyricum.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;  
OC Clostridiales; Clostridiaceae; Clostridium.  
OX NCBI\_Taxid=1492;  
RN [1]  
RC SEQUENCE FROM N.A.  
RA STRAIN=LCL 095;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (LCL 095) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [2]  
RC SEQUENCE FROM N.A.  
RA STRAIN=LCL 155;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Gyobu Y., Yamakawa K.,  
RA Kato H., Nakamura S., Karasawa T.;  
RT "C. butyricum (LCL 155) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [3]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1899;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (KZ 1899) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [4]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1897;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (KZ 1897) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [5]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1898;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (KZ 1898) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [6]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1886;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;

RT "C. butyricum (KZ 1886) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [7]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1887;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (KZ 1887) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [8]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1889;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (KZ 1889) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [9]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1890;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (KZ 1890) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [10]  
RC SEQUENCE FROM N.A.  
RA STRAIN=KZ 1891;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (KZ 1891) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [11]  
RC SEQUENCE FROM N.A.  
RA STRAIN=LCL 063;  
RA Wang X., Maegawa T., Kozaki S., Tsukamoto K., Kato H., Nakamura S.,  
RA Karasawa T.;  
RT "C. butyricum (LCL 063) gene for type E botulinum toxin.";  
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.  
RN [12]  
RC EMBL; AB037714; BAB03522.1;  
DR EMBL; AB037704; BAB03512.1;  
DR EMBL; AB037705; BAB03513.1;  
DR EMBL; AB037706; BAB03514.1;  
DR EMBL; AB037707; BAB03515.1;  
DR EMBL; AB037708; BAB03516.1;  
DR EMBL; AB037709; BAB03517.1;  
DR EMBL; AB037710; BAB03518.1;  
DR EMBL; AB037711; BAB03519.1;  
DR EMBL; AB037712; BAB03520.1;  
DR EMBL; AB037713; BAB03521.1;  
DR HSSP; P10845; 3BPA.  
DR MEROPS; M27.002; -;  
DR InterPro; IPR000395; Bontoxilysin.  
DR InterPro; IPR000130; Zn\_Mpeptidse.  
DR Pfam; PF01742; Peptidase\_M27; 1.  
DR PRINTS; PR00760; BONTOTOXILYSIN.  
DR Prodom; PD001963; Bontotoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
SQ SEQUENCE 1251 AA; 143751 MW; 2021F4E427070296 CRC64;  
Query Match 28.2%; Score 205; DB 2; Length 1251;  
Best Local Similarity 36.2%; Pred. No. 2.4e-10;  
Matches 50; Conservative 20; Mismatches 54; Indels 14; Gaps 5;  
OY 1 LNSSLYRGTFILIKRY-ASGNKDNIVRNNDRYINWVYKNEKRYLATNASQAGYEKIL 59  
DB 1117 LANRLYSGLIKYVIRVNDSTNDRVFRKNDQYIYINSSSYSLYADNTTDEKTIKS 1176  
OY 60 LEIPDVG-NLSQVYVYKSKNDGITTNCCKNLQDNNGNDIGFIFGHQFNNTAKLVASNY 118  
DB 1177 ---SSGNRFNDVYVANS-----VGNCTMNFKNNGNIGLGF---KADTVASTWY 1224  
OY 119 NROIERSSRTLCGSWEFI 136  
DB 1225 YTHMRDHTNSNGCFWNPFI 1242

```

RESULT 6
09FAR6 PRELIMINARY; PRT; 1255 AA.
AC 09FAR6;
DT 01-MAR-2001 (TREMblrel. 16, Created)
DT 01-MAR-2001 (TREMblrel. 16, last sequence update)
DE 01-DEC-2001 (TREMblrel. 19, last annotation update)
DE Type E botulinum toxin.
GN BONT/E.
OS Clostridium butyricum.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
OC Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_Taxid=1492;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BL 6340/ATCC 43755/BL 5520/K2 147;
RX MEDLINE=20509829; PubMed=11055954;
RA Wang X., Maegawa T., Katsawa T., Kozaki S., Tsukamoto K., Gyobu Y.,
RA Yamakawa K., Oguma K., Sakaguchi Y., Nakamura S.;
RT "Genetic Analysis of Type E Botulinum Toxin-Producing Clostridium
RT butyricum Strains.",
RL Appl. Environ. Microbiol. 66:4992-4997(2000).
DR EMBL; AB039264; BAB12249.1; -.
DR HSSP; P10845; 3BTA.
DR InterPro: IPR000395; Bontoxilysin.
DR InterPro: IPR000130; Zn_MTPeptidse.
DR Pfam: PF01742; Peptidase_M27; 1.
DR PRINTS; PR00760; BONTOTOXILYSIN.
DR ProDom; PD001963; Bontoxilysin; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
SQ SEQUENCE 1255 AA; 143918 MW; 1B557B9D5C8EAD CRC64;

Query Match 27.2%; Score 197.5; DB 2; Length 1255;
Best Local Similarity 38.4%; Pred. No. 1,2e-09;
Matches 53; Conservative 20; Mismatches 52; Indels 13; Gaps 6;

QY 1 LNSLYRGTEFIIRKY-ASGNKDNIVANNDRVYINVVYKKEKRLATNASQAGEKILSA 59
DB 1120 LANRLVSGIKVKIQVNNSTNDIVKKNQYVINFPA-SKTHLLPLVADTATTK-EKT 1177
QY 60 LEIPDVGN-LSQVYVMSKNDGKITNKCKMNLDDNNGNDIGTGFHGFNNIAKLVASNWY 118
DB 1178 IKISSGGRNQVYVYMS-----VGNCTMFRKNNNGNINIGLGF----KADTVVASTWY 1228
QY 119 NRQIERSRRLGCSWERT 136
DB 1229 YTHMDNTNSGFFWMT 1246

RESULT 7
008077 PRELIMINARY; PRT; 1291 AA.
AC 008077;
DT 01-NOV-1996 (TREMblrel. 01, Created)
DT 01-NOV-1996 (TREMblrel. 01, last sequence update)
DE 01-JUN-2001 (TREMblrel. 17, last annotation update)
DE Botulinum neurotoxin type B (EC 3.4.24.-) (BONT/B).
GN BONT/B.
OS Clostridium botulinum.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
OC Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_Taxid=1491;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=EKUND 17B ATCC25765;
RX MEDLINE=94122659; PubMed=7764370;
RA Hutson R.A., Collins M.D., East A.K., Thompson D.E.;
RT "Nucleotide sequence of the gene coding for non-proteolytic
RT Clostridium botulinum type B neurotoxin: comparison with other
RT Clostridia neurotoxins.",
RL Curr. Microbiol. 28:101-110(1994).

```

```

CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER
CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED
CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD
CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT
CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC
CC ENDOPEPTIDASE THAT CLEAVES SYNAPTOBREVIN-2.
CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A A
CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,
CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL
CC FORMATION AND TOXIN BINDING, RESPECTIVELY.
CC -1- SUBCELLULAR LOCATION: SECRETED.
CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF
CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.
CC -1- SIMILARITY: HIGH WITH OTHER BOTULINUM NEUROTOXINS AND WITH TETANUS
CC NEUROTOXIN.
CC -1- SIMILARITY: TO OTHER ZINC METALLOPROTEINASES IN THE ACTIVE SITE
CC REGION.
DR EMBL; X71343; CAA50482.1; -.
DR HSSP; P10845; 3BTA.
DR MEROPS; M27.002; -.
DR InterPro: IPR000395; Bontoxilysin.
DR InterPro: IPR000130; Zn_MTPeptidse.
DR Pfam: PF01742; Peptidase_M27; 1.
DR PRINTS; PR00760; BONTOTOXILYSIN.
DR ProDom; PD001963; Bontoxilysin; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.
SQ SEQUENCE 1291 AA; 150513 MW; 71BCAFE23D65FAAA CRC64;

```

```

Query Match 23.3%; Score 169.5; DB 2; Length 1291;
Best Local Similarity 28.3%; Pred. No. 4,8e-07;
Matches 43; Conservative 39; Mismatches 53; Indels 17; Gaps 7;

```

```

QY 4 SLVYRGTEFIIRKASGN-KDNIVANNDRVYINVVYKKEKRL-ATNASQAGEKILSLA 60
DB 1138 NLTYGEKFIIRRESNOSINDIVRKEDYIHDLVHHEMRVYAYKRYKEDEKFLPLSI 1197
QY 61 EIPDVGNLSQVYVMSKNDGKITNKCKM-NLDDNNGNDIGTGFHGFNNIAKL----- 112
DB 1198 -IDSNSMEFYVTEIEKEDGP-SYSCQLLEKKDEESPDDIGLGHFRFYSGLVLRKKYKD 1255
QY 113 --VASMNYNRQIERS--SRILGCSWERTIPVD 140
DB 1256 YFCISKRYLKEVKRKYKSNLGNMOLFIPKDE 1287

RESULT 8
09LAI3 PRELIMINARY; PRT; 451 AA.
AC 09LAI3;
DT 01-OCT-2000 (TREMblrel. 15, Created)
DT 01-OCT-2000 (TREMblrel. 15, last sequence update)
DE 01-DEC-2001 (TREMblrel. 19, last annotation update)
DE Tetanus toxin (Fragment).
GN Clostridium tetani.
OS Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
OC Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_Taxid=1513;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=20886;
RA He H.J., Shi H.J., He Z.Y., Yuan Q.S., Wu X.F.;
RT "Fragment C of Tetanus Toxin.",
RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF154826; AAF73267.1; -.
DR HSSP; P04958; 1ABD.
DR InterPro: IPR001064; Crystallin.
DR PROSITE; PS00225; CRYSTALLIN_BETAGAMMA; UNKNOWN_1.
FT NON_TER 1
SQ SEQUENCE 451 AA; 51823 MW; 69ABC5F030B6C8E CRC64;

Query Match 22.3%; Score 162; DB 2; Length 451;
Best Local Similarity 27.5%; Pred. No. 6,6e-07;

```

[illegible]

RESULT 9									
ID	09X708	PRELIMINARY:	PRF:	441 AA.					
AC	09X708:								
DT	01-NOV-1999 (TREMBlrel. 12, Created)								
DT	01-NOV-1999 (TREMBlrel. 12, Last sequence update)								
DT	01-DEC-2001 (TREMBlrel. 19, Last annotation update)								
DE	Bacillus neurotoxin type B (fragment).								
GN	BONT/B.								
OS	Clostridium botulinum.								
OC	Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;								
OC	Clostridiales; Clostridiaceae; Clostridium.								
OX	NCBI_TaxID=1491;								
RN	[1]								
RP	SEQUENCE FROM N.A.								
RX	MEDLINE=99343691; PubMed=10413679;								
RA	Lalli G., Herreros J., Osborne S.L., Montecucco C., Rossetto O.,								
RA	Schiavo G.;								
RT	"Functional characterisation of tetanus and botulinum neurotoxins								
RT	binding domains.";								
RL	J. Cell Sci. 112:2715-2724(1999).								
DR	EMBL; AJ242628; CAB43706.1; "-								
DR	HSSP; P10845; 3BTA.								
KM	Neurotoxin.								
FT	NON_TER	1	1						
FT	NON_TER	441	441						
SO	SEQUENCE	441 AA;	52772 MW;	7210DB468B8C95A4	CRC64;				
	Query Match	22.2%	Score 161.5;	DB 2;	Length 441;				
	Best Local Similarity	27.9%;	Pred. No. 7.2e-07;						
	Matches 41;	Conservative 33;	Mismatches 56;	Indels 15;	Gaps				
QY	4	SLYRGTKEPIIKKYYASGN--KDNIVANNDRVYINVVAKNKEYRLATNASAGYEKILSALE	61						
Db	296	NLYIGKEKPIIRKRSNSQSIINDIVAKEDYIYLDFFNSNEMRWYAVAKDFKEBEKKVLVLAN	355						
QY	62	IPDVNLSQVYVVMKSKKNOGITNKCKM--NLDDNNNGNDIGFGFQFNNAIKLV-----	113						
Db	356	IYDSNEFYKTIQIKFYDDP--TYSQLLFKKDEESTDEIGLIHFYESSGIYLDYKNY	414						
QY	114	--ASNMVNRQIERS--SRTLGSWEFI	136						
Db	415	FCISKWLKLEVKRKRYNPNLGCMQFI	441						
RESULT 10									
ID	093G71	PRELIMINARY:	PRF:	1291 AA.					
AC	093G71:								
DT	01-DEC-2001 (TREMBlrel. 19, Created)								
DT	01-DEC-2001 (TREMBlrel. 19, Last sequence update)								
DT	01-MAR-2002 (TREMBlrel. 20, Last annotation update)								
DE	Neurotoxin type B.								
OS	Clostridium botulinum.								
OC	Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;								
OC	Clostridiales; Clostridiaceae; Clostridium.								
OX	NCBI_TaxID=1491;								
RN	[1]								

RP SEQUENCE FROM N.A.  
RC STRAIN-1436;  
RA Klisma N., Ferreira J.L., Baumstark B.R.;  
RT "Characterization of six types of Clostridium botulinum that  
RL contain type B toxin gene sequences.";  
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF295926; AAK97132.1; ~  
DR InterPro: IPR000395; Bontoxilysin.  
DR InterPro: IPR000130; zn\_MTPeptide.  
DR Pfam: PF01742; Peptidase\_M27; 1.  
DR ProDom: PD001963; Bontoxilysin; 1.  
DR PROSITE: PS00142; ZINC\_PROTEASE; UNKNOWN\_1.  
SQ SEQUENCE 1291 AA; 150824 MW; D/CA07BAE2EB8C02 CRC64;

```
Query Match          22.1%; Score 160.5; DB 2; Length 1291;
Best Local Similarity 28.0%; Pred. No. 3.3e-06;
Matches 42; Conservative 31; Mismatches 62; Indels 15; Gaps 5;
```

```
OY      5 LYRGCFEIIKKKVASGN--KDNIVRNNDRYIVVVKNKREYLRTATNASQAGVEKITLSALEI 62
        ||| |::|| :: :   |:||| :|:: :    |:||| :   | :| | 
Db       1139 LYGKGFILRRKSNSQSINDLIVRKEDITYIDFNLQDMERYIKKYRKEEKLFAP I 1198
OY      63 PDVGMLSOVVVMKSKNDGITNNCKM--NLDDNGNDIGFGFHFNPIA-----KL 112
        : :| ::| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
Db       1199 SDSDFEVMTIQIKEVDGP-TYSCLLRKKDEESTDELGLIGHRFESGIYFKKEYDY F 1257
OY     113 VASNMWNRIOERS--SRTLGCSEFIIPDVD 140
        | || :::::| :| ::|||:||| :| :| :| :| :| :| :| :| :|
Db       1258 CISKWYLEKVRRKPYPNSRLGGCMWFEPDPD 1287


RESULT 11
O933KO          PRELIMINARY;             PRF: 1291 AA.
AC              O933K0;
DT       01-DEC-2001 (TREMBLElrel. 19, Created)
DT       01-DEC-2001 (TREMBLElrel. 19, last sequence update)
DT       01-MAR-2002 (TREMBLElrel. 20, last annotation update)
DE       Type B cryptic neurotoxin.
OC       Clostridium botulinum.
OC       Bacillaria; Firmicutes; Bacillus/Clostridium group; Clostridia;
OX       Clostridiales; Clostridiaceae; Clostridium.
OX       NCBI_TaxID=1491;
RN       [1]
RP       SEQUENCE FROM N.A.
RC       STRAIN=593, AND 588;
RA       Kirma N., Ferreira J.L., Baumstark B.R.;
RT       "Characterization of six type A strains of Clostridium botulinum that contain type B toxin gene sequences."
RI       Submitted (Aug-2000) to the EMBL/GenBank/DBJ databases.
DR       EMBL; AF300466; AAL11499.1; -
DR       EMBL; AF300465; AAL11498.1; -
DR       InterPro: IPRO000395; Bontoxilysin.
DR       InterPro: IPRO00130; Zn_Metpeptase.
DR       Pfam; PF01742; Peplidase_M27; 1.
DR       ProDom; PDOM01963; Bontoxilysin; 1.
DR       PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
FW       Neurotoxin.
SQ       SEQUENCE 1291 AA; 150843 MW; 7AC1737B0FA5A151 CRC64;
```

```
Query Match          22.1%; Score 160.5; DB 2; Length 1291;
Best Local Similarity 28.0%; Pred. NO. 3.3e-06;
Matches 42; Conservative 31; Mismatches 62; Indels 15; Gaps 5;
```

```
OY      5 LYRGCFEIIKKKVASGN--KDNIVRNNDRYIVVVKNKREYLRTATNASQAGVEKITLSALEI 62
        ||| |::|| :: :   |:||| :|:: :    |:||| :   | :| | 
Db       1139 LYGKGFILRRKSNSQSINDLIVRKEDITYIDFNLQDMERYIKKYRKEEKLFAP I 1198
OY      63 PDVGMLSOVVVMKSKNDGITNNCKM--NLDDNGNDIGFGFHFNPIA-----KL 112
        : :| ::~| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
Db       1199 SDSDFEVMTIQIKEVDGP-TYSCLLRKKDEESTDELGLIGHRFESGIYFKKEYDY F 1257
OY     113 VASNMWNRIOERS--SRTLGCSEFIIPDVD 140
        | || :::::| :| ::|||:||| :| :| :| :| :| :| :| :| :|
Db       1258 CISKWYLEKVRRKPYPNSRLGGCMWFEPDPD 1287
```

```

Db      1258 CISKWYLKEVKKRPYNSKLGCMNWQFIKPDE 1287
          | ||:::| : ||::||| |
RESULT 12
O9ZAJ8 ID O9ZAJ8 PRELIMINARY; PRT; 1291 AA.
AC O9ZAJ8;
DT 01-MAY-1999 (TREMBLrel. 10, Created)
DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)
DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
DE Bont protein.
GN BONT.
OS Clostridium botulinum.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
CC Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_TaxID=1491;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CDC 3281;
RC MEDLINE=98440323; PubMed=9767710;
RA Santos-Buelga J., Collins M.D., East A.K.;
RA "Characterization of the genes encoding the Botulinum neurotoxin
RT complex in a strain of clostridium botulinum producing type B & F
RT neurotoxins."
RL Curr. Microbiol. 37:312-318(1998).
DR EMBL; Y13630; CAA73968.1; -.
DR HSSP; P10845; 3BTA.
DR MEROPS; M27.002; -.
DR InterPro: IPR000395; Bontoxilysin.
DR InterPro: IPR000130; Zn_Mpeptidse.
DR Pfam; PF01742; Peptidase_M27; 1.
DR PRINTS; PR00760; BONT0XILYSIN.
DR PRODOM; PD001963; Bontoxilysin; 1.
DR POSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
SQ SEQUENCE 1291 AA; 150840 MW; E4D3B0E46AB2E735 CRC64;

Query Match 22 1%; Score 160.5; DB 2; Length 1291;
Best Local Similarity 28.0%; Pred. No. 3.3e-06;
Matches 42; Conservative 31; Mismatches 62; Indels 15; Gaps 5

OY 5 LYRGFTIIKKKVASGN--KDNIVRNNDRYIVVVVNKKERYLATNASQAGVEKITSLATEI 62
    || ||||::: : |||| |::: |::: |::: |::: |
DB 1139 LITGKFETIRRSKNSQSINDIVRKEDYLYLPFNLMQWRYYMKYFKKEBEKLFLAPI 1198
        : : : : | 1:: : : : | 1:1

OY 63 PYGVNLISOVYVVKSKNDCSTINKCKM--NLQDNNGNDIGFIFGHOFNNIA-----KL 112
        : : : : | 1:: : : : | 1:1

DB 1199 SDSDEFNYNTIQKEYDEGP-TYSCOLFKEKDESDTELGLIHREYESGIYFKEYKYDF 1257
        : : : : | 1::: ||::||| |

OY 113 VASNMVNRIOERS--SRITGCSEMFIPVD 140
    | ||:::| : ||::||| |
DB 1258 CISKWYLKEVKKRPYNSKLGCMNWQFIKPDE 1287

RESULT 13
O93AN27 ID O93AN27 PRELIMINARY; PRT; 1310 AA.
AC O93AN27;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
DE Tetanus toxin (Fragment).
OS Clostridium tetani.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
CC Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_TaxID=1513;
RN [1]
RP SEQUENCE FROM N.A.
RC Shumin Z., Dianliang L.;
RT "Cloning and sequence analysis of tetanus toxin gene.";
RL Submitted (JUN-2001) to the EMBL/Genbank/DBJ databases.
EMBL; AF369424; AAK72964.2; -.
InterPro: IPR000395; Bontoxilysin.

```

	DR	InterPro: IPR001064; Crystallin.
	DR	InterPro: IPR000130; zn_Mpeptide.
	DR	Pfam: PF01742; Peptidase_M27; 1.
	DR	ProDom: PD001963; Bontoxilysin; 1.
	DR	PROSITE: PS00225; CRYSTALLIN_BETAGAMMA; UNKNOWN_1.
	DR	PROSITE: PS00142; ZINC_PROTEASE; UNKNOWN_1.
	FT	NON_TER 1 1
	FT	NON_TER 1310 1310
	SQ	SEQUENCE 1310 AA; 150316 MW; 9EADDC914418EA50 CRC64;
	Query Match	22.0%; Score 160; DB 2; Length 1310;
	Best Local Similarity	27.7%; Pred. No. 3.7e-06;
	Matches 44; Conservative 24; Mismatches 49; Indels 42; Gaps 6;	
Oy	5	LYRGRKFIKKRASGNK-DNIVRNNDRIYINVVKNREY-----RLA 45
Dd	1170	LYSGLKFTIKRYTPPNNEIDFVRSDGFKLKYLVNNNEHVGPKDGAENNLDIRLVRG 1229
Oy	46	TNASOAGEKILISALEIPDVGNLSGVVWKSNDGDITKRCMNIODNNGNDIGFGFH- 104
Dd	1230	VNAAPILPLKKHVAVKLRDK-----TYSVDKLXDDKASLGVLGTIN 1273
Oy	105	-QFNNIAR--LVASNMYNRQIERSSRTLCGSWEFIPVD 139
Dd	1274	GQIGNDPNDRIILIASNWYFNHLK-DKTLTCOWYEVPTD 1310
	RESULT 14	
ID	O97FU1	PRELIMINARY; PRT; 315 AA.
AC	O97FU1:	
DT	01-OCT-2001 (TREMBRel. 18, Created)	
DT	01-OCT-2001 (TREMBRel. 18, Last sequence update)	
DT	01-OCT-2001 (TREMBRel. 18, Last annotation update)	
DE	Hypothetical protein CAC2635.	
OS	Clostridium acetobutylicum.	
OC	Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;	
OC	Clostridiales; Clostridiaceae; Clostridium.	
RX	NCBI_TaxID=1488;	
RN	[1]	
RP	SEQUENCE FROM N.A.	
RC	STRAIN-ATCC 824 / DSM 792 / VKM B-1787;	
RX	MEDLINE-21359325; PubMed=11466286;	
RA	Noelling J., Breton G., Omelchenko M.V., Makarova K.S., Zeng Q.,	
RA	Gibson R., Lee H.M., Dubois J., Qiu D., Hiltl J., Wolf Y.I.,	
RA	Tatusov R.L., Sabathe F., Doucette-Stamm L., Soucaille P., Daly M.J.,	
RA	Bennett G.N., Koonin E.V., Smith D.R.;	
RT	"Genome sequence and comparative analysis of the solvent-producing	
RT	bacterium Clostridium acetobutylicum.";	
RL	J. Bacteriol. 183:4823-4838(2001).	
DR	EMBL; AE007761; AAK80582.1; "	
KW	Hypothetical protein; Complete proteome.	
SQ	SEQUENCE 315 AA; 36592 MW; 1188CD3EE3A2124 CRC64;	
	Query Match	15.1%; Score 110; DB 16; Length 315;
	Best Local Similarity	32.6%; Pred. NO. 0.028;
	Matches 44; Conservative 21; Mismatches 52; Indels 18; Gaps 8;	
Oy	12	IIRKTV---ASGRKDIV--RNNDRIYINVVKNKEYRL--AINASOAGEKILISALE--I 62
Dd	47	IIRKDYVTGGDLKNDIYIKINNKKSIYAVKSKDIYTLQPSHKMLNSLGYKXSPLKLL 106
Oy	63	PDVG--NLTSVVVMKSKDOG----IINKCM-NLODNNGNDIGFIGPHQENNIAKLYA 114
Dd	107	TDSVDKNISELFQSSSENNNTNLQHLFIWDKTKFKDILTNNIIIGFIDVHN-NKITPKIIS 165
Oy	115	SNWYNROIERSSRTL 129
Dd	166	SNFNNDLVFSNYIL 180
	RESULT 15	

```

O93HT3
ID O93HT3 PRELIMINARY; PRT; 1291 AA.
AC O93HT3:
DT 01-DEC-2001 (TRENBLREL. 19, Created)
DT 01-DEC-2001 (TRENBLREL. 19, Last sequence update)
DT 01-MAR-2002 (TRENBLREL. 20, Last annotation update)
DE Neurotoxin.
GN NT.
OS Clostridium botulinum.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
OC Clostridiales; Clostridiaceae; Clostridium.
OX MCBL_TaxID=1491;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C-VOICHT:
RX MEDLINE=21534265; PubMed=11676492;
RA Sagane Y., Kouguichi H., Watanabe T., Sunagawa H., Inoue K.,
RA Fujinaga Y., Oguma K., Ohyama T.;
RT "Role of C-Terminal Region of HA-33 Component of Botulinum Toxin in
RT Hemagglutination.";
RL Biochem. Biophys. Res. Commun. 288:650-657(2001).
DR EMBL; AB061780; BAB71749.1;
DR InterPro; IPR000395; Bontoxilysin.
DR InterPro; IPR000130; Zn_MTPeptide.
DR Pfam; PF01742; Peptidase_M27; 1.
DR ProDom; PD001963; Bontoxilysin; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN; 1.
SQ SEQUENCE 1291 AA; 148869 MW; 4A21DB35B8743CF8 CRC64;

Query Match 13.8%; Score 100; DB 2; Length 1291;
Best Local Similarity 23.6%; Pred. No. 1.3;
Matches 37; Conservative 21; Mismatches 77; Indels 22; Gaps 4;

OY 2 NSSLYRGTKFIKKYASGNKDNIVANNDRVYINVVKKKEKRL-----ATNASQAGV 53
   | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1139 NDNFEGYKRIIRKIRGNTNDTRVAGDILYFDMTINKKAYNLFMKNETMYADNHSTEDI 1198
   | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |

OY 54 EKLSALEIPVGNLSQVYVVKSKNDQGITNKC-KMNLQDNNGNDIGFIFGHOF----- 106
   | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1199 YALGIREQTKINDNIITFQIQPMNNTYYASQIFKSNFNGENISGISIGYRFRGLGDW 1258
   | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |

OY 107 --NNIAKLVASNMWYNRQIERSSRTLAGCSWEFIPYVD 140
   | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1259 YRHNYLVPYVKGQNVASLLESTF---THMGFVPYSE 1291
   | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |

```

Search completed: March 13, 2003, 11:40:13  
 Job time : 23.4798 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.4.p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

## OM protein - protein search, using sw model

Run on: March 13, 2003, 11:38:07 ; Search time 10.8934 Seconds  
(without alignments)  
1235.505 Million cell updates/sec

Title: US-09-917-791-22

Perfect score: 727

Sequence: 1 LNSSLYRGTFRILKKYASGN.....QIERSRRLGCSWEPFIPVD 140

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

1: PIR\_73:\*  
2: PIR2:\*  
3: PIR3:\*  
4: PIR4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Query length	DB ID	Description
1	727	100.0	1296	1 BRCLAB	bontoxilysin (EC 3
2	671	92.3	1296	2 I40645	botulinum neurotox
3	282.5	38.9	1268	2 S33411	botulinum neurotox
4	258.5	35.6	1274	2 I40813	neurotoxin type F
5	206.5	28.4	1252	2 S21178	botulinum neurotox
6	190	26.1	1251	2 JH0256	botulinum neurotox
7	169.5	23.3	1291	2 I40631	non-protectolytic bo
8	165.5	22.8	1291	1 A48940	bontoxilysin (EC 3
9	163	22.4	1315	1 BRCLTN	tentoxilysin (EC 3
10	158.5	21.8	1297	2 S39791	neurotoxin - Clost
11	110	15.1	315	2 C97224	botulinum neurotox
12	100	13.8	1291	2 S46431	botulinum neurotox
13	100	13.8	1291	2 A49777	botulinum neurotox
14	95	13.1	1285	2 S70582	botulinum neurotox
15	85.5	11.8	467	2 D96901	probable dehydroge
16	83	11.4	4550	2 T18440	hypothetical prote
17	79.5	10.9	233	2 A11580	ABC transporter, A
18	79	10.9	122	2 A53878	type E neurotoxin
19	79	10.9	501	2 T43047	retrovirus-related
20	79	10.9	3394	2 T18501	hypothetical prote
21	78.5	10.8	319	2 D97066	periplasmic sugar-
22	78.5	10.8	528	2 T50330	hypothetical prote
23	78.5	10.8	659	2 A81293	ABC transporter (p
24	78.5	10.8	768	2 T18461	hypothetical prote
25	78	10.7	145	2 A82142	type I restriction
26	78	10.7	385	2 C97277	glycosyltransferas
27	77.5	10.7	236	2 H98058	hypothetical prote
28	77.5	10.7	504	2 D71615	hypothetical prote
29	77	10.6	271	2 D82314	transcription regu

30	77	10.6	4981	2 T18489	hypothetical prote
31	76.5	10.5	993	2 B64695	type I restriction
32	76.5	10.5	1278	2 B70236	hypothetical prote
33	76	10.5	472	2 AD2284	hypothetical prote
34	76	10.5	665	2 B71609	hypothetical prote
35	76	10.5	1175	2 F64489	hypothetical prote
36	75.5	10.4	233	2 AG1227	ABC transporter, A
37	75.5	10.4	323	2 C83940	sugar ABC transpor
38	75	10.3	257	2 A96908	ABC transporter, A
39	75	10.3	708	2 A95214	cell wall surface
40	75	10.3	719	2 B98078	hypothetical prote
41	75	10.3	732	2 C64972	probable ATPase -
42	75	10.3	1247	2 E71616	hypothetical prote
43	75	10.3	1711	2 T18429	hypothetical prote
44	74.5	10.2	233	2 C95192	ABC transporter, A
45	74.5	10.2	435	2 A11017	probable type-I se

## ALIGNMENTS

RESULT 1  
BRCLAB  
bontoxilysin (EC 3.4.24.69) A precursor - Clostridium botulinum  
N:Alternate names: botulinum neurotoxin type A  
C:Species: Clostridium botulinum  
C:Date: 31-Mar-1993 #sequence revision 31-Mar-1993 #text change 18-Jun-1999  
C:Accession: A35294; S69492; S68220; A33401; A53884; A60025; A27000  
R:Bliz, T.; Kurazono, H.; Wille, M.; Frevert, J.; Wernars, K.; Niemann, H.  
J. Biol. Chem. 265, 9153-9158, 1990  
A:Title: The complete sequence of botulinum neurotoxin type A and comparison with oth  
A:Reference number: A35294; MUID:90264400; PMID:2160960  
A:Accession: A35294  
A:Molecule type: DNA  
A:Residues: 1-1296 <BIN>  
A:Cross-references: GB:M20196; NID:9144864; PIDN:AAA23262.1; PID:9144865  
A:Experimental source: strain 62A, subtype A  
R:Thompson, D.E.; Brem, J.K.; Oultam, J.D.; Swinfield, T.J.; Shone, C.C.; Atkinson,  
Burr, J. Biochem. 189, 73-81, 1990  
A:Title: The complete amino acid sequence of the Clostridium botulinum type A neuroto  
A:Reference number: S09492; MUID:90235864; PMID:2185020  
A:Accession: S09492  
A:Molecule type: DNA  
A:Residues: 1-'Q', 3-26, 'V', 28-1296 <THO>  
A:Cross-references: EMBL:X52066; NID:940381; PIDN:CAA36289.1; PID:940382  
A:Experimental source: NCTC 2916  
R:Fujita, R.; Fujinaga, Y.; Inoue, K.; Nakajima, H.; Kumon, H.; Oguma, K.  
FEBS Lett. 376, 41-44, 1995  
A:Title: Molecular characterization of two forms of nontoxic-nonhemagglutinin compone  
A:Reference number: S67988; MUID:96096783; PMID:8521962  
A:Accession: S67988  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-12 <FUJ>  
A:Cross-references: EMBL:D67030; DBJ:D50421; NID:92160224  
Biochem. Biophys. Res. Commun. 162, 1388-1395, 1989  
A:Title: Characterization of botulinum type A neurotoxin gene: delineation of the N-t  
A:Reference number: A33401; MUID:89350959; PMID:2669749  
A:Accession: A33401  
A:Molecule type: DNA  
A:Residues: 1-35 <BEF>  
A:Cross-references: GB:M27892; NID:9144880; PIDN:AAA23269.1; PID:9551776  
R:Gimenez, J.A.; Dasgupta, B.R.  
J. Protein Chem. 12, 351-363, 1993  
A:Title: Botulinum type A neurotoxin digested with pepsin yields 132, 97, 72, 45, 42,  
A:Reference number: A53884; MUID:94000342; PMID:8397793  
A:Accession: A53884  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 867-880;1148-1217, 'Y', 1219 <GIN>  
A:Experimental source: strain Halli  
A:Note: sequence extracted from NCBI backbone (NCBIP:139159); sequence modified after

R:Dasgupta, B.R.; Dekleva, M.L.  
 Biochimie 72, 661-664, 1990  
 A:Title: Botulinum neurotoxin type A: sequence of amino acids at the N-terminus and around  
 A:Reference number: A60025; MUID:91120847; PMID:2126206  
 A:Accession: A60025  
 A:Molecule type: protein  
 A:Residues: 2-6:445-453, 'X', 455-457 <DAS1>  
 R:Dasgupta, B.R.; Foley, J.; Niece, R.  
 Biochemistry 26, 4162, 1987  
 A:Title: Partial sequence of the light chain of botulinum neurotoxin type A.  
 A:Reference number: A27000  
 A:Accession: A27000  
 A:Molecule type: protein  
 A:Residues: 2-47 <DAS2>  
 R:Binz, T.; Blasli, J.; Yamasaki, S.; Baumeister, A.; Link, E.; Suedhof, T.C.; Jahn, R.;  
 J. Biol. Chem. 269, 1617-1620, 1994  
 A:Title: Proteolysis of SNAP-25 by types E and A botulin neurotoxins.  
 A:Reference number: A49708; MUID:94124495; PMID:8294407  
 A:Contents: annotation  
 C:Comment: Botulinum neurotoxins inhibit neurotransmitter release from cholinergic synap  
 A:Genetics:  
 A:Gene: atx; botA  
 A:Function:  
 C:Description: catalyzes hydrolysis of an Asn-Arg peptide bond in synaptosomal-associate  
 C:Superfamily: tetanus toxin  
 C:Keywords: disulfide bond; hydrolase; metalloprotease; neurotoxin; transmembrane prot  
 F:2-444/Product: bontoxilysin A light chain #status experimental <LGHT>  
 F:445-1296/Product: bontoxilysin A heavy chain #status experimental <HVT>  
 F:223,227/Binding site: zinc (His) #status predicted  
 F:224/Active site: Glu #status predicted

Query Match 100.0%; Score 727; DB 1; Length 1296;  
 Best Local Similarity 100.0%; Pred. No. 5.9e-58;  
 Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LNSSLRGKFTIKKAYASGKNDIVRNNRVYINVVVKKKEYRLATNASQAGVEKILTSAL 60  
 |||||  
 DB 1150 LNSSLRGKFTIKKAYASGKNDIVRNNRVYINVVVKKKEYRLATNASQAGVEKILTSAL 1209

QY 61 EIPDVGNLSQVVMVKKSKNDGKITNCKKMLQDNGNDIGFIFGHQFNNTAKLAVASWYNR 120  
 |||||  
 DB 1210 EIPDVGNLSQVVMVKKSKNDGKITNCKKMLQDNGNDIGFIFGHQFNNTAKLAVASWYNR 1269

QY 121 QIERSSRTLCGSWEFTIPVD 140  
 |||||  
 DB 1270 QIERSSRTLCGSWEFTIPVD 1289

RESULT 2  
 140645  
 botulinum neurotoxin type A - Clostridium botulinum  
 C:Species: Clostridium botulinum  
 C:Date: 12-Aug-1996 #sequence\_revision 12-Aug-1996 #text\_change 16-Jul-1999  
 C:Accession: I40645  
 R:Williams, A.; East, A.K.; Lawson, P.A.; Collins, M.D.  
 Res. Microbiol. 144, 547-556, 1993  
 A:Title: Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A  
 A:Reference number: I40645; MUID:94143603; PMID:8310180  
 A:Accession: I40645  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-1296 <RES>  
 A:Cross-References: EMBL:X73423; NID:g507070; PIDN:CAA51824.1; PID:g507071  
 C:Superfamily: tetanus toxin  
 C:Keywords: neurotoxin

Query Match 92.3%; Score 671; DB 2; Length 1296;  
 Best Local Similarity 90.7%; Pred. No. 7.3e-53;  
 Matches 127; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

QY 1 LNSSLRGKFTIKKAYASGKNDIVRNNRVYINVVVKKKEYRLATNASQAGVEKILTSAL 60  
 |||||  
 DB 1150 LNSSLRGKFTIKKAYASGKNDIVRNNRVYINVVVKKKEYRLATNASQAGVEKILTSAL 1209

QY 61 EIPDVGNLSQVVMVKKSKNDGKITNCKKMLQDNGNDIGFIFGHQFNNTAKLAVASWYNR 120  
 |||||  
 DB 1210 EIPDVGNLSQVVMVKKSKNDGKITNCKKMLQDNGNDIGFIFGHQFNNTAKLAVASWYNR 1269

QY 121 QIERSSRTLCGSWEFTIPVD 140  
 |||||  
 DB 1270 QVCKASRTFCGSWEFTIPVD 1289

RESULT 3  
 S33411  
 botulinum neurotoxin type F - Clostridium baratii  
 C:Species: Clostridium baratii  
 C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 16-Jul-1999  
 C:Accession: S33411; S31860  
 R:Thompson, D.E.; Hutson, R.A.; East, A.K.; Allaway, D.; Collins, M.D.; Richardson, P  
 FEMS Microbiol. Lett. 108, 175-182, 1993  
 A:Title: Nucleotide sequence of the gene coding for Clostridium baratii type F neuroto  
 A:Reference number: S33411; MUID:93252228; PMID:8486245  
 A:Accession: S33411  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-1268 <THO>  
 A:Cross-References: EMBL:X68262; NID:g49138; PIDN:CAA48329.1; PID:g49139  
 C:Superfamily: tetanus toxin  
 C:Keywords: neurotoxin

Query Match 38.9%; Score 282.5; DB 2; Length 1268;  
 Best Local Similarity 45.3%; Pred. No. 1.5e-17;  
 Matches 63; Conservative 19; Mismatches 44; Indels 13; Gaps 5;

QY 2 NSSLYGTFKFTIKKAYASGKNDIVRNNRVYINVVVKKKEYRLATNASQAGVEKILTSAL 58  
 |||||  
 DB 1131 NALVYGVETLIRKVGSTFTSNTDNFVRKNDYIINVVGVGNSFYQLAYAVTSASVAKETIK 1190

QY 59 ALEIPVGNLSQVVMVKKSKNDGKITNCKKMLQDNGNDIGFIFGHQFNNTAKLAVASWYNR 117  
 |||||  
 DB 1191 LRRISNSNYNSNMOMITMDS----IGDCTMNFETNNNGNDIGLGFH-LNN--LVAASSW 1241

QY 118 YNRQIERSSRTLCGSWEFTI 136  
 |||||  
 DB 1242 YKKNIRNTRNNGCFWFSFI 1260

RESULT 4  
 I40813  
 neurotoxin type F - Clostridium botulinum  
 C:Species: Clostridium botulinum  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 16-Jul-1999  
 C:Accession: I40813; S48108  
 R:East, A.K.; Richardson, P.T.; Allaway, D.; Collins, M.D.; Roberts, T.A.; Thompson,  
 FEMS Microbiol. Lett. 96, 225-230, 1992  
 A:Title: Sequence of the gene encoding type F neurotoxin of Clostridium botulinum.  
 A:Reference number: I40813  
 A:Accession: I40813  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-1274 <RES>  
 A:Cross-References: GB:M92906; NID:g144866; PIDN:AAA23263.1; PID:g144867  
 R:Campbell, K.D.; Collins, M.D.; East, A.K.  
 J. Clin. Microbiol. 31, 2255-2262, 1993  
 A:Title: Gene probes for identification of the botulin neurotoxin gene and specific  
 A:Reference number: S48103; MUID:94013372; PMID:8408542  
 A:Accession: S48108  
 A:Status: preliminary; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 634-1002 <CAM>  
 A:Cross-References: EMBL:X70816; NID:g407788; PIDN:CAA50147.1; PID:g407789  
 C:Superfamily: tetanus toxin  
 C:Keywords: neurotoxin

Query Match 35.6%; Score 258.5; DB 2; Length 1274;



Best Local Similarity 43.2%; Pred. No. 2.4e-15;  
Matches 60; Conservative 20; Mismatches 44; Indels 15; Gaps 5;

Query 1 LNSSLYRGTKFLIKKYAS---GNKDNIVRNNDRYINVVYVANKERLATNASQAGVEKITL 57  
Db 1140 LNKLYKSEVEVYIRKNGPIDISNTDNEFRKNDLAINVNDGVEYRLAD--TKSEKEKII 1198  
Matches 58; Conservative 20; Mismatches 51; Indels 15; Gaps 6;  
Query 58 SALEIPDVGNLSQVYVMSKNDGKITNCKMNLQDNGNDIGFIFGHPFNNAKLVASNM 117  
Db 1199 RTSNND--SLGQITVMS-----IGNNCTMNFQNNNSNIGLGFHSNN-----LVASSW 1247  
Matches 118; Conservative 20; Mismatches 51; Indels 15; Gaps 6;  
Query 118 YNRQIERSRRLGCSWEFI 136  
Db 1248 YNNIRRTNSNGCFWSSI 1266  
Matches 124; Conservative 20; Mismatches 51; Indels 15; Gaps 6;

## RESULT 5

Species: Clostridium botulinum  
C:Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 15-Oct-1999  
C:Accession: S21178; S48107; JH0257; B35294; A60027; S18111  
R:Wheeler, S.M.; Elmore, M.J.; Bodsworth, N.D.; Atkinson, T.; Minton, N.P.  
Eur. J. Biochem. 204, 657-667, 1992  
A:Title: The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin  
A:Reference number: S21178; MUID:92174922; PMID:1541280  
A:Accession: S21178  
A:Molecule type: DNA  
A:Residues: 1-1252 <WHE>  
A:Cross-references: EMBL:X62683; NID:940397; PIDN:CAA44558.1; PID:940398  
R:Campbell, K.D.; Collins, M.D.; East, A.K.  
J. Clin. Microbiol. 31, 2255-2262, 1993  
A:Title: Gene probes for identification of the botulinum neurotoxin gene and specific id  
A:Reference number: S48103; MUID:94013372; PMID:8408542  
A:Accession: S48107  
A:Molecule type: DNA  
A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
A:Molecule type: DNA  
A:Residues: 616-982 <CAM>  
A:Cross-references: EMBL:X70815; NID:9407786; PIDN:CAA50146.1; PID:9407787  
R:Poulet, S.; Hauser, D.; Quanz, M.; Niemann, H.; Popoff, M.R.  
Biochem. Biophys. Res. Commun. 183, 107-113, 1992  
A:Title: Sequences of the botulinum neurotoxin E derived from Clostridium botulinum type  
A:Reference number: JH0256; MUID:92181428; PMID:1543481  
A:Accession: JH0257  
A:Status: nucleic acid sequence not shown  
A:Molecule type: DNA  
A:Residues: 1-176, 'R', 178-197, 'C', 199-339, 'R', 341-772, 'I', 774-962, 'FE', 965-966, 'R', 968-1  
A:Cross-references: EMBL:X62089; NID:940393; PIDN:CAA43999.1; PID:940394  
R:Binz, T.; Kurazono, H.; Wille, M.; Frevert, J.; Wernars, K.; Niemann, H.  
J. Biol. Chem. 265, 9153-9158, 1990  
A:Title: The complete sequence of botulinum neurotoxin type A and comparison with other  
A:Reference number: A35294; MUID:90264400; PMID:2160960  
A:Accession: B35294  
A:Status: not compared with conceptual translation  
A:Molecule type: DNA  
A:Residues: 1-176, 'R', 178-252 <BIN>  
A:Experimental source: strain Beluga  
R:Gienez, J.A.; Dasgupta, B.R.  
Biochimie 72, 213-217, 1990  
A:Title: Botulinum neurotoxin type E fragmented with endoproteinase Lys-C reveals the s  
A:Reference number: A60027; MUID:90344918; PMID:2116911  
A:Accession: A60027  
A:Molecule type: Protein  
A:Residues: 420-427 <GIM>  
A:Experimental source: strain Beluga  
A:Note: this fragment was generated by proteolysis with Lys-C rather than with trypsin  
C:Comment: The Clostridium neurotoxins are highly potent protein toxins that inhibit neu  
C:Comment: The heavy chain mediates the binding of toxin to cell receptors while the lig  
C:Superfamily: tetanus toxin  
C:Keywords: neurotoxin  
F:1-422/Product: botulinum neurotoxin type E light chain #status predicted <LCH>

F:423-1252/Product: botulinum neurotoxin type E heavy chain #status predicted <HCH>  
F:412-426/Dissulfide bonds: #status predicted

Query Match 28.4%; Score 206.5; DB 2; Length 1252;  
Best Local Similarity 38.1%; Pred. No. 1.2e-10;  
Matches 53; Conservative 20; Mismatches 51; Indels 15; Gaps 6;  
Query 1 LNSSLYRGTKFLIKKY-ASGNKDNIVRNNDRYINVVYVANKERLATNASQAGVEKITLS 58  
Db 1117 LANRYSIGIKYIQVNNSSSTNDNLVYRKNDQYINFAVSKTHLPFLYADTATNKEK--- 1173  
Matches 59; Conservative 20; Mismatches 51; Indels 15; Gaps 6;  
Query 59 ALEIPDVGNLSQVYVMSKNDGKITNCKMNLQDNGNDIGFIFGHPFNNAKLVASNM 117  
Db 1174 TIKISSGNRFNQVYVMS-----VGNCTMNFQNNNSNIGLGFHSNN-----KADTVASTW 1224  
Matches 118; Conservative 20; Mismatches 51; Indels 15; Gaps 6;  
Query 118 YNRQIERSRRLGCSWEFI 136  
Db 1225 YTHMRDHTNSNGCFWNPFI 1243  
Matches 124; Conservative 20; Mismatches 51; Indels 15; Gaps 6;

## RESULT 6

Species: Clostridium butyricum  
C:Date: 30-Jun-1992 #sequence\_revision 15-May-1998 #text\_change 16-Jul-1999  
C:Accession: JH0256; S16145  
R:Poulet, S.; Hauser, D.; Quanz, M.; Niemann, H.; Popoff, M.R.  
Biochem. Biophys. Res. Commun. 183, 107-113, 1992  
A:Title: Sequences of the botulinum neurotoxin E derived from Clostridium botulinum t  
A:Reference number: JH0256; MUID:92181428; PMID:1543481  
A:Accession: JH0256  
A:Status: nucleic acid sequence not shown  
A:Molecule type: DNA  
A:Residues: 1-27, 'E', 29-1251 <POU>  
A:Cross-references: EMBL:X62089; NID:940379  
A:Experimental source: strains ATCC 43181 and ATCC 43755  
R:Fujii, N.; Kimura, K.; Yasuhiki, T.; Indoh, T.; Murakami, T.; Tsuzuki, K.; Yokosawa,  
J. Gen. Microbiol. 137, 519-525, 1991  
A:Title: Cloning of a DNA fragment encoding the 5'-terminus of the botulinum type E t  
A:Reference number: S16145; MUID:91237316; PMID:2033376  
A:Accession: S16145  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-229, 'M', 231-252 <FNU>  
A:Cross-references: EMBL:X53180; NID:940407; PIDN:CAA37321.1; PID:940408  
A:Experimental source: strain B16340  
C:Comment: The Clostridium neurotoxins are toxins that inhibit neurotransmitter relea  
C:Comment: The heavy chain mediates the binding of toxin to cell receptors while the  
C:Superfamily: tetanus toxin  
C:Keywords: neurotoxin  
F:2-422/Product: botulinum neurotoxin type E light chain #status predicted <LIG>  
F:423-1251/Product: botulinum neurotoxin type E heavy chain #status predicted <HEA>  
F:412-426/Dissulfide bonds: #status predicted

Query Match 26.1%; Score 190; DB 2; Length 1251;  
Best Local Similarity 37.7%; Pred. No. 3.9e-09;  
Matches 52; Conservative 19; Mismatches 53; Indels 14; Gaps 6;

Query 1 LNSSLYRGTKFLIKKY-ASGNKDNIVRNNDRYINVVYVANKERLATNASQAGVEKITLS 59  
Db 1117 LANRYSIGIKYIQVNNSSSTNDNLVYRKNDQYINFAVSKTHLPFLYADTATNKEK---EKT 1174  
Matches 59; Conservative 20; Mismatches 51; Indels 15; Gaps 6;  
Query 60 LEIPDVGNLSQVYVMSKNDGKITNCKMNLQDNGNDIGFIFGHPFNNAKLVASNM 118  
Db 1175 IKISSGNRFNQVYVMS-----VGNCTMNFQNNNSNIGLGFHSNN-----KADTVASTW 1224  
Matches 118; Conservative 20; Mismatches 51; Indels 15; Gaps 6;  
Query 119 YNRQIERSRRLGCSWEFI 136  
Db 1225 YTHMRDHTNSNGCFWNPFI 1243  
Matches 124; Conservative 20; Mismatches 51; Indels 15; Gaps 6;

## RESULT 7

140631

non-proteolyticbotulinum neurotoxin type B precursor - Clostridium botulinum  
C.Species: Clostridium botulinum  
C.Date: 12-Aug-1996 #sequence\_revision 12-Aug-1996 #text\_change 16-Jul-1999  
C.Accession: I40631; S48103; S48104; S36015  
R:Hutson, R.A.; Collins, M.D.; East, A.K.; Thompson, D.E.  
Curr. Microbiol. 28, 101-110, 1994  
A.Title: Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum  
A.Reference number: I40631; MUID:94122659; PMID:7764370  
A.Accession: I40631  
A.Status: preliminary; translated from GB/EMBL/DDBU  
A.Molecule type: DNA  
A.Residues: 1-1291 <WHE>  
A.Cross-references: EMBL:X73343; NID:9296148; PIDN:CMA50482.1; PID:9296149  
R:Campbell, K.D.; Collins, M.D.; East, A.K.  
J. Clin. Microbiol. 31, 2255-2262, 1993  
A>Title: Gene probes for identification of the botulinum neurotoxin gene and specific loci  
A.Reference number: S48103; MUID:94013372; PMID:8408542  
A.Accession: S48103  
A.Status: preliminary; nucleic acid sequence not shown; translation not shown  
A.Molecule type: DNA  
A.Residues: 634-761, 'E', 763-841, 'M', 843, 'T', 845, 'N', 847-994 <CAMI>  
A.Cross-references: EMBL:X70814; NID:9407778; PIDN:CMA50145.1; PID:9407779  
Experimental source: non-proteolytic strain 2129B (Scott)  
Note: the nucleotide sequence was submitted to the EMBL Data Library, January 1993  
A.Accession: S48104  
A.Status: preliminary  
A.Molecule type: DNA  
A.Residues: 634-843, 'T', 845, 'N', 847-994 <CAM2>  
A.Cross-references: EMBL:X70819; NID:9407780; PIDN:CMA50150.1; PID:9407781  
Experimental source: non-proteolytic strain EK1und 2B (Colworth 229)  
C.Comment: Botulinum neurotoxin type B in these strains may possess a capable catalytic s  
C.Genetics:  
A.Gene: bont/b  
C.Superfamily: tetanus toxin  
C.Keywords: metalloprotein; neurotoxin; transmembrane protein; zinc  
F.2-441/Product: botulinum neurotoxin type B light chain #status predicted <LGHT>  
F.442-1291/Product: botulinum neurotoxin type B heavy chain #status predicted <HNY>  
F.230,234/Binding site: zinc (His) #status predicted  
F.231/Active site: Glu #status predicted

Query Match 23.3%; Score 169.5; DB 2; Length 1291;  
Best Local Similarity 28.3%; Pred. No. 3e-07;  
Matches 43; Conservative 39; Mismatches 53; Indels 17; Gaps 7;

OY 4 SYRRGTRPIKKYAAGN--KDNIVRNNDRYVINVYVKKEHYL-ATNASQAGEVEITLSAL 60  
DB 1138 NYIEKPELRRESQSINDIVRKEDYIHLDVLHNEWEVYVYKYKFEDEEKFLDSI 1197  
OY 61 EIPDVGNSIQVVVMKSKNDQGITNKCKM-NLDNNNGNDIGTGFHOVNINIAKL----- 112  
DB 1198 -ISDSENFEPKTLEIKEDQP-SYSCGLLFKKDESTDDIGLIGHRRYESGLAKKTKYD 1255  
OY 113 --VASNMNRQIERS-SRTGCSWEFI PVDD 140  
DB 1256 YFCISKWYLAEKVRKRPYSKNLGCNQMFIPKDE 1287

RESUT.F 8  
AA8940  
Dontoxilysin (EC 3.4.24.69) B precursor - Clostridium botulinum  
N.Alternate names: botulinum neurotoxin type B (BoNT/B)  
C.Species: Clostridium botulinum  
C.Date: 19-Dec-1993 #sequence\_revision 18-Nov-1994 #text\_change 18-Jun-1999  
C.Accession: AA8940; S48105; S21573; A42871; S07155; S08562; S07128; S08573; S08574  
R:Whelan, S.M.; Elmore, M.J.; Bodsworth, N.J.; Breilm, J.K.; Atkinson, T.; Minton, N.P.  
Appl. Environ. Microbiol. 58, 2345-2354, 1992  
A>Title: Molecular cloning of the Clostridium botulinum structural gene encoding the type  
A.Reference number: AA8940; MUID:92384550; PMID:1514783  
A.Accession: AA8940  
A.Status: preliminary  
A.Molecule type: DNA  
A.Residues: 1-1291 <WHE>  
A.Cross-references: GB:M01186; NID:9144734; PIDN:AAA23211.1; PID:9144735

A:Experimental source: type B, Danish  
A:Note: sequence extracted from NCBI backbone (NCBIN:112080, NCBIF:112081); this publ  
R:Campbell, K.D.; Collins, M.D.; East, A.K.  
J: Clin. Microbiol. 31, 2255-2262, 1993  
A:Title: Gene probes for identification of the botulinum neurotoxin gene and specific  
A:Reference number: S48103; MUID:94013372; PMID:8408542  
A:Accession: S48105  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 634-994 <CAN>  
A:Cross-references: EMBL:X70817; NID:9407782; PIDN:CAAS0148.1; PID:9407783  
A:Experimental source: proteolytic type B, strain NCTC 7273  
R:Szabo, E.A.; Pemberton, J.M.; Desmarchelier, P.M.  
submitted to the EMBL Data Library, April 1992  
A:Description: Partial amino acid sequence of botulinum neurotoxin type B and compari  
A:Reference number: S21575  
A:Accession: S21575  
A:Molecule type: DNA  
A:Residues: 36-217, 'G', 219-224, 'S', 226-246 <SZA>  
A:Cross-references: EMBL:Z11934; NID:940383; PIDN:CAAT7991.1; PID:940384  
R:Kuzanov, H.; Mochida, S.; Binz, T.; Eisel, U.; Quanz, M.; Grebenstein, O.; Wernars  
J: Biol. Chem. 267, 14721-14729, 1992  
A:Title: Multiple essential domains specifying toxicity of the light chains of tetanus  
A:Reference number: A42871; MUID:92340509; PMID:1634516  
A:Accession: A42871  
A:Status: nucleic acid sequence not shown  
A:Molecule type: mRNA  
A:Residues: 1-313, 'S', 315-451 <KUR>  
A:Experimental source: strain OKra  
A:Note: sequence extracted from NCBI backbone (NCBIF:109365)  
R:Dasgupta, B.R.; Datta, A.  
Biochimie 70, 811-817, 1988  
A:Title: Botulinum neurotoxin type B (strain 657): partial sequence and similarity wi  
A:Reference number: S07155; MUID:89000987; PMID:3139097  
A:Accession: S07155  
A:Molecule type: protein  
A:Residues: 2-29, 'M', 31-45 <DAS>  
A:Accession: S08562  
A:Molecule type: protein  
A:Residues: 442-463, 'R', 465-467 <DA2>  
R:Schmidt, U.J.; Satyamoorthy, V.; Dasgupta, B.R.  
Arch. Biochem. Biophys. 238, 344-348, 1985  
A:Title: Partial amino acid sequences of botulinum neurotoxins types B and E.  
A:Reference number: S07128; MUID:85197963; PMID:3888113  
A:Accession: S07128  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 2-16 <SCH1>  
A:Accession: S08573  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 2-17 <SCH2>  
A:Accession: S08574  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 442-459 <SCH3>  
R:Schiaivo, G.; Benfenati, F.; Poullain, B.; Rossello, O.; de Laureto, P.P.; Dasgupta,  
Nature 359, 833-835, 1992  
A:Title: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteo  
A:Reference number: S27125; MUID:93065293; PMID:1331807  
A:Contents: annotation  
A:Comment: Botulinum neurotoxins inhibit neurotransmitter release from cholinergic sy  
C:Genetics:  
A:Gene: hont/b  
C:Function:  
A:Description: catalyzes hydrolysis of a Gln-Phe peptide bond in synaptobrevin 2  
C:Superfamily: tetanus toxin  
C:Keywords: hydrolysis; metalloproteinase; neurotoxin; transmembrane protein; zinc  
F:2-441/Product: botenoxilysin B light chain #status experimental <GHT>  
F:442-1291/Product: botenoxilysin B heavy chain #status experimental <HNY>  
F:230,234/Binding site: zinc (HIS) #status predicted  
F:231/Active site:Glu #status predicted



RESULT 13  
A49777  
botulinum neurotoxin type C1 precursor - Clostridium botulinum phage (type C, strain  
C:Species: Clostridium botulinum phage  
C:Date: 10-Mar-1994 #sequence\_revision 07-Apr-1994 #text\_change 23-Mar-2001  
S:Accession: S11291; A35396; S22166; A49777  
R:Hauser, D.; Eklund, M.W.; Kurazono, H.; Blinz, T.; Niemann, H.; Gyll, D.M.; Boquet,  
Nucleic Acids Res. 18, 4924, 1990  
A:Title: Nucleotide sequence of Clostridium botulinum C1 neurotoxin.  
A:Reference number: S11291; MUID:90370487; PMID:2204031  
A:Accession: S11291  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-84, 'P', 86-1291 <HAU>  
A:Cross-references: EMBL:X53751; NID:G14905; PID:CA547780.1; PID:q14906  
R:Kikunaga, K.; Fujii, N.; Tsurukaki, K.; Murakami, T.; Indoh, T.; Yokosawa, N.; Takeshi,  
Biochem. Biophys. Res. Commun. 171, 1304-1311, 1990

A; Status: preliminary; not compared with conceptual translation

A:Residues: 1-669, 'R', 671-1291 <TS1>  
R:Tszukuri, K.; Kimura, K.; Fujii, N.; Yokosawa, N.; Oguma, K.  
submitted to the EMBL data library, December 1991  
A:Description: Nucleotide sequence of the gene for one of the components of hemagglutinin  
A:Reference number: S22163  
A:Accession: S22166  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-1291 <TS2>  
A:Cross-references: EMBL:X62389; NID:9558175; PIDN:CAA44263.1; PID:940390  
R:Kimura, K.; Fujii, N.; Tszukuri, K.; Murakami, T.; Inouy, T.; Yokosawa, N.; Oguma, K.

A; Reference number: A49777; MUID:91282468; PMID:20590335

```

A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-607 <TS3>
A:Cross-references: GB:D90210
C:Superfamily: tetanus toxin
C:Keywords: neurotoxin

Query Match      13.8%  Score 100;  DB 2;  Length 1291;
Best Local Similarity 23.6%  Pred. No. 0.62;
Matches 37;  Conservative 21;  Mismatches 77;  Indels 22;  Gaps 4;

```

[illegible]

Qy	107	---	NNIAKLVASNMWNRQIERSSRTLGCSWEFI	PVDD	140
			:     :     :		
Db	1259	YRHNVLVPTVKQGNVSL	LEST	---	THMGFVPVSE 1291

[illegible]

570582

C;species: Clostridium botulinum phage d-SA

```
C:\Accession: S70582
c/date: 19-mai-1997 #sequence_revision 15 mai 1997 #cecc_change 20 jan 2000
```

Biochim. Biophys. Acta 1307, 123-126, 1996

A:Accession: S70582  
A:Status: nucleic acid sequence not shown  
A:Molecule type: DNA  
A:Residues: 1-1285 <MOR>

A:Cross-references: EMBL:D38442, NID:q1374775, PIDN:BA07477.1; PID:q1374776  
C:Comment: The clostridial neurotoxins are highly potent protein toxins that inhibit neu  
a disulfide bond. The heavy chain mediates the binding of toxin to the presynaptic membr  
C:Superfamily: tetanus toxin  
C:Keywords: disulfide bond; neurotoxin; transmembrane protein  
F:1-447/Product: botulinum neurotoxin type Dsa light chain #status predicted <MAT1>  
F:448-1285/Product: botulinum neurotoxin type Dsa heavy chain #status predicted <MAT2>

Query Match 13.1%; Score 95; DB 2; Length 1285;

Best Local Similarity 23.8%; Pred. No. 1.8;  
Matches 38; Conservative 20; Mismatches 72; Indels 30; Gaps 7;

OY 2 NSSLYRGTFIKKYASGNKDNIVNDRVYINVVYKKEKRYLATNASQAGYEKILSALE 61

Db 1135 NNDENEGYKIIIRKRGNTNDRVGENVLYENTYIDNKQYSLGMYKPSRNL-----GTD 1189

OY 62 IPDVGNLSQVYVYVMSKNDGKITNKC-----KMNLDN-NGNDIGF--IGFHQFNNTA 110

Db 1190 LVPDLALDQPMDEIRKYSFTIQPCNTDYASQLFLSSNATYTRKGLISYSF---- 1245

OY 111 KLVASNMWYNRQ-----IERSSRYL--GCSWEFIPYDD 140

Db 1246 KLGDYWFNHEYLIPVTKIEHYASLSLESTHWVFVPASE 1285

#### RESULT 15

D96901  
probable dehydrogenase with iron-sulfur domain [imported] - Clostridium acetobutylicum

C:Species: Clostridium acetobutylicum

C:Date: 14-Sep-2001 #sequence\_revision 14-Sep-2001 #text\_change 14-Sep-2001

C:Accession: D96901

R:Noiling, J.; Brelton, G.; Omeichenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee,

J.; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.

J. Bacteriol. 183, 4823-4838, 2001

A:Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium Cl

A:Reference number: A96900; MUID:21359325; PMID:21359325

A:Accession: D96901

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-467 <KUR>

A:Cross-references: GB:AE001437, PIDN:AAK77999.1; PID:q15022830; GSPDB:GN00168

A:Experimental source: Clostridium acetobutylicum ATCC824

C:Genetics:

A:Gene: CAC0012

Query Match 11.8%; Score 85.5; DB 2; Length 467;

Best Local Similarity 28.8%; Pred. No. 3.9;  
Matches 40; Conservative 25; Mismatches 51; Indels 23; Gaps 8;

OY 1 INSSLYRGTFIKKYASGNKDNIVNDRVYINVVK-NKEYRLATNASQAGVEKILSA 59

Db 26 INVSL-----IEKEYEIGDPTSIY-NSDLVYDGIESKYNFNYGLETEGNOE-TEKICSV 77

OY 60 LEIPVGNLSQVYVYVMSKNDGKITNKC-----CKMNLQDNNGNDIGFIGFHQFNNTAK-LV 113

Db 78 LSPV-FKRVMAIVCSRDENEDPTINKIYSRGIRKIGKIDASLANIE-----SAIAKSIIT 129

OY 114 ASNMWYNRQIERSSRYLGS 132

Db 130 LKDIMNKIGIELKDIGIVCA 148

Search completed: March 13, 2003, 11:41:46  
Job time : 12.8934 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.4-p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 13, 2003, 11:36:37 ; Search time 9.54467 Seconds  
(without alignments)  
899.518 Million cell updates/sec

Title: US-09-917-791-21

Perfect score: 1071

Sequence: 1 IKVNNMDLFSPSEDNFTND.....NIGNMLYKDFVGLIFSGA 207

Scoring table: BIOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_40.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1071	100.0	1295	1 BXA1_CLOBO	P10845 clostridium
2	918	85.7	1295	1 BXA2_CLOBO	Q45894 clostridium
3	377	35.2	1296	1 BXG_CLOBO	Q60393 clostridium
4	374.5	35.0	1250	1 BXE_CLOBU	P30995 clostridium
5	368.5	34.4	1250	1 BXE_CLOBO	O00496 clostridium
6	366.5	34.2	1290	1 BXB_CLOBO	P10844 clostridium
7	316	29.5	1274	1 BXF_CLOBO	P30996 clostridium
8	312	29.1	1314	1 TFX_CLOTE	P04958 clostridium
9	290.5	27.1	1276	1 BXD_CLOBO	P19321 clostridium
10	263	24.6	1290	1 BXK1_CLOBO	P18640 clostridium
11	107	10.0	246	1 Y402_BUCAI	P57482 buchnera ap
12	106	9.9	1196	1 BXCNC_CLOBO	P46081 clostridium
13	98	9.2	345	1 VA0D_YEAST	P33366 saccharomyc
14	95.5	8.9	1032	1 M718_YEAST	P40469 saccharomyc
15	93.5	8.7	355	1 Y198_RICPR	O94677 rickettsia
16	91	8.5	635	1 HTPG_VIBCH	P22359 vibrio chol
17	91	8.5	1162	1 BXBEN_CLOBO	Q06366 clostridium
18	90.5	8.5	1186	1 CAGA_HELPY	P55980 helicobacte
19	89	8.3	1162	1 BXBEN_CLOBO	P46082 clostridium
20	88.5	8.3	556	1 SYR_LISIN	Q92742 listeria in
21	87	8.1	755	1 KHL5_HUMAN	O96P97 homo sapien
22	86.5	8.1	556	1 SYR_LISMO	O8Y493 listeria mo
23	86.5	8.1	1939	1 MYH4_HUMAN	O9Y623 homo sapien
24	86	8.0	610	1 MYH4_HUMAN	O51229 botreilla bu
25	86	8.0	844	1 SECA_STACA	P47994 staphylococ
26	86	8.0	891	1 SECA_PAVLU	Q001570 pavlova lut
27	86	8.0	974	1 TRP4_MOUSE	Q09495 mus musculu
28	86	8.0	977	1 TRP4_HUMAN	O94944 homo sapien
29	86	8.0	977	1 TRP4_RAT	O35119 rattus norv
30	86	8.0	981	1 TRP4_BOVIN	P79100 bos taurus
31	85.5	8.0	426	1 HEM1_SULSO	O96007 sulfolobus
32	85.5	8.0	1167	1 HEM1_SULSO	Q92171 helicobacte
33	85	7.9	336	1 Y05G_BP74	P39242 bacteriophage

## ALIGNMENTS

RESULT 1	ID	Sequence	Standard	PRT	AA
AC	BXA1_CLOBO	P10845: P18639: P01561:			
DT	01-JUL-1988 (Rel. 11, Created)				
DT	01-JUL-1993 (Rel. 26, Last sequence update)				
DT	15-JUN-2002 (Rel. 41, Last annotation update)				
DE	Botulinum neurotoxin type A precursor (EC 3.4.24.69) (BONT/A)				
DE	(Bontoxilysin A) (BOTOX) [Contains: Botulinum neurotoxin A, light-chain, Botulinum neurotoxin A, heavy-chain].				
GN	BOTA OR BNA OR AFX				
OS	Clostridium botulinum.				
OC	Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae; Clostridium.				
OX	NCBI_TaxID=1491;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=NCCT 2916;				
RX	MEDLINE=90235864; PubMed=2185020;				
RA	Thompson D.E., Brehm J.K., Oultram J.D., Swinfield T.-J.,				
RA	Shone G.C., Atkinson T., Melling J., Minton N.P.;				
RT	"The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene.";				
RT	Eur. J. Biochem. 189:73-81(1990).				
RL	[2]				
RN	SEQUENCE FROM N.A.				
RP	STRAIN=62A.				
RC	MEDLINE=90264400; PubMed=2160960;				
RA	Binz B., Kuatzen H., Wille M., Frevent J., Wernars K., Niemann H.;				
RT	"The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins.";				
RT	J. Biol. Chem. 265:9153-9158(1990).				
RL	[3]				
RN	SEQUENCE OF 1-65 FROM N.A.				
RP	STRAIN=62A.				
RC	MEDLINE=97016817; PubMed=8863443;				
RA	Fast A.K., Bhandari M., Stacey J.M., Campbell K.D., Collins M.D.;				
RT	"Organization and phylogenetic interrelationships of genes encoding components of the botulinum toxin complex in proteolytic Clostridium botulinum types A, B, and F: evidence of chimeric sequences in the gene encoding the nontoxic nonhemagglutinin component.";				
RT	Int. J. Syst. Bacteriol. 46:1105-1112(1996).				
RL	[4]				
RN	SEQUENCE OF 1-34 FROM N.A.				
RP	STRAIN=Hall.				
RC	MEDLINE=89350959; PubMed=2669749;				
RA	Betley M.J., Somers E., Dasgupta B.R.;				
RT	"Characterization of botulinum type A neurotoxin gene: delineation of the N-terminal encoding region.";				
RT	Biochem. Biophys. Res. Commun. 162:1388-1395(1989).				
RL	[5]				
RN	SEQUENCE OF 1-18 FROM N.A.				
RP	STRAIN=Type A NIH;				
RC	MEDLINE=96096783; PubMed=8521962;				
RA	Fujita R., Fujinaga Y., Inoue K., Nakajima H., Kumon H., Oguma K.;				

"Molecular characterization of two forms of nontoxic-nonhemagglutinin components of Clostridium botulinum type A progenitor toxins.";  
 FEBS Lett. 376:41-44(1995).  
 [6]  
 RP SEQUENCE OF 1-16.  
 RX MEDLINE=84178501; PubMed=6370252;  
 RA Schmidt J.J., Sarmyoorthy V., Dasgupta B.R.;  
 RT "Partial amino acid sequence of the heavy and light chains of  
 botulinum neurotoxin type A";  
 RL Biochem. Biophys. Res. Commun. 119:900-904(1984).  
 RN [7]  
 RP SEQUENCE OF 1-46.  
 RX Dasgupta B.R., Foley J., Niece R.;  
 RA "Partial sequence of the light chain of botulinum neurotoxin type A";  
 RT Biochemistry 26:4162-4162(1987).  
 RN [8]  
 RP SEQUENCE OF 1-5 AND 444-456.  
 RX MEDLINE=91120847; PubMed=2126206;  
 RA Dasgupta B.R., Dekleva M.L.;  
 RT "Botulinum neurotoxin type A: sequence of amino acids at the  
 N-terminus and around the nicking site.";  
 RL Biochimie 72:661-664(1990).  
 RN [9]  
 RP SEQUENCE OF 448-464 AND 872-895.  
 RX MEDLINE=89024662; PubMed=3178218;  
 RA Sathymoorthy V., Dasgupta B.R., Foley J., Niece R.L.;  
 RT "Botulinum neurotoxin type A: cleavage of the heavy chain into two  
 halves and their partial sequences.";  
 RL Arch. Biochem. Biophys. 266:142-151(1988).  
 RN [10]  
 RP SEQUENCE OF 448-482.  
 RX MEDLINE=85285016; PubMed=3896784;  
 RA Shone C.C., Hambleton P., Melling J.;  
 RT "Inactivation of Clostridium botulinum type A neurotoxin by trypsin  
 and purification of two tryptic fragments. Proteolytic action near  
 the COOH-terminus of the heavy subunit destroys toxin-binding  
 activity.";  
 RL Eur. J. Biochem. 151:75-82(1985).  
 RN [11]  
 RP IDENTIFICATION OF SUBSTRATE.  
 RX MEDLINE=94063091; PubMed=8243676;  
 RA Schiavo G., Santucci A., Dasgupta B.R., Mehta P.P., Jontes J.,  
 Bentenati F., Wilson M.C., Montecucco C.;  
 RT "Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct  
 COOH-terminal peptide bonds.";  
 RL FEBS Lett. 335:99-103(1993).  
 RN [12]  
 RP IDENTIFICATION OF SUBSTRATE.  
 RX MEDLINE=94124495; PubMed=8294407;  
 RA Jahn R., Biasi J., Yamasaki S., Baumeister A., Link E., Suedhof T.C.,  
 RT "Proteolysis of SNAP-25 by types E and A botulinum neurotoxins.";  
 RL J. Biol. Chem. 269:1617-1620(1994).  
 RN [13]  
 RP MUTAGENESIS OF GLU-261; PHE-265 AND TYR-365.  
 RX MEDLINE=21556941; PubMed=11700044;  
 RA Rigoni M., Caccin P., Johnson E.A., Montecucco C., Rossetto O.;  
 RT "Site-directed mutagenesis identifies active-site residues of the  
 light chain of botulinum neurotoxin type a.";  
 RL Biochem. Biophys. Res. Commun. 288:1231-1237(2001).  
 RN [14]  
 RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS).  
 RX MEDLINE=98455071; PubMed=9783750;  
 RA Lacy D.B., Tepp W., Cohen A.C., Dasgupta B.R., Stevens R.C.;  
 RT "Crystal structure of botulinum neurotoxin type A and implications  
 for toxicity.";  
 RL Nat. Struct. Biol. 5:898-902(1998).  
 CC -1- FUNCTION: Inhibits acetylcholine release. The botulinum toxin  
 binds with high affinity to peripheral neuronal presynaptic  
 membrane, is then internalized by receptor-mediated endocytosis.  
 The C-terminus of the heavy chain (H) is responsible for the  
 adherence of the toxin to the cell surface while the N-terminus  
 mediates transport of the light chain from the endocytic vesicle

to the cytosol. After translocation, the light chain (L)  
 hydrolyzes the 197-Gln-I-Arg-198 bond in SNAP-25, thereby blocking  
 neurotransmitter release. Inhibition of acetylcholine release  
 results in flaccid paralysis, with frequent heart or respiratory  
 failure.  
 CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
 neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
 detected action on small molecule substrates.  
 CC -1- SUBUNIT: Disulfide-linked heterodimer of a light chain (L) and a  
 heavy chain (H).  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- PHARMACEUTICAL: Available under the name BOTOX (Allergan) for  
 the treatment of strabismus and blepharospasm associated with  
 dystonia and cervical dystonia. Also used for the treatment of  
 hemifacial spasm and a number of other neurological disorders  
 characterized by abnormal muscle contraction.  
 CC -1- MISCELLANEOUS: There are seven antigenically distinct forms of  
 botulinum neurotoxin: types A, B, C1, D, E, F, and G.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -1- DATABASE: NAME-BOTOX product information Web site;  
 WWW="http://www.botox.com/index.jsp?hp&productinfo".  
 CC -1- DATABASE: NAME-protein Spotlight;  
 NOTE=Issue 19 of February 2002;  
 WWW="http://www.expasy.org/spotlight/articles/spl1019.html".  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: X52066; CAA36289.1; -  
 DR EMBL: M30196; AAA23262.1; -  
 DR EMBL: X82973; CAA63551.1; -  
 DR EMBL: D67030; BAA11051.1; -  
 DR EMBL: M27892; AAA23269.1; -  
 DR PIR: A35294; BFCIAB.  
 DR PIR: S09492; S09492.  
 DR PIR: 3BTA; 01-OCT-99.  
 DR MEROPS: M27.002; -  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_MTPeptidse.  
 DR Pfam: PF01742; Peptidase\_M27; 1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR ProDom: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
 DR Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc;  
 KW Pharmacological: 3D-structure.  
 FT INIT\_MET 0  
 FT CHAIN 1 447  
 FT METAL 448 1295  
 FT ACT\_SITE 222 222  
 FT METAL 223 223  
 FT METAL 226 226  
 FT METAL 261 261  
 FT DISULFID 429 453  
 FT DISULFID 1234 1279  
 FT TRANSMEM 626 646  
 FT TRANSMEM 655 675  
 FT VARIANT 26 26  
 FT MUTAGEN 261 261  
 FT MUTAGEN 265 265  
 FT MUTAGEN 365 365  
 FT CONFLICT 1 1  
 FT CONFLICT 479 479  
 FT CONFLICT 875 875  
 FT CONFLICT 891 891  
 FT SEQUENCE 1295 AA; 149322 MW; 858342F754862579 CRC64;  
 Query Match 100.0%; Score 1071; DB 1; Length 1295;



Best Local Similarity 100.0%; Pred. No. 1,5e-78;  
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKVNMNDLFFSPSEDNTNDLNGEITSDTNTNEAEENISLDLQOYLTFFNDEPEN 60  
CC |||||||  
CC 454 IKVNMNDLFFSPSEDNTNDLNGEITSDTNTNEAEENISLDLQOYLTFFNDEPEN 513  
CC |||||||  
QY 61 ISTEINSSDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRILATNSVNE 120  
CC |||||||  
DB 514 ISTEINSSDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRILATNSVNE 573  
CC |||||||  
QY 121 ALLNPSRVYTFSSDYVKKVNKATEAMFLGWVEQLVYDFTDETSEYSTDKIADITITII 180  
CC |||||||  
DB 574 ALLNPSRVYTFSSDYVKKVNKATEAMFLGWVEQLVYDFTDETSEYSTDKIADITITII 633  
CC |||||||  
QY 181 PYIGPALNIGNMLYKDDFVGALIFSGA 207  
CC |||||||  
DB 634 PYIGPALNIGNMLYKDDFVGALIFSGA 660  
CC |||||||

## RESULT 2

BXA2\_CLOBO STANDARD; PRT; 1295 AA.  
ID BXA2\_CLOBO  
AC Q45894; P77780;  
DT 15-JUN-2002 (Rel. 41, Created)  
DT 15-JUN-2002 (Rel. 41, Last sequence update)  
DT 15-JUN-2002 (Rel. 41, Last annotation update)  
DE Botulinum neurotoxin type A precursor (EC 3.4.24.69) (BONT/A)  
DE (Bontoxilysin A) (BOTOX) [contains: Botulinum neurotoxin A, light-chain; Botulinum neurotoxin A, heavy-chain].  
GN BOTA OR BNA OR ATX.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
OC Clostridium.  
OX NCBI\_TaxID=1491;  
RN 11)  
RP SEQUENCE FROM N.A.  
RC STRAIN-Kyoto-F;  
RX MEDLINE=97016817; PubMed=8863443;  
RA East A.K., Bhandari M., Stacey J.M., Campbell K.D., Collins M.D.;  
RT "Organization and phylogenetic interrelationships of genes encoding components of the botulinum toxin complex in proteolytic Clostridium botulinum types A, B, and F: evidence of chimeric sequences in the gene encoding the nontoxic nonhemagglutinin component.";  
RT Int. J. Syst. Bacteriol. 46:1105-1112(1996).  
RL -1- FUNCTION: Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane, is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-gln-1-Arg-198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure (by similarity).  
CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on small molecule substrates.  
CC -1- SUBUNIT: Disulfide-linked heterodimer of a light chain (L) and a heavy chain (H) (By similarity).  
CC -1- SUBCELLULAR LOCATION: Secreted.  
CC -1- MISCELLANEOUS: There are seven antigenically distinct forms of botulinum neurotoxin: Types A, B, C1, D, E, F, and G.

-1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see <http://www.isb.ch/announce/>  
CC or send an email to [license@isb.slb.ch](mailto:license@isb.slb.ch)).

DR EMBL; X73423; CAA51824.1; -;  
DR EMBL; X87974; CAA61234.1; -;  
DR HSSP; P10845; 3BTA.  
DR MEROPS; M27.002; -;  
DR InterPro; IPR000395; Bontoxilysin.  
DR InterPro; IPR000130; Zn\_MTPeptide.  
DR Pfam; PF01742; Peptidase\_M27; 1.  
DR ProDom; PD001963; Bontoxilysin; 1.  
DR PROSITE; PS00142; ZINC\_PROTEASE; FALSE NEG.  
KM Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.  
FT INIT\_MET 0  
FT CHAIN 1 447  
FT CHAIN 448 1295  
FT METAL 222 222  
FT ACT\_SITE 223 223  
FT METAL 226 226  
FT DISULFID 429 453  
FT DISULFID 1234 1279  
FT TRANSMEM 626 646  
FT TRANSMEM 655 675  
SQ SEQUENCE 1295 AA; 149279 MW; 5DA04A1D98D6372 CRC64;

Query Match 85.7%; Score 918; DB 1; Length 1295;

Best Local Similarity 85.4%; Pred. No. 3.3e-66;  
Matches 176; Conservative 12; Mismatches 18; Indels 0; Gaps 0;

QY 1 IKVNMNDLFFSPSEDNTNDLNGEITSDTNTNEAEENISLDLQOYLTFFNDEPEN 60  
DB 454 IKVNMNDLFFSPSEDNTNDLNGEITSDTNTNEAEENISLDLQOYLTFFNDEPEN 513  
CC |||||||  
QY 61 ISTEINSSDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRILATNSVNE 120  
CC |||||||  
DB 514 ISTEINSSDIIGOLELMPNIEFPNGKKYELDKYTMFHYLRAQEFHGKSRILATNSVNE 573  
CC |||||||  
QY 121 ALLNPSRVYTFSSDYVKKVNKATEAMFLGWVEQLVYDFTDETSEYSTDKIADITITII 180  
CC |||||||  
DB 574 ALLNPSRVYTFSSDYVKKVNKATEAMFLGWVEQLVYDFTDETSEYSTDKIADITITII 633  
CC |||||||  
QY 181 PYIGPALNIGNMLYKDDFVGALIFSG 206  
DB 634 PYIGPALNIGNMLYKDDFVGALIFSG 659  
CC |||||||

## RESULT 3

BXG\_CLOBO STANDARD; PRT; 1296 AA.  
ID BXG\_CLOBO  
AC Q60393;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 15-JUN-2002 (Rel. 41, Last annotation update)  
DE Botulinum neurotoxin type G precursor (EC 3.4.24.69) (BONT/G)  
GN BONG.  
OS Clostridium botulinum.  
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
OC Clostridium.  
OX NCBI\_TaxID=1491;  
RN 11)  
RP SEQUENCE FROM N.A.  
RC STRAIN=113 / 30;  
RX MEDLINE=94092745; PubMed=8268233;  
RA Campbell K., Collins M.D., East A.K.;  
RT "Nucleotide sequence of the gene coding for Clostridium botulinum

RT (Clostridium argentinense) type G neurotoxin: genealogical comparison  
 RT with other clostridial neurotoxins."  
 RL Biochim. Biophys. Acta 1216:487-491(1993).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE.  
 CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
 CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
 CC detected action on small molecule substrates.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N- AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: Secreted (By similarity).  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: X74162; CAA52275.1; -.  
 DR HSSP: P10845; 3BTA.  
 DR MEROPS: M27.002; -.  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_MTPeptidse.  
 DR Pfam: PF01742; Peptidase\_M27.1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR ProDom: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
 KM Neurotoxin; Hydrolase; Metalloprotease; Zinc.  
 FT INIT MET 0  
 FT CHAIN 1 441 BOTULINUM NEUROTOXIN G, LIGHT-CHAIN.  
 FT METAL 442 1296 BOTULINUM NEUROTOXIN G, HEAVY-CHAIN.  
 FT ACT\_SITE 229 229 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT METAL 230 230 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT METAL 233 233 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT DISULFID 435 449 INTERCHAIN (PROBABLE).  
 SQ SEQUENCE 1296 AA; 149013 MW; DC8E47E15F665C31 CRC64;  
 Query Match 35.2%; Score 377; DB 1; Length 1296;  
 Best local similarity 41.3%; Pred. No. 1.3e-22;  
 Matches 88; Conservative 34; Mismatches 75; Indels 16; Gaps 3;

DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-JUL-1993 (Rel. 26, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Botulinum neurotoxin type E precursor (EC 3.4.24.69) (BONT/E)  
 DE (Bontoxilysin E).  
 OS Clostridium butyricum.  
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
 OC Clostridium.  
 OX NCBI\_TaxID=1492;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=ATCC 43181, and ATCC 43755;  
 RX MEDLINE=92181428; PubMed=15434481;  
 RA Poullet S., Hauser D., Quanz M., Niemann H., Popoff M.R.;  
 RT "Cloning of a DNA fragment encoding the 5'-terminus of the botulinum  
 RT type E toxin gene from Clostridium butyricum strain B16340.";  
 RL J. Gen. Microbiol. 137:519-525(1991).  
 RN [3]  
 RP SEQUENCE OF 1-48.  
 RC STRAIN=5262;  
 RA Gimenez J., Foley J., Dasgupta B.R.;  
 RT "Neurotoxin type E from Clostridium botulinum and C. butyricum;  
 RT partial sequence and comparison.";  
 RL FASEB J. 2:41750-41750(1988).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE.  
 CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
 CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
 CC detected action on small molecule substrates.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N- AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: X62088; CAA43998.1; -.  
 DR EMBL: X53180; CAA37321.1; -.  
 DR PIR: JH0256; JH0256.  
 DR PIR: S16145; S16145.  
 DR HSSP: P10845; 3BTA.  
 DR MEROPS: M27.002; -.  
 DR InterPro: IPR000395; Bontoxilysin.  
 DR InterPro: IPR000130; Zn\_MTPeptidse.  
 DR Pfam: PF01742; Peptidase\_M27.1.  
 DR PRINTS: PR00760; BONTOXILYSIN.  
 DR ProDom: PD001963; Bontoxilysin; 1.  
 DR PROSITE: PS00142; ZINC\_PROTEASE; 1.  
 KM Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.  
 KW

```

FT INIT_MET 0 0
FT CHAIN 1 421 BOTULINUM NEUROTOXIN E, LIGHT-CHAIN.
FT CHAIN 422 1250 BOTULINUM NEUROTOXIN E, HEAVY-CHAIN.
FT METAL 211 211 ZINC (CATALYTIC) (BY SIMILARITY).
FT AC1_SITE 212 212 BY SIMILARITY.
FT METAL 215 215 ZINC (CATALYTIC) (BY SIMILARITY).
FT DISULFID 411 425 INTERCHAIN (PROBABLE).
FT CONFLICT 229 229 K -> M (IN REF. 2).
SQ SEQUENCE 1250 AA; 143265 MW; 8171B5B2C2312857 CRC64;

Query Match 35.0%; Score 374.5; DB 1; Length 1250;
Best Local Similarity 38.9%; Pred. No. 1.9e-22;
Matches 84; Conservative 51; Mismatches 60; Indels 21; Gaps 7;

OY 1 IKVNMMDLFEPSSENFND-LNKGEI-----TSDNTIAEENISLDLIQYILFNFD 55
DB 426 IEINNGELFEVASENSYNDNDINTFPEIDVTSTNNVE-----NLDVYLINSE 477
OY 56 NEPENISIEIISDIIIGOLELMPNIEFEPNG---KYLEDRYWFHYRAQEFHGKSR 111
DB 478 SAP-GISDEKMLTIQND-AIIPKYD--SNGTSDIEQHVNELNVEFYIDAKRVEGENN 533
OY 112 IALTSVNEALLNPSRVYTFESSDYKVKYKATEAPAMLGWVQLYVDFDTSEYSTTD 171
DB 534 VNLTSIDPALLEOPRIYTFESSEFINNVNKPVALLEFGWIOQYLVDFTEANOKSTVD 593
OY 172 KIADITIIIPYIGPALNIGNMLYKDDFVGLIFSG 207
DB 594 KIADISIVPIYIGLALNIGNEAKGNFKDLELILGA 629

RESULT 5
BXE_CLOBO STANDARD; PRT; 1250 AA.
AC 000496;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Botulinum neurotoxin type E precursor (EC 3.4.24.69) (BONT/E)
DE (Bontoxilysin E)
OS Clostridium botulinum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OC NCBI_TaxID=1491;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Beluga.
RA MEDLINE=92181428; PubMed=1543481;
RA Poulet S., Hauser D., Quanz M., Niemann H., Popoff M.R.;
RA "Sequences of the botulinum neurotoxin E derived from Clostridium
RA botulinum type E (strain Beluga) and Clostridium butylicum (strains
RA ATCC 43181 and ATCC 43755).";
RL Biochem. Biophys. Res. Commun. 183:107-113(1992).
RN [2]
RP SEQUENCE FROM N.A.
RC MEDLINE=92174922; PubMed=1541280;
RA Whelan S.M., Elmore M.J., Bodsworth N.J., Atkinson T., Minton N.P.;
RA "The complete amino acid sequence of the Clostridium botulinum type-E
RA neurotoxin, derived by nucleotide sequence analysis of the encoding
RA gene.";
RL Eur. J. Biochem. 204:657-667(1992).
RN [3]
RP SEQUENCE OF 1-251 FROM N.A.
RC MEDLINE=90264400; PubMed=2160960;
RA Birz T., Kurazono H., Wille M., Frevert J., Wernars K., Niemann H.;
RA "The complete sequence of botulinum neurotoxin type A and comparison
RA with other clostridial neurotoxins.";
RL J. Biol. Chem. 265:9153-9158(1990).
RN [4]
RP SEQUENCE OF 1-13.
RC MEDLINE=85197963; PubMed=388113;
RA Schmidt J.J., Sathymoorthy V., Dasgupta B.R.;
RA "Partial amino acid sequences of botulinum neurotoxins types B and

```

```

RT E.";
RL Arch. Biochem. Biophys. 238:544-548(1985).
RN [5]
RP SEQUENCE OF 419-426.
RA MEDLINE=90344918; PubMed=2116911;
RA Gimenez J.A., Dasgupta B.R.;
RA "Botulinum neurotoxin type E fragmented with endoprotease Lys-C
RA reveals the site trypsin nicks and homology with tetanus
RA neurotoxin.";
RL Biochimie 72:213-217(1990).
RN [6]
RP IDENTIFICATION OF SUBSTRATE.
RX MEDLINE=94063091; PubMed=8243676;
RA Schiavo G., Santucci A., Dasgupta B.R., Mehta P.P., Jontes J.,
RA Benfenati F., Wilson M.C., Montecucco C.;
RA "Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct
RA COOH-terminal peptide bonds.";
RL FEBS Lett. 335:99-103(1993).
RN [7]
RP IDENTIFICATION OF SUBSTRATE.
RX MEDLINE=94124495; PubMed=8294407;
RA Birz T., Blas J., Yamasaki S., Baumeister A., Link E., Suedhof T.C.,
RA Jahn R., Niemann H.;
RA "Proteolysis of SNAP-25 by types E and A botulinum neurotoxins.";
RL J. Biol. Chem. 269:1617-1620(1994).
CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER
CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED
CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD
CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT
CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC
CC ENDOPEPTIDASE THAT CATALYZES THE HYDROLYSIS OF THE 180-ARG-1-ILE-
CC 181 BOND IN SNAP-25.
CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the
CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No
CC detected action on small molecule substrates.
CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A
CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,
CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL
CC FORMATION AND TOXIN BINDING, RESPECTIVELY.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF
CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; X62089; CAA43999.1; -
DR EMBL; X62683; CAA44558.1; -
DR PIR; A60027; A60027.
DR PIR; B35294; B35294.
DR PIR; JH0257; JH0257.
DR PIR; S08575; S08575.
DR PIR; S18111; S18111.
DR PIR; S21178; S21178.
DR HSSP; P10845; 3BPA.
DR MEROPS; M27.002; -.
DR InterPro; IPR000395; Bontoxilysin.
DR InterPro; IPR000130; Zn_Mpeptidase.
DR Pfam; PF01742; Peptidase_M27; 1.
DR PRINTS; PR00760; BONTTOXILYSIN.
DR PRODOM; PD001963; BONTTOXILYSIN.
DR PROSITE; PS00142; ZINC_PROTEASE; 1.
KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.
FT INIT_MET 0 0
FT CHAIN 1 421 BOTULINUM NEUROTOXIN E, LIGHT-CHAIN.
FT CHAIN 422 1250 BOTULINUM NEUROTOXIN E, HEAVY-CHAIN.
FT METAL 211 211 ZINC (CATALYTIC) (BY SIMILARITY).

```

```
FT ACT_SITE 212 212 BY SIMILARITY.
FT METAL 215 215 ZINC (CATALYTIC) (BY SIMILARITY).
FT DISULFID 411 425 INTERCHAIN (PROBABLE).
FT CONFLICT 176 176 R -> G (IN REF. 2).
FT CONFLICT 197 197 C -> S (IN REF. 2 AND 3).
FT CONFLICT 339 339 R -> A (IN REF. 2).
FT CONFLICT 772 772 I -> L (IN REF. 2).
FT CONFLICT 962 963 FE -> LQ (IN REF. 2).
FT CONFLICT 966 966 R -> A (IN REF. 2).
FT CONFLICT 1194 1194 N -> NN (IN REF. 2).
SQ SEQUENCE 1250 AA; 143712 MW; D9FCE26DDA041EB4 CRC64;

Query Match 34.4%; Score 368.5; DB 1; Length 1250;
Best Local Similarity 38.4%; Pred. No. 5,8e-22;
Matches 83; Conservative 51; Mismatches 61; Indels 21; Gaps 7;

OY 1 IKVNNNDLFSPEDNFTND-LNKGEI-----TSDNIEAEENISLDLQGYLFNFED 55
DB 426 IEINNGELFFVASSENSYNDNDNTPKEIDYVSNMNYE-----NDLDVYILNFNSE 477
OY 56 NEPENISINLSDDIIGOLELMPNIEFPNG---KKYELDKYTMHYLRAQEFEGKSR 111
DB 478 SAP-GLSDKRLNLTIOND-AVYIPKYD--SNGTSDIEOHQDVNELNVEFYLDQAQKVPGEEN 533
OY 112 IALTNSVNALLNPSRVYFFFSDDYKKNKATKAEAMFLGWVQLVYDFDDESEVSTD 171
DB 534 VNTSTIDPALLEQPKRYFFESSEFTNNVKPVQALFVSWIQOVLVDFTEANQKSTVD 593
OY 172 KIADITIIIPYIGPALNIGNMLTKDQVGLIFSGA 207
DB 594 KIADISIVPYIGLALNIGNEAKGNFKDALLELGA 629

RESULT 6
BXE CLOBO STANDARD: PRT; 1290 AA.
AC 01-JUL-1988 (Rel. 11, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Botulinum neurotoxin type B precursor (EC 3.4.24.69) (BONT/B)
DE (Bontoxilysin B).
GN BONT.
OS Clostridium botulinum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=1491;
RN [1]
RP MEDLINE=92384550; PubMed=1514783;
RX Wheelan S.M., Elmore M.J., Bodsworth N.J., Brehm J.K., Atkinson T.,
RA Minton N.P.;
RT "Molecular cloning of the Clostridium botulinum structural gene
RT encoding the type B neurotoxin and determination of its entire
RT nucleotide sequence.";
RL Appl. Environ. Microbiol. 58:2345-2354(1992).
RN [2]
RP SEQUENCE OF 35-245 FROM N.A.
RC STRAIN=NCTC 7273;
RA Szabo E.A., Pemberton J.M., Desmarchelier P.M.;
RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE OF 633-993 FROM N.A.
RC STRAIN=NCTC 7273;
RX MEDLINE=94013372; PubMed=8408542;
RA Campbell K., East A.K., Collins M.D.;
RT "Gene probes for identification of the botulin neurotoxin gene and
RT specific identification of neurotoxin types B, E, and F.";
RL J. Clin. Microbiol. 31:2255-2262(1993).
RN [4]
RP SEQUENCE OF 1-44 AND 441-466.
RC STRAIN=657;
RX MEDLINE=89000987; PubMed=3139097;
```

```
RA Dasgupta B.R., Datta A.;
RT "Botulinum neurotoxin type B (strain 657): partial sequence and
RT similarity with tetanus toxin.";
RL Biochimie 70:811-817(1988).
RN [5]
RP SEQUENCE OF 1-16 AND 441-458.
RC STRAIN=OKRA;
RX MEDLINE=85197963; PubMed=3888113;
RA Schmidt J.J., Sathyanarthy V., Dasgupta B.R.;
RT "Partial amino acid sequences of botulinum neurotoxins types B and
RT E.";
RL Arch. Biochem. Biophys. 238:544-548(1985).
RN [6]
RP IDENTIFICATION OF ZINC-PROTEASE.
RX MEDLINE=93054694; PubMed=1429650;
RA Schiavo G., Benfenati F., Poulain B., Rossetto O., de Laureto P.P.,
RA Dasgupta B.R., Montecucco C.;
RT "Tetanus and botulinum-B neurotoxins block neurotransmitter release
RT by proteolytic cleavage of synaptobrevin.";
RL Nature 359:832-835(1992).
CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER
CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED
CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD
CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT
CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC
CC ENDOPEPTIDASE THAT CLEAVES THE 76-GLN-1-PHE-77 BOND OF
CC SYNAPTOSOMAL-2.
CC -1- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the
CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. NO
CC detected action on small molecule substrates.
CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A
CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,
CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL
CC FORMATION AND TOXIN BINDING, RESPECTIVELY.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF
CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sdb.ch/announce/
CC or send an email to license@sdb.ch).
CC
CC EMBL: M81186; AAA3211.1; -
CC EMBL: Z11934; CAA77991.1; -
CC EMBL: X70817; CAA50148.1; -
CC
CC PIR: S07128; S07128.
CC PIR: S07135; S07135.
CC PIR: S08562; S08562.
CC PIR: S08573; S08573.
CC PIR: S08574; S08574.
CC PIR: A48940; A48940.
CC HSSP: P10845; 3BTA.
CC MEROPS: M27.002; -.
CC InterPro: IPR000395; Bontoxilysin.
CC InterPro: IPR000130; Zn_MTPeptidase.
CC Pfam: PF01742; Peptidase_M27; 1.
CC PRINTS: PR00760; BONTOXILYSIN.
CC ProDom: PD001963; Bontoxilysin; 1.
CC PROSITE: PS00142; ZINC_PROTEASE; 1.
CC Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.
FT INIT MET 0 0
FT CHAIN 1 440 BOTULINUM NEUROTOXIN B, LIGHT-CHAIN.
```

```

FT CHAIN 441 1290 BOTULINUM NEUROTOXIN B, HEAVY-CHAIN.
FT METAL 229 229 ZINC (CATALYTIC) (BY SIMILARITY).
FT ACT_SITE 230 230 BY SIMILARITY.
FT METAL 233 233 ZINC (CATALYTIC) (BY SIMILARITY).
FT DISULFID 436 445 INTERCHAIN (PROBABLE).
FT CONFLICT 29 29 T -> M (IN REF. 4).
FT CONFLICT 217 217 R -> G (IN REF. 2).
FT CONFLICT 224 224 A -> S (IN REF. 2).
FT CONFLICT 463 463 S -> R (IN REF. 4).
SQ SEQUENCE 1290 AA: 150670 MW: D21746E2C024DF43 CRC64:

Query Match 34.2%; Score 366.5; DB 1; Length 1290;
Best Local Similarity 39.4%; Pred. No. 8.8e-22;
Matches 87; Conservative 39; Mismatches 62; Indels 33; Gaps 4;

OY 1 IKVNMNDFSPSEDNFTNDLNGKEITSDPTNIEAENISLDLQOYYLTFFNDEPEN 60
DB 446 IDVDNEDLFPIADKNFSFSDLSKNERLEYNT-----GSNYIENDF---PIN 488
OY 61 ISTEINSDITIGOLEL-----MPNIERPNCKKYEYLDKVTMFMHLYRAQEE 106
DB 489 ELI--LDTDLISKTELEPSENTESTLDENVDPYERKOPAIKFTDENTLFOYLYSOTFP 546
OY 107 HGKSRALITNSVNEALINPSRYVTFSSDYKKVKNKATEAMFLGWEOQLVFTDETSE 166
DB 547 LDIRDISTSSFDALLFSKVKVSPFSMDYIKTANKVVEAGLFGAGWKQIVNDFVLEANK 606
OY 167 VSTTDKIADITITIPYIGPALNTGNMUYKDEVGALIFSCA 207
DB 607 SNTMDKIADISLIVPYIGLALNVGNETAKGNFENAEPIAGA 647

RESULT 7
BXF_CLOBO STANDARD; PRT; 1274 AA.
ID BXF_CLOBO
AC P30996;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Botulinum neurotoxin type F precursor (EC 3.4.24.69) (BONT/F)
GN BONT.
OS Clostridium botulinum.
OC Bacteria: Firmicutes; Clostridia; Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_TaxID=1491;
RN 11
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 23387;
RX MEDLINE=93012902; PubMed=1398040;
RA East A.K., Richardson P.T., Allaway D., Collins M.D.,
RA Roberts T.A., Thompson D.E.;
RT "Sequence of the gene encoding type F neurotoxin of Clostridium botulinum."
RL FEMS Microbiol. Lett. 75:225-230(1992).
RN 12
RP SEQUENCE OF 1-64 FROM N.A.
RC STRAIN=Hobbs FT10;
RX MEDLINE=94297488; PubMed=7764998;
RA East A.K., Collins M.D.;
RT "Conserved structure of genes encoding components of botulinum neurotoxin complex M and the sequence of the gene coding for the non-toxic component in nonproteolytic Clostridium botulinum type F."
RL Curr. Microbiol. 29:69-77(1994).
RN 13
RP SEQUENCE OF 634-1002 FROM N.A.
RX MEDLINE=94013372; PubMed=8408542;
RA Campbell K., East A.K., Collins M.D.;
RT "Gene probes for identification of the botulinum neurotoxin gene and specific identification of neurotoxin types B, E, and F."
RL J. Clin. Microbiol. 31:2255-2262(1993).
RN 14
RP IDENTIFICATION OF SUBSTRATE.

```

```

RX MEDLINE=94230352; PubMed=8175689;
RA Yamasaki S., Baumeister A., Binz T., Blas J., Link E., Cornille F.,
RA Rogues B., Fyfe E.M., Suedhof T.C., Jahn R., Niemann H.,
RT "Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinum neurotoxins and tetanus toxin."
RL J. Biol. Chem. 269:12764-12772(1994).
OY 1 FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC ENDOPEPTIDASE THAT CATALYZES THE HYDROLYSIS OF THE 58-GLN-1-LYS-59 BOND OF SYNAPTOBREVIN-1 AND -2.
CC -1 CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on small molecule substrates.
CC -1 SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY, WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL FORMATION AND TOXIN BINDING, RESPECTIVELY.
CC -1 SUBCELLULAR LOCATION: Secreted.
CC -1 MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.
CC -1 SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC
CC EMBL: M92906; AAA23263.1; -
CC DR EMBL: S73676; AAC60475.1; -
CC DR EMBL: X70820; CAA50151.1; -
CC DR EMBL: X70816; CAA50147.1; -
CC DR HSSP: P10845; 3BTA.
CC MEROPS: M27.002; -.
CC DR InterPro: IPR000395; Bontoxilysin.
CC DR InterPro: IPR000130; Zn_MTPeptidse.
CC DR Pfam: PF01742; Peptidase_M27; 1.
CC DR PRINTS: PR00760; BONTTOXILYSIN.
CC DR ProDom: PD001563; Bontoxilysin; 1.
CC DR PROSITE: PS00142; ZINC_PROTEASE; 1.
CC KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.
FT CHAIN 1 436 BOTULINUM NEUROTOXIN F, LIGHT-CHAIN.
FT CHAIN 437 1274 BOTULINUM NEUROTOXIN F, HEAVY-CHAIN.
FT METAL 227 227 ZINC (CATALYTIC) (BY SIMILARITY).
FT ACT_SITE 228 228 BY SIMILARITY.
FT METAL 231 231 ZINC (CATALYTIC) (BY SIMILARITY).
FT DISULFID 429 445 INTERCHAIN (PROBABLE).
SQ SEQUENCE 1274 AA: 146709 MW: 5B99756A743B921 CRC64:

Query Match 29.5%; Score 316; DB 1; Length 1274;
Best Local Similarity 36.2%; Pred. No. 1e-17;
Matches 79; Conservative 51; Mismatches 62; Indels 26; Gaps 11;

OY 1 IKVNMNDFSPSEDNFTNDLNGKEITSDPTNIEAENISLDLQOYYLTFFNDEPEN 59
DB 446 IRVNNSELFVASESSVENDIMPKRIDPTJMLNNRYR-NLD---EVLIDVNSQITPQ 501
OY 60 NISTENISDITIGOLELMPNIERPNPNC---KYEYLDKVTMFMHLYRAQEEHKSRIALT 115
DB 502 -ISNRLNT-LVODNSVPPRYD--SNQTSIEEDVDVDFVFLYLAOKVBEETNLSLT 557
OY 116 NSVNEALINPSRYVTFSSDYKKVKNKATEAMFLGWEOQLVDFDETSEVSTTKIAD 175
DB 558 SSIDTALLEESK-DIFFSSEFIOTINKPVNAALFIDMISVIVDTFTTEATOKSTVKIAD 616
OY 176 ITIITIPYIGPALNI-----GNMLYKDF-----VGALI 203
DB 617 ISLIVPYGALNIITEAKGN--FEAFELLCVGLL 652

```

RESULT 8			
TETX_CLOTE		PRT: 1314 AA.	
ID	REFX_CLOTE	STANDARD:	
AC	P04958;		
DT	13-AUG-1987 (Rel. 05, Created)		
DT	13-AUG-1987 (Rel. 05, Last sequence update)		
DT	15-JUL-1999 (Rel. 38, Last annotation update)		
DE	Tetanus toxin precursor (EC 3.4.24.68) (Tentoxylysin).		
OC	Clostridium tetani.		
OC	plasmid.		
OC	Bacteria: Firmicutes; Clostridia; Clostridiales; Clostridiaceae;		
OC	Clostridium.		
OX	NCBI_TaxID=1513;		
OX	[1]		
RP	SEQUENCE FROM N.A.		
RX	MEDLINE=87053814; PubMed=3536478;		
RA	Eisel U., Jarausch W., Goretzki K., Henschen A., Engels J.,		
RA	Weiler U., Hudel M., Habermann E., Niemann H.;		
RT	"Tetanus toxin: primary structure, expression in E. coli, and		
RL	homology with botulinum toxins.";		
RL	EMBO J. 5:2495-2502(1986).		
RN	[2]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=CN3911;		
RC	MEDLINE=87040747; PubMed=3774547;		
RA	Fairweather N.F., Lyness V.A.;		
RA	"The complete nucleotide sequence of tetanus toxin.";		
RL	Nucleic Acids Res. 14:7809-7812(1986).		
RN	[3]		
RP	SEQUENCE OF 742-1314 FROM N.A.		
RX	MEDLINE=86085672; PubMed=3510187;		
RA	Fairweather N.F., Lyness V.A., Pickard D.J., Allen G., Thomson R.O.;		
RT	"Cloning, nucleotide sequencing, and expression of tetanus toxin		
RT	fragment C in Escherichia coli.";		
RL	J. Bacteriol. 165:21-27(1986).		
RN	[4]		
RP	PARTIAL SEQUENCE, AND DISULFIDE BONDS.		
RX	MEDLINE=90201034; PubMed=2108021;		
RA	Kriegelstein K., Henschen A.H., Weiler U., Habermann E.;		
RT	"Arrangement of disulfide bridges and positions of sulfhydryl groups		
RT	in tetanus toxin.";		
RL	Eur. J. Biochem. 188:39-45(1990).		
RN	[5]		
RP	PARTIAL SEQUENCE.		
RX	MEDLINE=92037649; PubMed=1935979;		
RA	Kriegelstein K.G., Henschen A.H., Weiler U., Habermann E.;		
RT	"Limited proteolysis of tetanus toxin. Relation to activity and		
RT	identification of cleavage sites.";		
RL	Eur. J. Biochem. 202:41-51(1991).		
RN	[6]		
RP	IDENTIFICATION AS ZINC-PROTEASE.		
RX	MEDLINE=93010948; PubMed=1396558;		
RA	Schavo G., Poulain B., Rossetto O., Benfenati F., Tauc L.,		
RA	Montecucco C.;		
RT	"Tetanus toxin is a zinc protein and its inhibition of		
RT	neurotransmitter release and protease activity depend on zinc.";		
RL	EMBO J. 11:3577-3583(1992).		
RN	[7]		
RP	IDENTIFICATION OF SUBSTRATE.		
RX	MEDLINE=93063293; PubMed=131807;		
RA	Schavo G., Benfenati F., Poulain B., Rossetto O., de Laureto P.P.,		
RA	Dasgupta B.R., Montecucco C.;		
RT	"Tetanus and botulinum-B neurotoxins block neurotransmitter release		
RT	by proteolytic cleavage of synaptobrevin.";		
RL	Nature 359:832-835(1992).		
RN	[8]		
RP	X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 874-1314.		
RX	MEDLINE=97475217; PubMed=9334741;		
RA	Umland T.C., Wingert L.M., Swaminathan S., Furey W.F., Schmidt J.J.,		
RA	Sax M.;		
RT	"Structure of the receptor binding fragment HC of tetanus		

```

RT neurotoxin.";
RL Nat. Struct. Biol.4:788-792(1997).
CC
CC -1- FUNCTION: TETANUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER
CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED
CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD
CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT
CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC
CC ENDOPEPTIDASE THAT CATALYZES THE HYDROLYSIS OF THE 76-GLN-1-PHE-77
CC BOND OF SYNAPTOBREVIN-2.
CC -1- CATALYTIC ACTIVITY: HYDROLYSIS OF 76-GLN-1-PHE-77 BOND IN
CC SYNAPTOBREVIN.
CC -1- SUBUNIT: THE PRECURSOR POLYPEPTIDE IS SUBSEQUENTLY CLEAVED TO
CC YIELD SUBCHAINS L AND H. THESE REMAIN LINKED BY A DISULFIDE BRIDGE
CC AND ARE NON-TOXIC AFTER SEPARATION.
CC -1- MISCELLANEOUS: THE C-TERMINAL OF THE HEAVY CHAIN BINDS TO
CC GANGLIOSIDE RECEPTORS.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: X04436; CAA28033.1; -.
DR EMBL: M12739; AAA23282.1; -.
DR EMBL: X06214; CAA29564.1; -.
DR PIR: A25689; BTCUTN.
DR PDB: 1AF9; 29-APR-98.
DR PDB: 1A8D; 14-OCT-98.
DR MEROPS: M27.001; -.
DR InterPro: IPR000395; Bontoxilysin.
DR InterPro: IPR000130; Zn_MTPeptide.
DR Pfam: PF01742; Peptidase_M27; 1.
DR PRINTS: PR00760; BONTOTOXILYSIN.
DR ProDom: PD001963; Bontoxilysin; 1.
DR PROSITE: PS00142; ZINC_PROTEASE; 1.
KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; zinc; Plasmid;
KW 3D-structure.
FT INIT_MET 0
FT CHAIN 1 456 TETANUS TOXIN LIGHT CHAIN.
FT CHAIN 457 1314 TETANUS TOXIN HEAVY CHAIN.
FT METAL 232 232 ? ZINC (CATALYTIC) (BY SIMILARITY).
FT ACT_SITE 233 233 BY SIMILARITY.
FT METAL 236 236 ZINC (CATALYTIC) (BY SIMILARITY).
FT TRANSMEM 226 246 POTENTIAL.
FT TRANSMEM 669 689 POTENTIAL.
FT DISULFID 438 466 INTERCHAIN.
FT DISULFID 1076 1092
SQ SEQUENCE 1314 AA; 150550 MW; 13AC3657133EF81D CRC64;

Query Match 29.1%; Score 312; DB 1; Length 1314;
Best Local Similarity 33.2%; Pred. NO. 2.2e-17;
Matches 74; Conservative 44; Mismatches 67; Indels 38; Gaps 4;

Oy 1 IKVNWMDLFFSPSDNPFNDLNKGEIITSDNIEAEENISLDLQOYYLTFNFDNEPEN 60
Db 467 IKINKEDITFAEKNSFEPEPDEIVSYNKNPPLNFNSLDKIIVDY----- 515
Oy 61 ISIENTSSDIGOLELMPNIRPFNGKK-----YELDKYTMHYLRQAQ 103
Db 516 -----NLQSKI-----TLPNDRTTPVTKGIPAPPEKYSMAASTIEIHNNDDTITIOYLYAQ 566
Oy 104 EFERGKSRIALTVNSVEALNLPNSRVYTFESSDYVKYKNKRATEAMALGWAEOLVYDFTE 163
Db 567 KSPTLTORITFTNSVDALINSTKIYSYFES-VISKVNOGAQGLTFQWVRDIDDFTE 625
Oy 164 TSEVSTDKADIADITITIPYGPALNIGMLAKKDFVQALIFSG 206
Db 626 SSQKTTDIDSVDSTIVYIGPALNIVKQEGNFIQALEFTG 668

```

RESULT 9  
 BXL\_CLOBO STANDARD; PRT; 1276 AA.  
 ID BXL\_CLOBO  
 AC P19321;  
 DT 01-NOV-1990 (Rel. 16, Created)  
 DT 01-NOV-1990 (Rel. 16, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Botulinum neurotoxin type D precursor (EC 3.4.24.69) (BONT/D)  
 DE (Bontoxilysin D).  
 GN BONT.  
 OS Clostridium botulinum.  
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
 OC Clostridium.  
 OC NCBI\_Taxid=1491;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-BVD/-3;  
 RX MEDLINE=91016853; PubMed=2216736;  
 RA Binz T., Kurazono H., Popoff M.R., Eklund M.W., Sakaguchi G.,  
 RA Kozaki S., Kriegstein K., Henschen A., Gill D.M., Niemann H.;  
 RT "Nucleotide sequence of the gene encoding Clostridium botulinum  
 RT neurotoxin type D.";  
 RL Nucleic Acids Res. 18:5556-5556(1990).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-CB16;  
 RX MEDLINE=93042276; PubMed=1420572;  
 RA Sunagawa H., Ohnaka T., Watanabe T., Inoue K.;  
 RT "The complete amino acid sequence of the Clostridium botulinum type D  
 RT neurotoxin, deduced by nucleotide sequence analysis of the encoding  
 RT phase d-16 phi genome.";  
 RL J. Vet. Med. Sci. 54:905-913(1992).  
 RN [3]  
 RP PARTIAL SEQUENCE.  
 RC STRAIN-D-SA, and D-1873;  
 RX MEDLINE=89339741; PubMed=2668193;  
 RA Morishiki K., Syuto B., Kubo S., Oguma K.;  
 RT "Molecular diversity of neurotoxins from Clostridium botulinum type D  
 RT strains.";  
 RL Infect. Immun. 57:2886-2891(1989).  
 RN [4]  
 RP IDENTIFICATION OF SUBSTRATE.  
 RX MEDLINE=94230352; PubMed=8175689;  
 RA Yamasaki S., Baumeister A., Binz T., Biasi J., Link E., Cornille F.,  
 RA Rogues B., Fyke E.M., Suedhof T.C., Jahn R., Niemann H.;  
 RT "Cleavage of members of the synaptobrevin/VAMP family by types D and  
 RT F botulinum neurotoxins and tetanus toxin.";  
 RL J. Biol. Chem. 269:12764-12772(1994).  
 CC -1- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 CC RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 CC AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 CC WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 CC INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 CC ENDOPEPTIDASE THAT CLEAVES THE 60-LYS-1-LEU-61 BOND OF  
 CC SYNAPTOSOMAL-1 AND -2.  
 CC -1- CATALYTIC ACTIVITY: limited hydrolysis of proteins of the  
 CC neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No  
 CC detected action on small molecule substrates.  
 CC -1- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 CC HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 CC WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 CC FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 CC BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -1- MISCELLANEOUS: BOTULINUM TYPE D NEUROTOXIN IS SYNTHESIZED BY D  
 CC STRAIN OF CLOSTRIDIUM BOTULINUM WHICH CARRY THE APPROPRIATE  
 CC BACTERIOPHAGE.  
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.1sb-sib.ch/announce/>  
 CC or send an email to [license@1sb-sib.ch](mailto:license@1sb-sib.ch)).  
 CC -----  
 DR EMBL; X54254; CAA38175.1; -;  
 DR EMBL; S49407; AAB24244.1; -;  
 DR PIR; S11455; S11455.  
 DR HSP; P10845; 3BTA.  
 DR MEROPS; M27.002; -;  
 DR InterPro; IPR000395; Bontoxilysin.  
 DR InterPro; IPR000130; Zn\_MTPeptide.  
 DR Pfam; PF01742; Peptidase\_M27; 1.  
 DR PRINTS; PR00760; BONTOTOXILYSIN.  
 DR PRODOM; PD001963; Bontoxilysin; 1.  
 DR PROSITE; PS00142; ZINC\_PROTEASE; 1.  
 KW Neurotoxin; Transmembrane; Hydrolyase; Metalloprotease; Zinc.  
 FT CHAIN 1 442  
 FT CHAIN 1 1276  
 FT METAL 229 229  
 FT ACT\_SITE 230 230  
 FT METAL 233 233  
 FT DISULFID 437 450  
 FT VARIANT 15 16  
 FT VARIANT 17 18  
 FT VARIANT 452 452  
 FT VARIANT 457 457  
 FT VARIANT 457 457  
 FT VARIANT 462 462  
 FT VARIANT 489 489  
 FT VARIANT 644 644  
 FT VARIANT 1122 1122  
 SQ SEQUENCE 1276 AA; 146871 MW; C1EC50F46C8233E2 CRC64;  
 Query Match 27.1%; Score 290.5; DB 1; Length 1276;  
 Best Local Similarity 32.6%; Pred. No. 1,1e-15;  
 Matches 71; Conservative 39; Mismatches 79; Indels 29; Gaps 5;  
 QY 1 IKVNNMDLFPSPEDNFTNDLNKGEITSDPTNEAENISLDLIDQYVTFENDEPEN 60  
 DB 451 IKVNNMDLFPSPEDNFTNDLNKGEITSDPTNEAENISLDLIDQYVTFENDEPEN 60  
 QY 61 ISLENSSDILGDELMPNERP-----NGKYEYDKMTMFLRAQEREG 108  
 DB 508 VD-----PLPNNMDELNIPGEIIFYDDITY-VDYLSYLLSSQKISNN 554  
 QY 109 KSRIATNSYNEALLNPSRYTFESSDYKVKKATEAAMFLGWEDLVYDFTDETSEVS 168  
 DB 555 VENITLTVSVEALGYSNKITYFLPS-LAEKVKGVAGGLFWMANVYVEDFTTNIMKD 613  
 QY 169 TTDKIADITITIPYIGPALNIGMKLYKDFVGLAIFSG 206  
 DB 614 TLDKISDVSVIIPYIGPALNIGMSALGNFNOAFATAG 651  
 RESULT 10  
 BXL\_CLOBO STANDARD; PRT; 1290 AA.  
 ID BXL\_CLOBO  
 AC P18640;  
 DT 01-NOV-1990 (Rel. 16, Created)  
 DT 01-NOV-1990 (Rel. 16, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Botulinum neurotoxin type C1 precursor (EC 3.4.24.69) (BONT/C1)  
 DE (Bontoxilysin C1).  
 OS Clostridium botulinum.  
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;  
 OC Clostridium.  
 OC NCBI\_Taxid=1491;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=90370487; PubMed=2204031;  
 RA Hauser D., Eklund M.W., Kurazono H., Binz T., Niemann H., Gill D.M.,



RA Boquet P., Popoff M.R.:  
 "Nucleotide sequence of Clostridium botulinum C1 neurotoxin.";  
 Nucleic Acids Res. 18:4924-4924(1990).  
 [2]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN-TYPE C Stockholm / C-ST:  
 RC MEDLINE=91024998; PubMed=2222445;  
 RX Kimura K., Fujii N., Tsuruki K., Murakami T., Indoh T.,  
 RA Yokosawa N., Takeshi K., Syuto B., Oguma K.:  
 "The complete nucleotide sequence of the gene coding for botulinum  
 type C1 toxin in the C-ST phage genome.";  
 Biochem. Biophys. Res. Commun. 171:1304-1311(1990).  
 [3]  
 RN SEQUENCE OF 2-25  
 RP STRAIN-TYPE C Stockholm / C-ST:  
 RC MEDLINE=88153072; PubMed=2450068;  
 RX Tsuruki K., Yokosawa N., Syuto B., Ohishi I., Fujii N., Kimura K.,  
 RA Oguma K.:  
 "Establishment of a monoclonal antibody recognizing an antigenic site  
 common to Clostridium botulinum type B, C1, D, and E toxins and  
 tetanus toxin.";  
 Infect. Immun. 56:898-902(1988).  
 [4]  
 RN IDENTIFICATION OF SUBSTRATE.  
 RP MEDLINE=94038966; PubMed=7901002;  
 RX Blasi J., Chapman E.R., Yamasaki S., Binz T., Niemann H., Jahn R.:  
 "Botulinum neurotoxin C1 blocks neurotransmitter release by means of  
 cleaving HPC-1/syntaxin.";  
 EMBO J. 12:4821-4828(1993).  
 CC -I- FUNCTION: BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER  
 RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED  
 AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD  
 WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT  
 INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC  
 ENDOPEPTIDASE THAT CLEAVES SYNTAXIN.  
 CC -I- CATALYTIC ACTIVITY: Limited hydrolysis of proteins of the  
 neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. NO  
 detected action on small molecule substrates.  
 CC -I- SUBUNIT: DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A  
 HEAVY CHAIN (H). THE LIGHT CHAIN HAS THE PHARMACOLOGICAL ACTIVITY,  
 WHILE THE N- AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL  
 FORMATION AND TOXIN BINDING, RESPECTIVELY.  
 CC -I- SUBCELLULAR LOCATION: Secreted.  
 CC -I- MISCELLANEOUS: THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF  
 BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.  
 CC -I- MISCELLANEOUS: BOTULINUM TYPE C1 NEUROTOXIN IS SYNTHESIZED BY C  
 STRAIN OF CLOSTRIDIUM BOTULINUM WHICH CARRY THE APPROPRIATE  
 BACTERIOPHAGE.  
 CC -I- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M27.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X66433; CAA47060.1; -  
 DR EMBL; X72793; CAA51313.1; -  
 DR EMBL; X53751; CAA37780.1; -  
 DR EMBL; D90210; BAA14235.1; -  
 DR EMBL; X62389; CAA44263.1; -  
 DR PIR; S11291; S11291.  
 DR PIR; A35396; A35396.  
 DR PIR; A43503; A43503.  
 DR HSSP; P10845; 3BTA.  
 DR MEROPS; M27.002; -  
 DR InterPro; IPR000395; Bontoxilysin.  
 DR InterPro; IPR000130; Zn\_MTPeptidase.  
 DR Pfam; PF01742; Peptidase\_M27; 1.  
 DR PRINTS; PR00760; BONTOXILYSIN.  
 DR ProDom; PD001963; Bontoxilysin; 1.

DR PROSITE; PS00142; ZINC\_PROTEASE; 1.  
 KW Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc.  
 FT INIT\_MET 0 0  
 FT CHAIN 1 448 BOTULINUM NEUROTOXIN C1, LIGHT-CHAIN.  
 FT CHAIN 449 1290 BOTULINUM NEUROTOXIN C1, HEAVY-CHAIN.  
 FT METAL 228 228 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT ACT\_SITE 229 229 BY SIMILARITY.  
 FT METAL 232 232 ZINC (CATALYTIC) (BY SIMILARITY).  
 FT DISULFID 436 452 INTERCHAIN (PROBABLE).  
 FT CONFLICT 84 84 P -> T (IN REF. 2).  
 SQ SEQUENCE 1290 AA; 148734 MW; 71FBE379F97129E8 CRC64;  
 Query Match 24.6%; Score 263; DB 1; Length 1290;  
 Best Local Similarity 31.2%; Pred. No. 1.9e-13;  
 Matches 64; Conservative 39; Mismatches 94; Indels 8; Gaps 4;  
 QY 3 VNNMFLFSPSDNFTNDLNKGEITSPNFAEENISLDIQOYVTFNFDNPEPNTS 62  
 DB 457 VKNTPDLPFGDISDVKTDFLRKADINETEVIYVDNVSVD---QVILS---KNISEHQ 510  
 QY 63 IENLSDIIGOLELMPNIEP-FPNCKKYELEKTYMEHYLRAGQEFHGRSRIALTNSVNEA 121  
 DB 511 IDLVPISDSESEILPGENOVFYDNRQNVLYNSYYLESQKLSDNVEDFTFRTSIEBA 570  
 QY 122 LNPESRVYTFESDVKYKNTKTEAMFLGWQELVYFTDTSVSTTKRADIITIIIP 181  
 DB 571 LDNSAKVYTFYFPT-LANNVAGVQGLFLMANVDVEFTTNILRKDTLKDIDVSAIIP 629  
 QY 182 YIGPALNIGNMLYKDDFVGAIFSG 206  
 DB 630 YIGPALNINSVNRQNFTEAFVATG 654  
 RESULT 11  
 Y402\_BUCAL  
 ID Y402\_BUCAL STANDARD; PRT; 246 AA.  
 AC P57482;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Hypothetical protein BU402.  
 GN BU402.  
 OS Buchnera aphidicola (subsp. Acyrthosiphon pisum) (Acyrthosiphon pisum  
 symbiotic bacterium).  
 OC Bacteria; Proteobacteria; gamma subdivision; Buchnera.  
 OX NCBI\_TaxID=118099;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-Tokyo 1998;  
 RX MEDLINE=20445173; PubMed=10993077;  
 RA Shigenobu S., Watanabe H., Hattori M., Sakaki Y., Ishikawa H.:  
 "Genome sequence of the endocellular bacterial symbiont of aphids  
 RT Buchnera sp. Aps.";  
 RL Nature 407:81-86(2000).  
 CC -I- SIMILARITY: BELONGS TO THE UPF0169 (COML) FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; AP001119; BAB13105.1; -  
 DR InterPro; IPR005156; UPF0169.  
 DR Pfam; PF03696; UPF0169; 1.  
 KW Hypothetical protein; Complete proteome.  
 SQ SEQUENCE 246 AA; 29937 MW; 1289ED7ACD94088F CRC64;  
 Query Match 10.0%; Score 107; DB 1; Length 246;  
 Best Local Similarity 21.8%; Pred. No. 0.088;  
 Matches 44; Conservative 40; Mismatches 74; Indels 44; Gaps 8;



```

OY 14 EDNFTNDLNKGEITSDTN-TEAEENISDLIQOYYLTFNPDNEBENIS-----62
DB 46 KENFDNAISLIERIKKNNNTANISNDKIQIDLIYAYKILINPDQARKNIEEFYEPNHP 105
OY 63 -----IENLSSDIIGOLELMPNIEFPNGKRYELD-----KYTFMHYLRAOEFH 107
DB 106 NIDYVYVYIQLLSMSLDKRNFEVFP-INVKNKYDYKANAFFQKLFYIYQYKSYVVA 164
OY 108 GSR-1ALNSVNEALLNRSYTFPSSDYKKVKATE-----AMFLGWEQ- 155
DB 165 AKNKLIIYINRLSEHDLSTIKFY-FPHKEVIAVINRGEMLORYSETPSARKALIIYERKS 223
OY 156 ----LWYDFDSESEVSTDKI 173
DB 224 YVAKLTFDPAKIKSTILINKI 245

RESULT 12
BXCN.CLOBO
ID BXCN.CLOBO STANDARD: PRT: 1196 AA.
AC P46081;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DE 01-NOV-1995 (Rel. 32, Last annotation update)
OS Botulinum neurotoxin type C1, nontoxic component.
OC Clostridium botulinum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae; Clostridium.
OX NCBI_TaxId=1491;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Type C Stockholm / C-ST;
RA MEDLINE=92231894; PubMed=1567404;
RA Tsuzuki K., Kimura K., Fujii N., Yokosawa N., Oguma K.;
RT "The complete nucleotide sequence of the gene coding for the nontoxic-nonhemagglutinin component of Clostridium botulinum type C progenitor toxin."
RT Blochem. Biophys. Res. Commun. 183:1273-1279(1992).
RL -I- FUNCTION: THE NONTOTOXIC COMPONENT IS NECESSARY TO MAINTAIN TOXICITY.
CC -----
CC CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC -----
CC DR EMBL: X62389; CA44262.1; -
CC DR InterPro: IPR000395; Bontoxilysin.
CC DR Pfam: PF01742; Peptidase_M27; 1.
CC DR PRINTS: PR00760; BONTOXILYSIN.
CC DR ProDom: PD001963; Bontoxilysin; 1.
CC KW Neurotoxin.
SQ SEQUENCE 1196 AA; 138740 MW; 4BD5956274D7F9C3 CRC64;

Query Match 9.9%; Score 106; DB 1; Length 1196;
Best Local Similarity 20.4%; Pred. No. 0.77;
Matches 50; Conservative 48; Mismatches 81; Indels 66; Gaps 11;

```

```

OY 143 APEAMFLGWEQVYVDFDSEVSTDKIADITIIIFIGPALNIGMLKYPDVGAL 202
DB 553 DTDKRYTL-WLKEVKNYSFDINLTQEDISMGGINVFLFGALINLT--SNSFVEEX 609
OY 203 IESGA 207
DB 610 QDSGA 614

RESULT 13
VAOD.YEAST
ID VAOD.YEAST STANDARD: PRT: 345 AA.
AC P32366;
DT 01-OCT-1993 (Rel. 27, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DE 15-JUN-2002 (Rel. 41, Last annotation update)
DE Vacuolar ATP synthase subunit d (BC 3.6.3.14) (V-ATPase d subunit) (Vacuolar proton pump d subunit) (V-ATPase 39 kDa subunit) (V-ATPase subunit M39).
DE VMA6 OR YLR447C OR I9324.8.
GN VMA6 OR YLR447C OR I9324.8.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX NCBI_TaxId=4932;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC MEDLINE=93286119; PubMed=8509410;
RA Bauerle C., Ho M.N., Lindorfer M.A., Stevens T.H.;
RT "The Saccharomyces cerevisiae VMA6 gene encodes the 36-kDa subunit of the vacuolar H(+)-ATPase membrane sector."
RT J. Biol. Chem. 268:12749-12757(1993).
RL -I- FUNCTION: VACUOLAR ATPASE IS RESPONSIBLE FOR ACIDIFYING A VARIETY OF INTRACELLULAR COMPARTMENTS IN EUKARYOTIC CELLS. THE ACTIVE ENZYME CONSISTS OF A CATALYTIC V1 DOMAIN ATTACHED TO AN INTEGRAL MEMBRANE V0 PROTON PORE COMPLEX. THIS SUBUNIT IS A NON-INTEGRAL MEMBRANE COMPONENT OF THE MEMBRANE PORE DOMAIN AND IS REQUIRED FOR PROPER ASSEMBLY OF THE V0 SECTOR. MIGHT BE INVOLVED IN THE REGULATED ASSEMBLY OF V1 SUBUNITS ONTO THE MEMBRANE SECTOR OR ALTERNATIVELY MAY PREVENT THE PASSAGE OF PROTONS THROUGH V0 PORES.
CC -I- CATALYTIC ACTIVITY: ATP + H(2O) + H(+)(In) = ADP + phosphate + H(+)(Out).
CC -I- SUBUNIT: V-ATPase is a heteromultimeric enzyme composed of a peripheral catalytic V1 complex (components A to H) attached to an integral membrane V0 proton pore complex (components: a, c, c', c'', and d).
CC -I- SIMILARITY: BELONGS TO THE V-ATPASE V0D/AC39 SUBUNIT FAMILY.
CC -----
CC CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC -----
CC DR EMBL: L1184; AAA35210.1; -
CC DR EMBL: U22382; AAB67533.1; -
CC DR PIR: S35105; S35105.
CC DR PIR: A45994; A45994.
CC DR SGD: S0004439; VMA6.
CC DR InterPro: IPR002843; ATPsynth_AC39sub.
CC DR Pfam: PF01992; VATP-synth_AC39; 1.
CC KW Hydrolyase; Hydrolase ion transport.
CC FT CONFLICT 32 N->T (IN REF. 1).
CC FT CONFLICT 32
SQ SEQUENCE 345 AA; 39790 MW; 53A19450CAF35632 CRC64;

Query Match 9.2%; Score 98; DB 1; Length 345;
Best Local Similarity 29.0%; Pred. No. 0.71;
Matches 36; Conservative 17; Mismatches 41; Indels 30; Gaps 6;
OY 11 SPSEDNFTNDLNKGEITSDTNIEAEENISDLIQOYY-----LTF 52
DB 11 SPSEDNFTNDLNKGEITSDTNIEAEENISDLIQOYY-----LTF 52

```

DB 156 TPLAPYKNCPTAEEL-DMNIEIINKLYKALEDFYVTEIEPEPAKECQTLIGF 214  
 QY 53 NFDNEPENISIEML-SSDIIGOL--ELMPNIEEPNGKYEKDYTMFHYLRAQEFHKG 109  
 DB 215 EADRRSINITALNLOSSIDIDPDLKSLDLPNT-----GKLYPL--AATPHLAQAQDFEGVR 266  
 QY 110 SRTA 113  
 DB 267 AALA 270

RESULT 14  
 MT18\_YEAST  
 ID MT18\_YEAST STANDARD; PRT; 1032 AA.  
 AC P40469; P89106;  
 DT 01-FEB-1995 (Rel. 31, Created)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 15-JUL-1998 (Rel. 36, Last annotation update)  
 DE DNA repair/transcription protein MET18/MMS19.  
 GN MET18 OR MMS19 OR YIL128W.  
 OS Saccharomyces cerevisiae (Baker's yeast).  
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;  
 NC Saccharomycetales; Saccharomycetaceae; Saccharomyces.  
 NX NCBI\_TaxId=4932;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND FUNCTION.  
 RX MEDLINE=97098656; PubMed=8943333;  
 RA Lauder S., Bankmann M., Guzder S.N., Sung P., Prakash L.,  
 RA Prakash S.;  
 RT "Dual requirement for the yeast MMS19 gene in DNA repair and RNA  
 RT polymerase II transcription.";  
 RL Mol. Cell. Biol. 16:6783-6793(1996).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=S288c / AB972;  
 RA Churchill B.G., Badcock K., Bankier A.T., Brown D.,  
 RA Churcher C.M., Connor R., Copsey T., Dear S., Devlin K., Fraser A.,  
 RA Gentsles S., Hamlyn N., Horsnell T.S., Hunt S., Jagsels K., Jones M.,  
 RA Louis E., Lye G., Moule S., Moule T., Odell C., Pearson D.,  
 RA Rajandream M.A., Riles L., Rowley N., Skelton J., Smith V.,  
 RA Walsh S.V., Whitehead S.;  
 RL Submitted (DEC-1994) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE OF 1-161 FROM N.A.  
 RC STRAIN=S288c / AB972;  
 RA Churcher C., Barrell B.G., Rajandream M.A.;  
 RL Submitted (SEP-1994) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE OF 162-1032 FROM N.A.  
 RC STRAIN=S288c / AB972;  
 RA Hamlyn N., Churcher C., Barrell B.G., Rajandream M.A.;  
 RL Submitted (NOV-1994) to the EMBL/GenBank/DBJ databases.  
 CC -I- FUNCTION: INVOLVED IN NUCLEOTIDE EXCISION REPAIR (NER) AND RNA  
 CC POLYMERASE II (POL II) TRANSCRIPTION. IT PROBABLY DOES NOT  
 CC PARTICIPATE DIRECTLY IN NER AND POL II TRANSCRIPTION BUT EXERTS  
 CC ITS BIOLOGICAL EFFECTS BY INFLUENCING THE ACTIVITY OF TFIIH AND  
 CC POSSIBLY OTHER DNA REPAIR AND TRANSCRIPTION FACTORS AS AN UPSTREAM  
 CC REGULATORY ELEMENT. INVOLVED IN SPORULATION AND POSSIBLY IN THE  
 CC RAD52 RECOMBINATIONAL REPAIR PATHWAY.  
 CC -I- SUBCELLULAR LOCATION: Nuclear.  
 CC -I- DOMAIN: HAS 15 TANDEN LECITINE RICH REPEATS.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL: U70559; AAB38865.1; -  
 CC EMBL: Z38059; CAA86150.1; -  
 CC EMBL: Z46833; CAA86864.1; -

DR TRANSFAC; T03493; -  
 DR SGD; S0001390; MET18.  
 KW DNA repair; Nuclear protein; Repeat.  
 FT CONFLICT 230 230 P -> Q (IN REF. 1).  
 FT CONFLICT 329 329 D -> G (IN REF. 1).  
 FT CONFLICT 335 335 V -> M (IN REF. 1).  
 FT CONFLICT 361 361 V -> I (IN REF. 1).  
 SQ SEQUENCE 1032 AA; 117882 MW; D05DC48B8098814 CRC64;

Query Match 8.9%; Score 95.5; DB 1; Length 1032;  
 Best Local Similarity 22.1%; Pred. No. 4.5;  
 Matches 46; Conservative 33; Mismatches 76; Indels 53; Gaps 10;

QY 3 VNMMDLFFSP-----SEDNFTNDLNK--GEITSDTNIEAEENISLDLIQY 48  
 DB 297 LEWMTLLMNAKFEMQNSGENETILLNPNKQSDVDGQYINYPACLTIKIIMALQY 356  
 QY 49 YLFPNPNENISIEMLSSDIIGOLELMNIEEPNGKYEKDYTMFHYLRAQEFHKG 108  
 DB 357 ---NFD---KVSFEKFFTHVD--ELKPNF-----KYEDLKQTCQLSA---IG 395  
 QY 109 KSRIATLNSVNEA-----LLNPSRV-----YFPSSDYKKVKKATEAMFLGWE 154  
 DB 396 SGNVEINPKYISSTFPLFLINTSEVAKLLIMNFSEFVSYIDLRGRTSKESLGTPVP 455  
 QY 155 QLVYDFPDE---TSEVSTDKIADIYI 178  
 DB 456 NKMAEYKDEIMLSMALTRSSKAQYVI 483

RESULT 15  
 Y198\_RICPR  
 ID Y198\_RICPR STANDARD; PRT; 355 AA.  
 AC 092DM7;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Hypothetical protein RP198 precursor.  
 GN RP198.  
 OS Rickettsia prowazekii.  
 OC Bacteria; Proteobacteria; alpha subdivision; Rickettsiales;  
 OC Rickettsiaceae; Rickettsiae; Rickettsia.  
 OX NCBI\_TaxId=782;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Madrid E;  
 RX MEDLINE=99039499; PubMed=9823893;  
 RA Andersson S.G.E., Zomorodipour A., Andersson J.O.,  
 RA Sichteritz-Ponten T., Alsmark U.C.M., Podowski R.M., Naelund A.K.,  
 RA Eriksson A.-S., Winkler H.H., Kurland C.G.;  
 RT "The genome sequence of Rickettsia prowazekii and the origin of  
 RT mitochondria.";  
 RL Nature 396:133-140(1998).  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL: AJ235270; CAA14663.1; -  
 CC Hypothetical protein; Signal; Complete proteome.  
 KW SIGNAL 1 21  
 FT CHAIN 22 355 HYPOTHETICAL PROTEIN RP198.  
 SQ SEQUENCE 355 AA; 40780 MW; A08B7655BCDBE0 CRC64;

Query Match 8.7%; Score 93.5; DB 1; Length 355;  
 Best Local Similarity 26.4%; Pred. No. 1.7;  
 Matches 57; Conservative 32; Mismatches 76; Indels 51; Gaps 14;

QY 1 IKVNMMDL--FFSPSEDNF--TNDLNKGEITSDTNIEAEENISLDLIQY YLFPNDNEP 58

```

Db 146 IKLNKTLISIFKONQEIFKINDL---AFILTKHNL-ASQENISLFLMHYY-----SEK 195
OY 59 ENISIEMLSDIIGOLELMP-----NIRF-----PNGKKYELDKYTMFHYLRAQ 103
Db 196 DILNFKNANLDMATSFPAKNGKDAILENLIERFIETCDNESKVNUNGTLOFF---AN 252
OY 104 EFHGRSRIALT--NSVNEALLNPSRYTFESSDYKKV-----NKATEAAMFLGWVEOL 156
Db 253 KLPKGIISFELNYSIVDKIL-PNST--LFSKKTITIIAKAMNKTSD-----EOL 301
OY 157 VYDFDETSEVSTYDKIADITIIIPYIGPALNIGNM 192
Db 302 ---NFDKNDJNSVYNNIKNAKFDIAFSDKGINIGSM 334

```

Search completed: March 13, 2003, 11:40:36  
 Job time : 13.5447 secs

**THIS PAGE BLANK (USPTO)**